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ABSTRACT
Development of Ligand Guided Selection (LIGS) To Identify Specific DNA Aptamers
Against Cell Surface Proteins
by
Hasan Ekrem Zumrut
Advisor: Prabodhika Mallikaratchy
Oligonucleotide aptamers (nucleic acid-based affinity reagents) are an emerging class of
synthetic molecules that display high affinity and specificity towards their targets. Aptamer molecules
for a target of interest are obtained using a combinatorial chemistry-based method termed systematic
evolution of ligands by exponential enrichment (SELEX). SELEX is an in vitro selection process in
which a random oligonucleotide library is subjected to repeated cycles of target incubation, separation,
and amplification until target-specific evolved sequences become prevalent in the library. Typically,
SELEX is used against target molecules such as small molecules and proteins, in their purified state.
However, aptamers selected against purified cell surface proteins show limited scope, due to aptamer’s
inability to recognize the cell surface protein expressed in its natural environment. To address this
issue, a modified SELEX method, named cell-SELEX, was developed, which uses the whole live cells
as targets. Cell-SELEX enabled the identification of aptamers against cell surface proteins in their
native environment without the need for target purification. A major limitation of cell-SELEX,
however, is that the targeting epitope on the cell surface cannot be predefined. In this dissertation, we
developed a novel variant of the SELEX method named ligand-guided selection (LIGS) to successfully
identify specific aptamers against predetermined cell surface proteins in their native, functional state.
This method is designed to uniquely exploit the selection step, which is the core of the SELEX process.

iv

In chapter 2, the LIGS method is introduced as a new biochemical-screening platform that
employs the binding of naturally occurring, stronger and highly specific secondary molecular entity to
its target as a partition step, to identify highly specific artificial nucleic acid ligands. Here, we used an
antibody (Ab) that binds to the membrane-bound Immunoglobulin M (mIgM) to selectively elute
aptamers that are specific for mIgM from a SELEX pool that is partially enriched toward mIgM
expressing Ramos cells. Three aptamers that were selected showed high specificity toward Ramos
cells. Furthermore, our results show that the aptamers identified by LIGS could be outcompeted by
mIgM Ab, demonstrating that LIGS can be successfully applied to select aptamers from a partially
evolved cell-SELEX library, against predetermined receptor proteins using a cognate ligand.
In Chapter 3, we explored the applicability of LIGS towards a multi-domain receptor complex,
using an anti-CD3ε mAb against the cluster of differentiation 3 (CD3ε), as the guiding ligand against
one of the domains of the T-cell Receptor (TCR) complex expressed on Jurkat.E6 cells. We discovered
three specific aptamers against TCR complex expressed on an immortalized line of human T
lymphocyte cells. These findings demonstrate that specific aptamers can be identified utilizing an
antibody against a single domain of a multidomain protein complex in their endogenous state with
neither post- nor pre-SELEX protein manipulation.
Chapter 4 outlines, the systematic truncation of an aptamer named R1, which was selected
against mIgM in the study concluded in chapter one, to design shorter variants with enhanced affinity.
Importantly, herein, we succeeded to show that the specificity of the most optimized variant of R1
aptamer (R1.2) is similar to that of the anti-IgM antibody, indicating that the specificity of the ligand
utilized in selective elution of the aptamer determines the specificity of the LIGS-generated aptamer.
Furthermore, the results demonstrated that truncated variants of R1 are able to recognize mIgMpositive human B lymphoma BJAB cells at physiological temperature indicating that low-affinity
v

aptamers generated in LIGS could be enhanced by post-SELEX modifications without compromising
their specificity.
Since the aptamers obtained from initial LIGS experiments possessed only moderate binding
affinities to their target receptors, we developed a comprehensive version of ligand-guided selection
(LIGS), by optimizing LIGS to identify higher affinity aptamers with high specificity. In addition, we
expanded the LIGS method by performing specific aptamer elution at 25 °C, utilizing multiple
monoclonal antibodies (mAbs) against cultured cells and primary cells obtained from human donors
expressing the same receptor. Eluted LIGS libraries were subjected to Illumina high-throughput (HT)
DNA sequencing and were analyzed by bioinformatics tools to discover five DNA aptamers with
apparent affinities ranging from 3.06 ± 0.485 nM to 325 ± 62.7 nM against the target, T-cell receptorcluster of differentiation epsilon (TCR-CD3ε) expressed on human T-cells. The specificity of the
aptamers was validated utilizing multiple strategies, including competitive binding analysis and a
double-knockout Jurkat cell line generated by CRISPR technology. The cross-competition
experiments using labeled and unlabeled aptamers revealed that all five aptamers compete for the same
binding site. Collectively, the data presented in Chapter 5, introduce a modified LIGS strategy as a
universal platform to identify highly specific multiple aptamers toward multi-component receptor
proteins in their native state without changing the cell-surface landscape. These aptamers can be used
to develop therapeutic agents, especially for cancer immunotherapy.
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Chapter 1: Introduction
1.1

Introduction to Aptamers
Nucleic acids are essential to life, mainly functioning to store and transmit genetic

information. However, they also form unique shapes by folding into three-dimensional structures,
as evident in the crystal structure of transfer RNA (tRNA)1. Additionally, it is known that certain
RNA molecules named ribozymes2 can catalyze chemical reactions3, 4. As biological catalysts,
enzymes including ribozymes accomplish their function through the formation of threedimensional active sites, which require a well-defined shape. The presence of natural ribozymes
proves that nucleic acid molecules can form structured scaffolds.
In 1990, two independent groups determined that single-stranded nucleic acids can fold
into unique three-dimensional structures and specifically bind to any target with high affinity5, 6.
These synthetic oligonucleotide ligands were named “aptamers,” a term derived from the Latin
word aptus, which means “to fit.” Since then, specific aptamers have been selected for use against
a wide range of targets, including small molecules7,8, amino acids9, peptides10,11, and
proteins6,12–20, as well as against complex targets such as viruses21, whole cells22–25, and tissues26,27.
Aptamer–target complexes are stabilized through noncovalent interactions, such as hydrogen
bonding, van der Waals contacts, and hydrophobic or hydrophilic interactions, as well as
electrostatic interactions.
Since the discovery of hybridoma technology in 1975 by Kohler and Milstein, monoclonal
antibodies have become well-established tools for molecular recognition and are being used
extensively in diagnostic and therapeutic applications28, 29. Aptamers, as a novel class of affinity
reagents, are often compared to antibodies30 and dubbed “chemical antibodies.” Because of their
1

chemical nature, aptamers have certain properties not found in antibodies. First, aptamers are
chemically synthesized, unlike antibodies, which are produced using animals through a process
that is prone to batch-to-batch variations. The chemical synthesis of aptamers enables their easy
and reproducible scale-up at a much lower cost than that for antibodies. The synthetic nature of
aptamers also enables easy chemical modification during synthesis, whereby labeling moieties
such as fluorophores and functional groups can be conjugated at precise sites, however, such
conjugation is not as straightforward in the case of antibodies. Aptamers are relatively smaller than
antibodies, and their size thus enables superior tissue penetration and results in higher blood
clearance rates. Additionally, aptamers are more chemically and thermally stable than antibodies
because their denaturation is usually reversible, which increases their shelf life30, 31.
The discovery of the possibility of using nucleic acid aptamers as synthetic probes and the
identification of aptamers effective against a variety of targets have prompted the research and
development of aptamers as new tools in science and medicine. Aptamers have generally been
studied for applications in the bioanalytics field, especially in biosensor development32–34, the
development of diagnostic tools based on aptamers35,36, and the development of therapeutic
agents31, 37, 38. Examples of selected aptamers with their reported applications are detailed in Table
1.1.

2

Table1.1 Applications of Aptamers
Aptamers as biosensors
Aptamer
Name

Target

Reported Application

Significance

Reference

MNS-7.9

Cocaine

Detection of cocaine
concentration in
serum using a
fluorescence-based
sensor

A simple and efficient
strategy based on
fluorescence resonance
energy transfer (FRET) in
which ligand binding
results in fluorescence
quenching due to
conformation change

(39)

G15D5d

Thrombin

Detection of thrombin
protein using an
aptamer beacon

This is the first example
(40)
of using aptamer beacons.
Detection is achieved by
the generation of
fluorescence signal upon
ligand binding whereas
signal is quenched when
no ligand is bound to the
aptamer

Thrombinbinding
aptamer
(TBA)

Thrombin

Detection of thrombin
protein using aptamer
capped quantum dots

This study showed that
quantum-dots (QDs) can
be utilized instead of
fluorescent dyes for the
development of aptamerbased biosensors

(41)

PDGFbinding
aptamer

plateletderived
growth
factor
(PDGF)

Detection of PDGF
protein in blood serum
based on an
electrochemical sensor

This example shows that
aptamers can also be used
as electrochemical
sensors in addition to
optical sensors

(42)

Aptamers as diagnostic tools
Aptamer
Name

Target

Reported Application

Significance

Reference

06.15 and
06.50

basic
fibroblast
growth

A diagnostic system for
the detection of
bFGF(155) protein in
serum

In this study, aptamers
(43)
are immobilized in a solid
support and an aptamer
based diagnostic system
3

factor
bFGF(155)

similar to ELISA was
introduced

NX21909

Elastase

Detection of
inflammation by
aptamer-based
diagnostic in vivo
imaging

This study was the first
example to demonstrate
the use of aptamers in
diagnostic imaging

(44)

DT3 and
Ep23

EpCAM

Use of aptamers for
immunofluorescence
and chromogenic
staining of formalinfixed paraffinembedded tissue
sections obtained from
breast cancer patients

In this study higher
sensitivities and reduced
incubation times were
achieved using aptamers
when compared to
conventional antibodies

(45)

Aptamer9,

CD4

Staining of human
lymphocytes and
detection by flow
cytometry

Demonstrated the
applicability of aptamers
in flow cytometry for
diagnosis

(17)

Aptamer12

Aptamers as therapeutic agents
pegaptanib

VEGF

Approved by the FDA
for the treatment of
age-related macular
degeneration.

Pegaptanib is the first
federally approved
aptamer drug

(46)

AS1411

nucleolin

Used in clinical trials
for the treatment of
acute myeloid
leukemia.

First aptamer drug to
enter clinical trials for the
treatment of human
cancer

(47, 48)

Del-60

CTLA-4

An
immunomodulatory
aptamer that inhibits
CTLA-4 function,
enhancing the
antitumor activity of
T-cells in a mice
model of melanoma.

The first demonstration of (49)
the utility of aptamers for
immunomodulation

A9

PSMA

An aptamer
conjugated with a
toxin (gelonin) was
used to specifically

Demonstrated the
applicability of aptamers

(50)
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A10

1.2

PSMA

kill cancer cells
overexpressing a
tumor marker:
prostate-specific
membrane antigen
(PSMA)

as targeted delivery
agents

An aptamer targeting
PSMA was used to
specifically deliver
small interfering RNA
to target two survival
genes, PLK1 and
BCL2. Specific
antitumor activity was
achieved in mice
using a xenograft
prostate cancer model.

Demonstrated the
applicability of aptamers
for the targeted delivery
of siRNA into cells

(51)

The SELEX Process
Aptamers are generated through an iterative in vitro selection process that integrates

combinatorial chemistry and molecular evolution and is termed systematic evolution of ligands by
exponential enrichment, abbreviated as SELEX5, 6. The SELEX process is the established method
for identifying aptamers active against desired targets. In this section, the early SELEX methods
using pure targets are described. The SELEX process begins with the chemical synthesis of an
oligonucleotide library. This library contains 15–20 base constant regions on both ends for primer
annealing and a randomized region in the middle to create diversity. The diversity of the library
depends on the number of sequences in the randomized region, which is typically designed in the
range of 20–40 bases, although longer lengths up to 120 bases have also been explored52. Standard
solid-phase oligonucleotide synthesis at a 1-µmol scale can yield 1014 to 1015 individual molecules,
and consequently, a library containing 25 random bases nears the practical limit (425 = 1015) of
sequence diversity52. Library diversity of this order of magnitude supersedes other types of
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combinatorial libraries in light of the fact that current high-throughput screening libraries consist
of up to 3 million compounds53.
The SELEX process consists of three interconnected steps: incubation, separation, and
recovery and amplification, as illustrated in Figure 1.1. In the first step, the library is incubated
with its target to allow for binding. Next, the unbound sequences are separated from the binding
complex that consists of the target and the bound sequences. Finally, the bound sequences are
recovered from the target and are amplified using polymerase chain reaction (PCR). These steps
are repeated multiple times (rounds) until the specific target binders dominate the library. Finally,
the resultant library, enriched with target-specific target sequences, is sequenced to obtain
individual aptamer sequences.

Figure 1.1: Schematic of the SELEX process. (1) The random oligonucleotide library is
incubated with the target. (2) Unbound sequences are separated from target-bound sequences. (3)
Bound sequences are recovered from the target and amplified using polymerase chain reaction.
This process is repeated for as many rounds as necessary until target binders dominate the library.
6

Separating unbound sequences from the target-bound sequences is one of the most critical
steps in the SELEX process, and depending on the type of target, many techniques have been
employed to accomplish it. In one of the first SELEX experiments that mark the invention of the
SELEX process, nitrocellulose filters were used to select RNA aptamers against T4 DNA
polymerase6. This separation technique is based on the facts that the protein target remains on the
filter due to high molecular weights and unbound sequences are filtered through. Because of its
ease of use, nitrocellulose filter-based separation has been commonly employed in the early
SELEX experiments against protein targets12–14, 54, 55. For other targets, such as small molecules,
an affinity chromatography–based separation technique has been widely utilized7, 8, 56, 57 after being
introduced by Ellington and Szostack in 19905. In this technique, the target is immobilized on an
affinity column, and unbound sequences are removed by washing; only the target-bound sequences
are retained in the column and are subsequently eluted through the addition of denaturing agents.
Additionally, novel techniques have also been developed such as using magnetic beads to
immobilize the target58–60, gel-based separation techniques15, 61, and capillary electrophoresis62, 63;
all these have proven to be useful in separating bound complexes from unbound sequences.
During the SELEX process, it is crucial to monitor the enrichment of target-binding
sequences in the library to determine when to end the selection. This can be accomplished by
evaluating the percent binding of SELEX pools towards the target compared with the unselected
control library. To be able to detect target binding, the SELEX library is labeled during PCR.
Radioactive labeling (such as 32P) has been commonly employed for this purpose because of its
high sensitivity; however, it requires the handling of radioactive isotopes, which is not
environment-friendly and is expensive. Alternatively, fluorescent-based labeling can also be used
to evaluate library binding64. Another approach is to monitor the sequence diversity of the library
7

during selection. The evaluation of library diversity enables quantitative monitoring of library
enrichment and SELEX progression. The measurement of the rate of DNA renaturation was
originally used to determine the extent of repeated sequences in genomic DNA65 and has also
proved to be useful for determining the diversity of SELEX libraries66, 67. Recently, the sequencing
of SELEX pools in every round has been made possible through advances in next-generation
sequencing (NGS). The analysis of NGS data in successive SELEX rounds enables the calculation
of library diversity, thus, it is also used to monitor the progress of selection68,69. The SELEX
process is usually terminated at the point at which enrichment of the library reaches a plateau and
no longer increases with additional SELEX rounds.
1.3

Selection of Aptamers Against Cell Surface Proteins
Membrane proteins constitute approximately 23% of the human genome70 and function as

enzymes, receptors, and transporters71. They are embedded in plasma membranes and are not water
soluble. Membrane proteins are commonly post-translationally modified, and alterations in
membrane protein structures are associated with a variety of diseases, including cancer72.
Additionally, the solvated regions outside the membrane are highly accessible to drugs. Because
of these properties, membrane proteins constitute more than 60% of current drug targets. Among
these targets, receptor proteins, notably G-protein-coupled receptors, are the most highly
represented class73. In addition to being common drug targets, membrane proteins are also targeted
for diagnostic applications and molecular imaging. Flow cytometric immunophenotyping is the
most essential tool used for the diagnosis of hematological malignancies74 and entails the
evaluation of the expression profiles of specific receptors (known as cluster of differentiation [CD]
receptors) using fluorochrome-labeled antibodies. For these reasons, membrane proteins are also
attractive targets against which to develop aptamer ligands.
8

In 1996, aptamer selection against L-selectin using an RNA library modified with 2´-amino
pyrimidines was the first reported aptamer selection against a cell surface receptor20. In this study,
a chimeric construct containing the extracellular domain of the L-selectin attached to an IgG2 Fc
domain was purified and immobilized on sepharose beads on the basis of Protein A–Fc
interactions. In 1998, another group successfully identified 2´-fluoro-modified RNA aptamers
against the CD4 receptor. Again, the target was the purified extracellular region of the CD4 protein
which was immobilized on the surface of beads prior to SELEX17. In these early examples, both
membrane protein targets used for in vitro selection experiments were monomeric proteins that are
produced in transgenic expression systems and purified prior to conducting SELEX. However, the
use of purified membrane proteins as SELEX targets has inherent shortcomings that hinder the
universal application of this approach. First, the purified protein targets are not presented in their
native environment, which is the cell membrane, and their structural conformations are altered
upon purification. Consequently, the selected aptamers may not recognize the native protein when
it is encountered on the cell surface. Additionally, many membrane proteins require the assembly
and interaction of multiple subunits and coreceptors to function, which cannot be achieved in a
purified form75. Thus, purified protein–based SELEX is not applicable for complex receptor
proteins with multiple subunits. Consequently, new methods that enable in vitro aptamer selection
against a complex mixture of targets without the need for target purification have been developed,
as illustrated in Figure 1.2. In the following sections, each of these SELEX methods is summarized.
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Figure 1.2: Development of SELEX methods to generate aptamers against membrane
proteins.
1.3.1

SELEX Against Cell Membrane Preparations
In 1998, Morris et al. reported the first in vitro selection against a complex mixture of

targets using preparations of the membranes of red blood cells (RBC ghosts)

(76)

. The SELEX

approach used in this study was very similar to the methods used for pure protein targets, except
for the choice of target. However, the library was found to be highly diverse containing only a few
repeated sequences even after performing 25 rounds of SELEX. In contrast, with respect to single
protein targets, 10-15 rounds of SELEX usually generates a library with little diversity consisting
of a few converged sequence families with many repeating sequences12, 13, 20. Nevertheless, two
distinct sequence motifs were present in approximately 26% of the entire pool. Truncated
sequences containing each of the motifs were photo crosslinked to RBC ghosts, and their protein
targets exhibited distinct bands when analyzed using SDS-PAGE. This study thus provided the
first experimental evidence that a random oligonucleotide library can generate multiple aptamers
against distinct targets within a complex mixture. The authors did not aim for a specific protein
target in the mixture and did not confirm the identity of the target proteins; nevertheless, this study
laid the groundwork for the use of even more complex targets.
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1.3.2

SELEX Against Whole Living Cells (cell-SELEX)
In 2001, Blank et al. used a target even more complex than cell membrane preparations for

the first time in a SELEX experiment: whole living mammalian cells22. This SELEX method is
thus referred to as cell-SELEX.

In this experiment, specific aptamers for rat endothelial

(YPEN-1) cells were identified employing a counterselection strategy in which the single-stranded
DNA library was incubated with nonendothelial cells (N9 microglial cells) in each round prior to
incubation with target cells. The commonly employed detection method of radioactive labeling of
oligonucleotides was replaced by a fluorescence reporter molecule, and flow cytometry was used
to monitor enrichment of the target cell-specific aptamers within the library. This selection was
concluded after eight rounds, and individual sequences from the eighth round were characterized
using a two-step approach. First, the authors characterized the binding affinities of 25 aptamer
candidates against the target YPEN-1 cells through flow cytometry. Second, they used
fluorescence microscopy to determine the staining of brain tumor microvessels by the aptamer
candidates. The aptamer III.1 exhibited the most intensive staining of the brain tumor microvessels
in the areas of tumor growth. The molecular target III.1 was identified by mass spectroscopy as
the rat homologue of the mouse pigpen protein, an oncogenic endothelial protein that is required
for angiogenesis77. This study demonstrated for the first time the utility of applying whole living
mammalian cells in SELEX experiments and determined that fluorescence labeling followed by
flow cytometry and fluorescence microscopy can be used to monitor library enrichment during
SELEX as well as for characterization of aptamer candidates. Additionally, the authors used
affinity purification, SDS-PAGE, and mass spectroscopy to identify the molecular target of the
selected aptamer.
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In 2003, Daniels et al. performed SELEX against a monolayer of the glioblastoma tumor
cell line, U251, and named the method tumor cell-SELEX23. Here, the elimination of nonspecific
binders was achieved using a non-amplifiable tRNA as a competitor, and the competitor
concentration was gradually increased during SELEX. After 21 rounds of SELEX, 10% of the
library was dominated by sequence GBI-10 and its homologues, which were found to be specific
for U251 cells. Affinity purification followed by mass spectroscopy was performed to identify the
binding target of the GBI-10 aptamer; the result showed the target was tenascin-C, an extracellular
matrix protein that is abundantly expressed in malignant tumors78.
Since 2006, the Tan research group at University of Florida has made significant
contributions to the further development and refinement of the cell-SELEX method. First, a panel
of high-affinity DNA aptamers was selected for the acute T-cell lymphoma cell-line, CCRFCEM24. In this study, cells from a B-cell line (Ramos, Burkitt’s lymphoma) were used as negative
cells for the counterselection and enrichment of the library, which was evaluated by flow
cytometry analysis. The use of negative cells enables the elimination of aptamer sequences that
binds to common cell surface components and the identification of aptamers specific to the target
cell. Twenty rounds of cell-SELEX resulted in significant enrichment of target-binding sequences
(CCRF-CEM cells) in the library compared with the control (Ramos cells). Ten aptamers were
identified that recognized only the target (CCRF-CEM) cells with high affinities. The authors next
evaluated the binding of selected aptamers against a panel of cell lines and discovered that these
aptamers could identify a variety of cultured T-cell lines but not B-cell lines. Moreover, these
aptamers could recognize cells obtained from patients with T-cell acute lymphoblastic leukemia
(T-ALL) but not the cells from patients with large B-cell lymphoma. These results demonstrated
the applicability of the selected aptamers for use in molecular diagnosis. Later, the protein target
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of one of the selected aptamers, sgc8, was identified as protein tyrosine kinase-7 (PTK7)79. In
another study by the same group, aptamers against Ramos cells (Burkitt’s lymphoma) were
identified by performing 23 rounds of cell-SELEX without employing a counterselection25. The
target of aptamer TD05 was identified as the membrane-bound immunoglobin heavy mu chain
(IGHM) of IgM, which is the major component of the B-cell receptor complex (BCR)80. Because
IgM is highly expressed in Ramos cells, this study demonstrated that cell-SELEX without any
counterselection step can be used to identify aptamers against the most prevalent receptors. The
same group also utilized cell-SELEX and identified aptamers for other cancer types such as liver
cancer81 and lung cancer82; however, the target proteins of these aptamers have not been
determined. In conclusion, these studies successfully identified a variety of aptamers against
multiple cancer cells; moreover, these aptamers were used as probes to profile patient cancer
samples, thereby demonstrating the widespread applicability of the cell-SELEX method in clinical
settings.
The optimized cell-SELEX method developed by the Tan research group83 is similar to the
original SELEX process described previously (see section 1.2) in that it also contains three
interconnected steps: incubation, separation, and recovery and amplification. In cell-SELEX, the
target is replaced by whole cells, and separation of unbound sequences from the target cell–bound
sequences is achieved through centrifugation. In the positive selection step, after centrifugation,
the target cells are retained and are heated to denature and elute target-bound sequences, whereas
the supernatant that contains unbound sequences is discarded. In the counterselection step, upon
centrifugation, the supernatant containing unbound sequences is amplified for the next round,
whereas the sequence bound to negative cells is discarded. During PCR, to assess target
enrichment of the library, the 5´ end of the sense strand is labeled by a fluorophore, and the 3´ end
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of the antisense strand is labeled using biotin. Biotin–streptavidin interactions followed by
denaturation of the two strands are used to obtain a single-stranded library after each round of
selection. Flow cytometry binding analysis of the library during the selection process is performed,
and selection is terminated when a significant increase in the binding signal is achieved compared
with the unselected control library, which remains stable for two to three successive rounds of
selection83.
To summarize, the cell-SELEX method enables the identification of aptamers against cell
surface proteins in their native environment without the need for target purification or prior
knowledge of the targeting epitope. During the cell-SELEX process, all cell surface proteins are
retained in their native conformations with all possible posttranslational modifications. This
feature allows for the selection of aptamers that can be translated into clinical settings for
diagnostic or therapeutic applications. Additionally, it captures molecular differences between the
positive and negative cells, and this can result in the identification of novel biomarkers, provided
that the targeting epitope of the selected aptamer is determined. However, several limitations of
the cell-SELEX method hinder its applicability for the selection of aptamers against a predefined
epitope expressed on the cell surface. In cell-SELEX, aptamers are predominantly evolved against
most abundant proteins expressed on the target cells; however, the desired target might not be
highly expressed. Additionally, cell-SELEX requires many rounds to achieve target enrichment
because it depends heavily on counterselection strategies that use negative cells. Another challenge
is the identification of the target epitope; this requires affinity pull-down and mass spectroscopy.
However, due to the low solubility and high hydrophobicity of cell surface proteins, attempts to
identify aptamer targets have failed on many occasions84, 85.
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1.3.3

Crossover (Hybrid) SELEX
A hybrid SELEX approach that includes both purified protein SELEX and cell-SELEX

method has been developed to obtain specific aptamers against a predefined cell surface protein.
This method was first used by Hicke et al. in 2001 to select aptamers against human TN-C
protein86. In this study, nine rounds of cell-SELEX were performed using TN-C-expressing U251
glioblastoma cells, which was followed by two rounds of SELEX using purified human TN-C.
Completing two rounds of crossover SELEX was sufficient to obtain human TN-C–specific
aptamers with 50-fold improved affinity towards the target. An alternative hybrid SELEX (reverse
crossover) approach was also developed in which SELEX using the purified recombinant protein
target is first performed and is followed by cell-SELEX. The reverse crossover SELEX method is
used to identify cell-internalizing RNA aptamers for the human transferrin receptor87. Although
crossover SELEX is useful for identifying target-specific aptamers and decreases the selection
time compared with cell-SELEX, it still suffers from the drawbacks associated with the
purification of the target protein.

1.3.4

Target Expressed on Cell Surface-SELEX (TECS-SELEX)
To identify aptamers against predefined cell surface proteins without needing to purify the

target, a variation of cell-SELEX was developed in 2006 that is named target expressed on cell
surface (TECS)-SELEX88. Ohuchi et al. ectopically expressed transforming growth factor-beta
receptor type III (TbRIII) protein on Chinese hamster ovary (CHO) cells to select RNA aptamers
against TbRIII; the parental cells were used for counterselection. After 11 rounds of selection, an
RNA aptamer named A07 was determined to bind specifically to TbRIII protein expressed on the
cell surface. The specificity of the selected aptamer was demonstrated through the addition of
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excess soluble TbRIII protein, which interfered with the binding of aptamer A07 to the target cells.
Alternatively, target proteins can be overexpressed in the desired cell line, and the negative cells
can be generated through gene-silencing strategies such as siRNA or microRNA-mediated
knockdown of the target protein. This approach was used to obtain DNA aptamers against the
integrin alpha V (ITGAV) receptor89.
The major limitation of this approach is the imperfectness of the negative selection step;
even after repeated rounds of negative selection, sequences binding to highly abundant proteins on
the positive as well as the negative cells may be retained in the selection pool90, which makes it
difficult to identify target-specific aptamers.
1.3.5

Ligand-Guided Selection (LIGS)
To address the limitations of using previously described SELEX methods for the selection

of aptamers against predefined cell surface proteins, the Mallikaratchy research group developed
a novel aptamer selection method named ligand-guided selection (LIGS), which is presented in
the following chapters of this dissertation. Briefly, LIGS enables the selection of aptamers against
cell surface proteins that are retained in their native environment and at natural expression levels.
Neither target purification nor overexpression of the target is necessary because the LIGS method
is based on competitive elution of target-specific aptamers and uses a high-affinity ligand known
to specifically bind to the target of interest, such as a monoclonal antibody. The binding of the
competitor can be accomplished either by directly displacing sequences bound to the same target
or by indirectly causing a conformation change in the target protein, which causes loss of binding
and the subsequent release of these sequences from the cell surface. The LIGS method is especially
useful for selecting aptamers against complex receptor proteins with multiple subunits and has
been successfully applied for the identification of aptamers against the CD3-TCR complex
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expressed on T-cells91,92 as well as membrane IGM expressed on B-cells93. The only limitation of
this method is that it is only applicable for targets in which an existing high-affinity secondary
ligand is available.
1.4

Aptamer Truncation and Modifications
Aptamers obtained through SELEX are normally 50–90 bases in length, as described in

section 1.2; however not all the bases are necessary for the binding. Hence, shorter versions of
aptamers can be obtained by conducting post-SELEX truncation studies to obtain the functional
structure with minimum length. The binding of an aptamer to its target is mainly facilitated by
structural folds such as hairpin loops, G-quadruplexes, and pseudoknots94. Through the use of a
secondary structure prediction software such as Mfold or RNAfold, the bases that do not contribute
to the formation of structural motifs can be identified and removed to obtain truncated aptamer
variants. For example, Shangguan et al. reported the truncation of an aptamer 88 bases long (8gc8)
to obtain a new a variant with a considerably diminished length of 41 bases but maintained its
affinity towards the target95. In another study, truncation of a G-quadruplex-forming aptamer
resulted in an aptamer with approximately 50-fold higher affinity towards its target96. Truncating
aptamers to obtain shorter variants not only reduces the cost of chemical aptamer synthesis, but
also enables the synthesis of multivalent aptamers. The generation of multivalent aptamers has
been shown to increase the target-binding affinity of aptamers and to expand their biological
activity49, 97.
In addition to truncations, aptamers are commonly modified at the nucleobase level to endow
them with nuclease resistance and to expand their functional and structural diversity. In RNA, the
2´ position of the ribose sugar is often modified through the addition of amino, fluoro, or O-methyl
groups, which confers nuclease resistance98. Another common site for modification is the 517

position of the pyrimidine base in which hydrophobic groups can be attached to increase the
functional diversity of aptamers99. Modification of this type led to the generation of a novel class
of aptamers named slow off-rate modified aptamers (SOMAmers). SELEX based on SOMAmer
libraries has been demonstrated to enable the identification of high-affinity aptamers against a
range of protein targets, including difficult targets100. More recently, novel wholly unnatural base
pairs (UBPs) were generated and implemented in aptamer discovery98. The use of UBPs in aptamer
selection confers functional and structural diversity to nucleic acid libraries and also expands their
information content. Examples of UBPs that have been successfully used in SELEX include the
hydrophobic unnatural bases, called the Ds and Px bases, that were developed by the Hirao
laboratory. These bases exclusively pair with each other on the basis of hydrophobic and packing
forces101. In another UBP system, two unnatural bases (named Z and P) pair with each other on
the basis of hydrogen bonding and Watson–Crick geometry. DNA libraries containing artificial Z
and P bases have been used to generate aptamers against a number of targets such as breast cancer
cells, Glypican 3, and anthrax protective antigen 3102–104.
1.5

Influence of Next-Generation Sequencing Technologies on Aptamer Identification
During the first two decades of SELEX experiments, the final selected pool was cloned and

sequenced using traditional DNA sequencing platforms such as Sanger sequencing. However, this
approach enabled access to only a small portion of the sequences present in SELEX libraries105.
By contrast, next-generation sequencing (NGS) technologies enable high-throughput and parallel
sequencing of millions of sequences from multiple DNA libraries. In the case of SELEX, NGS
technologies enable the simultaneous sequencing of multiple SELEX rounds; thus, it enables novel
approaches for identifying aptamers.
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In 2010, Cho et al. applied NGS to select aptamers against platelet-derived growth factor BB
(PDGF-BB)106. In this SELEX experiment, a MicroMagnetic Separation device was used to
eliminate weakly and nonspecifically bound sequences from the target, and three rounds of
selection were performed. Each round of SELEX was subjected to NGS that yielded over 10
million sequences per round. Aptamer identification was achieved by calculating the fold
enrichment (ratio of copy numbers between two selection rounds) for each sequence. The
researchers found that the three sequences with the highest fold enrichment ratio bound to the
target with high affinity. Interestingly, the highest-affinity aptamer was not the sequence most
abundant in the final round of selection. This finding was confirmed by Schultze et al.; they
discovered that the superior binding sequences appeared in the earliest rounds; however, in the
later rounds, they were outcompeted by lower-affinity sequences that can be amplified through
PCR more efficiently107. These studies demonstrated the utility of using NGS to identify aptamers
in earlier rounds; additionally, using fold enrichment ratio rather than simply choosing the most
abundant sequences in the final round of SELEX has been identified as an alternative approach for
selecting aptamer candidates.
1.6

Selection of Aptamers Against CD3-TCR
The T-cell receptor complex (TCR) is a hallmark of T-cells. T-cells are a subtype of white

blood cells (lymphocytes) that are central to adaptive immune system108. The TCR complex is
composed of highly variable TCR-α and β chains that recognize distinct peptides and the invariant
CD3 molecule that functions in signal transduction. CD3 is made of two heterodimers of εδ and
εγ chains and one homodimer of ζ chains, and these are noncovalently associated with the TCR
antigen109. Most of the available anti-CD3 antibodies target a conserved region on either εδ or εγ
chains110. The therapeutic potential of anti-CD3 antibodies has been investigated in connection
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with cancer immunotherapy111,112. The first CD3 monoclonal antibody (mAb) that has been
approved by the FDA is named OKT3 and has been used for the treatment of transplant
rejection113. Anti-CD3 antibodies have also been shown to be efficient in the treatment of type-1
diabetes114. In another therapeutic approach, anti-CD3 mAbs have been used to generate bispecific
antibodies, which are also termed bispecific T-cell engagers (biTEs), to promote cell killing by
bringing cytotoxic T-cells and cancer cells into proximity115. One such bispecific antibody,
blinatumomab, is made of a CD3/CD19 construct in which the CD3 portion targets the T-cell and
CD19-expressing cells. CD19 is expressed in healthy mature B-cells but is also considered to be a
hallmark of B-cell tumors and is overexpressed in certain B-cell malignancies116. These examples
demonstrate that specific targeting of human CD3 has major importance in biomedical research,
which makes it an important target for aptamer generation. To the best of the author’s knowledge,
prior to the reporting of the research data presented in this thesis dissertation, no aptamer molecules
that target the human CD3-TCR complex have been reported.
1.7

Overview of the Dissertation
The research data presented in this thesis dissertation describe the development of a novel

aptamer selection method to target predefined epitopes expressed on the cell surface. The method,
named ligand-guided selection (LIGS), is a useful approach for developing oligonucleotide
aptamers that target multisubunit receptor complexes. Chapter 2 outlines the development of the
LIGS method and selection of aptamers against membrane-bound immunoglobulin M (mIgM)
with high specificity using LIGS. Chapter 3 describes the use of the LIGS method to identify
specific aptamers against the T-cell receptor (TCR) complex expressed on cultured cells. The
aptamers obtained through the experiments detailed in Chapters 2 and 3 exhibited good specificity
against the target but possessed low affinity. Chapter 4 describes the efforts to optimize the
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structure of the aptamer selected against mIgM and details the generation of a shorter aptamer
variant with improved binding characteristics. Finally, Chapter 5 explains the optimization of the
LIGS method to obtain aptamers with higher affinities against the TCR complex expressed on
cultured T-cells as well as primary T-cells.

21

Chapter 2: Ligand-Guided Selection of Target-Specific Aptamers: A Screening Technology
for Identifying Specific Aptamers Against Cell-Surface Proteins
Disclaimer: Reprinted (adapted) with permission from: Nucleic Acid Therapeutics, 26, Zumrut,
H.E., Ara, M.N., Fraile, M., Maio, G., and Mallikaratchy, P., Ligand-Guided Selection of TargetSpecific Aptamers: A Screening Technology for Identifying Specific Aptamers Against CellSurface Proteins. 190-198., Copyright © Mary Ann Liebert Inc. 2016 93.

2.1

Introduction
Nucleic acid aptamers (nucleic acid-based antibody analogs) are being investigated to

develop therapeutic molecules for the treatment of a variety of diseases31. The synthetic nature of
aptamers makes them attractive for the introduction of elegant chemistries to engineer molecular
tools, especially compared with the use of antibodies, their protein-based rival117. The process by
which aptamers are selected is referred to as SELEX5, 6. The SELEX process is a screening method
that combines in vitro evolution and combinatorial chemistry118.
Recently, considerable efforts have been aimed at improving SELEX to generate aptamers
that are suitable for applications in translational research. For example, SELEX methods have been
introduced to select aptamers against whole cells to identify cell-surface proteins; modified nucleic
acids have been introduced to enhance the diversity of SELEX libraries to produce high-affinity
aptamers; and methods have been introduced to increase the efficiency of the polymerase chain
reaction (PCR) of SELEX against proteins24,119–122. However, no biochemical techniques have thus
far been introduced to select specific aptamers against a predetermined epitope of a receptor
protein in its endogenous state with no prior manipulation of the target.
Herein, we report a novel biochemical technique for identifying specific aptamers from a
partially evolved library directed by binding of a pre-existing secondary ligand with its cognate
receptor. This strategy, termed ligand-guided selection (LIGS), takes advantage of the
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evolutionary selection step of SELEX. The aptamers are evolved in the SELEX process based on
the survival of high-affinity ligands by outcompeting the low-affinity ligands during the partition
step followed by PCR amplification. We exploited this feature of the partition step to isolate
specific aptamers. This is accomplished by introducing a stronger secondary high-affinity ligand,
in this example, an antibody against IgM expressed on Burkitt’s lymphoma cells (Ab) to
outcompete and replace the aptamer candidates binding to the same target of the Ab. Based on the
specificity of Ab toward its target, the aptamers identified by LIGS are also expected to show
specificity toward Ab’s target. The selected aptamers show specificity toward Ramos cells. As
expected, the identified specific aptamers for membrane-bound Immunoglobulin M (mIgM)
compete with the cognate Ab binding to its target. This proof-of-concept study introduces a new
biochemical-screening platform that exploits the binding of a secondary stronger molecular entity
to its target as a partition step, to identify highly specific artificial nucleic acid ligands.
2.2

Materials and Methods

2.2.1

Cell Culture
Cell lines, Ramos (Burkitt’s lymphoma) and Jurkat.E6 (T lymphocyte), were a generous

gift from David Scheinberg lab and Morgan Huse lab, Memorial Sloan Kettering Cancer Center.
All cells were cultured in RPMI 1640 medium supplemented with 100 units/mL penicillin–
streptomycin and 10% fetal bovine serum (heat inactivated; Invitrogen).
2.2.2

DNA Synthesis and Buffer Formulations
All of the DNA reagents needed for DNA synthesis were purchased from Glen Research

or ChemGenes. All the DNA oligo sequences were chemically synthesized by attaching a
fluorophore at the 3´ end using standard solid-phase phosphoramidite chemistry on an ABI394
DNA (Biolytics) synthesizer using a 0.2 µmol scale. The completed DNA sequences were de23

protected and purified by using HPLC (Waters) that was equipped with a C-18 reversed phase
column (Phenomenex).
All in vitro experiments were performed by using a binding buffer composed of Dulbecco’s
phosphate-buffered saline (DPBS) and 4.5 g/L glucose (Sigma-Aldrich), 5mM MgCl2, 100mg/L,
tRNA (Sigma-Aldrich), and 1 g/L BSA(Sigma-Aldrich). The wash buffer was composed of DPBS
with 5mM MgCl2 and 4.5 g/L glucose (Sigma-Aldrich).
2.2.3

SELEX Primers and Library
Primers and SELEX library were obtained from Sefah et al.83:
Forward primer: 5´-FITC-ATCCAGAGTGACGCAGCA-3´.
Reverse Primer: 5´-biotin-ACTAAGCCACCGTGTCCA-3´
Library: 5´-ATCCAGAGTGACGCAGCA-45N-TGGACACGGTGGCTTAGT-3´
The SELEX library consisting of primers flanked by a 45-nucleotide randomized region

was purchased from IDT DNA Technologies.
2.2.4

Cell-SELEX Procedure
The PI staining of the cells and the flow cytometric analysis of expression of mIgM

utilizing fluorescein isothiocyanate (FITC)-labeled anti-IgM antibody (1 µg, Goat anti human; Life
Technologies) along with an isotype control (1 µg, Goat anti mouse IgG2a; Biolegend) were
performed on a regular basis to maintain high-quality cells expressing mIgM before performing
each round of SELEX.
The ss-SELEX DNA library binding buffer was heated at 95 ℃ for 5 min and snap cooled
on ice for 30 min before selection. Cells were prepared for SELEX experiments by washing thrice
with the wash buffer; subsequently, they were re-suspended in 100 µL of a cell suspension buffer
(cell binding buffer with 2 g/L BSA) before incubation with 100 µL of an ss-DNA library for 40
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min on ice. The first round of selection was done with 10 x 106 cells and 100 nmol of the ss-DNA
SELEX library.
The supernatant was collected as the unbound fraction. The cells that bound to the library
were washed with wash buffer (10 mL) to remove weak or nonspecifically bound DNA strands.
The bound DNA library was eluted by heating at 95 ℃ for 10 min in 200 µL of DNAse/RNAse
free water. A two-step PCR was employed for the optimization of the PCR conditions, and a largescale PCR was employed to expand the evolved library as reported elsewhere123. A doublestranded, PCR-amplified DNA library was made single-stranded by using avidin agarose beads
(Pierce) and desalted by using NAP-10 columns (GE) as described by Sefah et al.83. For subsequent
SELEX rounds, 250nM of the FITC-tagged ss-DNA library was used from round 2 to round 13.
2.2.5

Flow Cytometric Analysis
The progress of the selection was evaluated by utilizing flow cytometric analysis. The

PCR-amplified DNA library is labeled with fluorescence tag FITC at the 5´ end and analyzed by
a flow cytometric assay. A 250nM FITC-tagged ss-DNA library (25 µL) was incubated with 2.5
x 105 Ramos cells in binding buffer for 40 min on ice. After washing twice with wash buffer (3
mL), the cells were suspended in 500 µL of wash buffer and were analyzed by an FACS Calibur
flow cytometer (Cytek) by counting 10,000 events.
2.2.6

Cell-Binding Assays
The affinities of the aptamer sequences were evaluated by incubating Ramos cells (2.0 x

105) with a series of concentrations of FITC-labeled aptamer in 200 µL of binding buffer on ice
for 60 min. The cells were then washed twice with 1mL of wash buffer at 4 ℃ and reconstituted
in 400 µL of wash buffer. The binding of the constructs was analyzed using flow cytometry by
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counting 5000 events for each concentration. The calculation of Bmax/2 was done by using the
same method as described in Sefah et al.83.
The specific binding of each aptamer was evaluated by incubating Ramos cells (0.5 or 1.0
x 105) and Jurkat.E6 cells (0.5 or 1.0 x 105) with FITC-labeled aptamers of concentrations at 0.5
or 1 µM in 100 µL of cell suspension buffer on ice for 60 min. The cells were then washed twice
with 1mL of wash buffer at 4 ℃ and reconstituted in 250 µL of wash buffer. Aptamer binding was
analyzed using flow cytometry by counting 5000 events for each concentration. As a positive
control, a similar assay was performed by using an Alexa Fluor® 647 labeled anti-IgM antibody
(1 µg, Goat anti human µ-chain; Life Technologies) along with an isotype control (1 µg;
Biolegend).
2.2.7

Ligand-Guided Cell-Selection Protocol
The enriched 13th pool FITC-tagged ss-DNA pool or control zero cycle ss-DNA pool was

heated at 95 ℃ for 5 min and cooled on ice for 20 min. 2.5 x 105 cells were incubated with 250nM
13th SELEX-pool and 25 µL ss-DNA pool for 40 min on ice and washed once with 3mL of wash
buffer. The pre-treated Ramos cells with the 13th SELEX pool were suspended in 50 µL of binding
buffer and then incubated with an Alexa Fluor® 647 goat anti-human IgM antibody (1 µg) for 30
min on ice to compete and elute the potential aptamer candidates. After incubation, the eluted 13th
pool was obtained through competition, which in the supernatant was collected and amplified by
PCR. To ensure the presence of mIgM expressed on Ramos cells, 2.5 x 105 cells were incubated
in parallel with an Alexa Fluor® 647 goat anti human IgM or Alexa Fluor® 647 goat IgG Isotype
antibody for 30 min. After incubation, all the samples were washed and analyzed by FACS Calibur
flow cytometry (Cytek) by counting 10,000 events.
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Two different SELEX libraries generated from; 1) the DNA pool from the SELEX 13th
round specifically enriched against Ramos cells, and 2) the competitively eluted fraction of the
SELEX 13th round by using antibody competition specific for epitopes on the mIgM were cloned
into bacteria by using a TOPO TA cloning kit (Invitrogen), and positive colonies were
subsequently sequenced by the DNA sequencing core facility at Albert Einstein College of
Medicine.
2.2.8

Antigen Specificity
Antigen specificity is determined by the competition between anti-IgM antibody and

aptamers. To investigate the competition between anti-IgM (mu) antibody and aptamers, first, 0.5
µg/mL of APC anti-human CD20 antibody and 0.25 µg/mL of Alexa Fluor® 647 goat anti-human
IgM antibody were incubated with 4 x 105 Ramos cells on ice for 30 min. Then, the free antibody
was washed with 3mL of wash buffer, and cells were reconstituted with 400 µL of cell suspension
buffer. A final concentration of 0.4–0.5 µM of FITC-labeled aptamer or corresponding random
control was incubated in 125 µL of cell suspension buffer for another 60 min on ice. Then, the
cells were washed with 1 mL of wash buffer and binding events were monitored in FL1 for the
aptamer and in FL4 for the antibody counting 5000 events using flow cytometry.
We also conducted blocking experiments with aptamers that had been pre-incubated with
antibody. First, 10 x 104 of Ramos cells were incubated with 1 µM of corresponding aptamer or
random control on ice for 45 min. Then, the preincubated cells with the aptamer or random DNA
were added to serially diluted concentrations from 20 ng/µL to 0.2 g/µL of anti-IgM solution and
allowed free competition for an additional 35 min on ice. Next, the cells were washed twice with
1 and 0.5 mL of wash buffer and re-suspended in 300 µL of wash buffer, and the antibody binding
was analyzed with flow cytometry.
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2.3

Results and Discussion
The selection method is outlined in Figure 2.1. Briefly, the conventional cell-SELEX

method was first employed against Ramos cells that naturally express high levels of the desired
epitope (mIgM). Cell-SELEX was continued until a partial enrichment of the evolved SELEX
library against the target cells was observed83. Next, the partially enriched library was divided into
fractions. The first fraction was PCR amplified, cloned, and sequenced. These sequences are
specific toward target cells (Figure 2.2). An excess of Ab was introduced on the second fraction,
which was pre-incubated with Ramos cells that were subsequently washed to remove nonbinding
sequences, to selectively outcompete and elute potential aptamers that bind to the cognate epitope
less strongly when the anti-IgM Ab is present (Figure 2.1). The sequences outcompeted by Ab
were PCR amplified, cloned, and sequenced. Finally, sequences obtained from DNA sequencing
of two fractions of the SELEX pool were aligned using the ClustalX.2 program and based on set
criteria; specific aptamer candidates against mIgM in target cells were screened and
identified124,125.

Figure 2.1. Schematic representation of ligand-guided selection.
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Figure 2.2. Outline of ligand-guided selection.
The SELEX-library used in the selection has been published elsewhere25. Cell-SELEX was
carried out without incorporating a negative selection, because we hypothesized that if potential
aptamer candidates could be partially enriched toward the desired epitope, that is, mIgM, applying
an antibody against the aptamer would elute these sequences, despite the existence of unrelated
off-target sequences in the partially evolved pool. We first validated the expression of mIgM on
Ramos cell lines utilizing anti-IgM antibody (Figure 2.3).
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Figure 2.3. Flowcytometric analysis of expression of mIgM on Ramos cells. An alexafluor 488
labeled anti-mIgM antibody (1 µg) was incubated with 2.5 x 105 Ramos cells on ice for 45 min.
After washing with 1mL of phosphate-buffered saline and reconstituting in 500 µL of binding
buffer, the sample was analyzed by flow cytometry. Fluorescence intensity on the x-axis for FL1
shifts to a higher value in the presence of the antibody, indicating BCR expression in Ramos cells.
BCR, B-cell receptor complex.
Ten million cells and a high concentration of the initial DNA library were employed during
the first round of selection to increase the probability of capturing potential ‘‘binders.’’ We
detected a partial enrichment of the evolved pool starting at round 13 of the cell- SELEX pool,
compared with the unselected pool (Figure 2.4a). At this point, the remaining round 13 was used
in LIGS. To elute mIgM-specific sequences, we introduced an excess amount of Ab (1 µg) to
compete with the aptamer from the fraction of round 13 of the cell-SELEX pool that was preincubated with Ramos cells followed by a wash to remove nonbinding DNA molecules. The
supernatant containing sequences outcompeted by Ab were then collected. To confirm that the Ab
had, indeed, interacted with mIgM, and to investigate Ab’s effect on aptamer pool 13 fraction-2
binding to Ramos cells, cells after Ab competition were analyzed by flow cytometry (Figure 2.4B
red histogram for binding of SELEX pool round 13 after adding Ab and Figure 2.4C blue
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histogram for binding of anti-IgM Ab). As shown in Figure 2.4B and C, the binding of the antiIgM Ab to its epitope on Ramos cells replaces the binding of some aptamer sequences that are
enriched in the evolved pool. This observation suggests that at least few sequences that are
enriched in the round 13 fraction-2 are eluted by anti-mIgM Ab. Based on the PCR of eluted pool
at this step, we observed that a low number of sequences was eluted during this step, mainly
because: (1) the DNA pool was only partially evolved, with a low number of aptamer copies; (2)
a low number of cells was employed in the LIGS; and (3) Ab competition, which is designed to
selectively elute specific sequences, only generates a low number of specific sequences for one
target epitope.

Figure 2.4. Flow cytometric analysis of evolved library and LIGS. Fluorescence intensity on
x-axis is indicative of binding of fluorescently labeled R10 that evolved round 13 pool or antiIgM. (a) Analysis of binding of evolved pool from round 13 against Ramos cells. At the 13th
round, an increase in fluorescence intensity was observed, indicating that the library was partially
evolved with Ramos-specific DNA aptamer sequences. (b) Pool from round 13 during LIGS,
introduction of anti-IgM Ab to round 13 bound Ramos cells, resulted in decreased fluorescence
intensity. (c) Binding of anti-IgM mAb during LIGS showing Ab binding to Ramos cells (blue
line). LIGS, ligand-guided selection.
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Since the SELEX pool is partially enriched, we cloned and sequenced multiple fractions of
round 13 of the cell-SELEX pool and competitively eluted a fraction of round 13 of the cellSELEX pool. About 500 sequences were obtained from all fractions, which could be categorized
into families based on their sequence homology. We hypothesized that enriched sequences toward
the cell line (Ramos) predominate in the library and have a higher probability in ‘‘surviving’’ the
pool. Therefore, the sequences resulting from sequencing of round 13 of the cell-SELEX pool
would contain all of the sequences that were enriched toward Ramos cells. On the other hand, the
sequences obtained from LIGS would favor the set of sequences selectively eluted by the ligand.
Analysis of the sequences obtained from sequencing of the competitively eluted pool or the cellSELEX round 13 pool showed two types of sequences: (1) Sequences share motifs that are
common to sequences in round 13 of the cell-SELEX pool and the competitively eluted pool. (2)
Sequences are repeated within the competitively eluted library. We focused on both types of
sequences that repeatedly appeared within a family with common motifs from both pools or within
the competitively eluted pool. For example, as shown in Figure 2.5, sequence R10 only appeared
on cell-SELEX round 13; however, a shorter version of a common motif was identified to appear
in the competitively eluted pool. Also, R6, R8, and R1 share a common GGG motif, differing only
in few bases within the motif (Figure 2.5). We also observed the same sequence repeated within
the competitively eluted library (Appendix 1) and within the main cell-SELEX round 13 pool.
Since the scope of this research is to identify sequences that are specific toward mIgM, even though
sequences repeated within the main library might be potential aptamer candidates, we did not
investigate the sequences that did not show any common motifs with competitively eluted
sequences. Based on these criteria, we synthesized and tested 33 different sequences either from
the competitively eluted library or from the main SELEX-library of round 13. Out of 33 sequences,
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27 sequences are from the competitively eluted library and 6 sequences share the same motif as
that of the competitively eluted library but from the cell-SELEX round 13 main pool.

Figure 2.5. Sequence alignment of the major family of LIGS using ClustalX2. Sequences
repeated in the competitively eluted library were synthesized and screened against Ramos cells.
Also, sequences from the main library share common motifs with competitively eluted sequences
that are synthesized and screened against Ramos cells. MainLib, sequences obtained from SELEX13 round; ComLib, sequences obtained from competitively eluted SELEX-13 round. Three
specific aptamer candidates R1, R10, and R15 were evaluated and their Bmax/2 was calculated.

Since the LIGS is predominantly aimed at increasing specificity, individual chemically
synthesized sequences based on set criteria of sequence selection were first tested for specificity.
We used target Ramos cells, which express high levels of mIgM and nontarget Jurkat.E6 cells.
Since Jurkat. E6 cells are human T-cell leukemia that are mainly designed to investigate the T-cell
receptor complex, by definition, these cells do not express mIgM; thus, Jurkat.E6 cells are
comparable to a cell line that does not express the antigen that validates its use as a nonspecific
cell line (126). All specificity assays were done by using FITC-labeled aptamers, and a randomized
DNA sequence was used as a control. Tested aptamer candidates are listed in Table 2.1, and
corresponding histograms of specificity analysis are in Figure 2.6 A and B. Interestingly, we
observed three types of binding patterns within tested 33 sequences: (1) Sequences do not bind to
either Ramos cells or Jurkat.E6 cells, which might be nonspecific amplicons in the library. (2)
Sequences bind to both Ramos and Jurkat.E6 cells, and these sequences might be binding to
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commonly present Fcγ receptors that are present in both types of cells that are eluted by the Ab
competition. (3) Sequences bind to only Ramos cells but not to Jurkat.E6 cells, which might be
specific sequences toward Ramos cells. This suggests that the pool resulting from competitive
elution does not necessarily contain only specific sequences, and screening of individual aptamer
candidates for specificity is needed to identify epitope-specific aptamer candidates. Out of the
tested 33 sequences, we identified three unique sequences that show specificity toward Ramos
cells (Figure 2.7).
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Table 2.1. Tested aptamer candidates for binding specificity against mIgM
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A.
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B.

Figure 2.6. Analysis of binding specificity of aptamers selected using ligand-guided selection against Ramos cells (A) and Jurkat.E6
cells (B). FITC-labeled aptamers and random library were incubated with 1.0 or 0.5 x 105 Ramos cells on ice for 45 min to 1 h. After
washing twice with 0.5 or 1mL of wash buffer, the sample was reconstituted in 250 µL of wash buffer and analyzed by flow cytometry
by counting 5000 events. FITC, fluorescein isothiocyanate.
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Figure 2.7. Analysis of specificity of R1, R10, and R15 aptamers. Specificity of aptamers was
analyzed against mIgM-expressing Ramos cells and mIgM-negative Jurkat.E6.
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The sequences that showed specificity toward mIgM-positive Ramos cells were further
investigated for binding affinity. We evaluated Bmax/2 for the sequences that showed specific
binding. The calculated Bmax/2 for R1, R10, and R15 are in the sub-micro molar range (see
affinity curves in Figure 2.8) against Ramos cells, suggesting that sequences generated using LIGS
show lower affinities. The issue of lower affinities of the identified aptamers could be
predominantly because LIGS was applied to a partially evolved SELEX pool, and the evolution of
sequences was interrupted. Therefore, a partially evolved SELEX pool might contain sequences
with lower to moderate affinities. However, the affinity of these aptamers could be further
enhanced given their high specificity by post-SELEX modification followed by linear
multimerization approaches, as described earlier97. We are currently investigating the effect of the
degree of enrichment of a SELEX pool against whole cells on LIGS to improve LIGS technique.

Figure 2.8. Affinity curves for R1, R10, and R15 aptamers. The affinities of aptamer sequences
were evaluated by incubating Ramos cells (2.0 x 105) with a series of concentrations (0.5 µM to 1
nM) of FITC-labeled aptamers in 200 µL of binding buffer on ice for 45 min to an hour. Cells
were then washed twice with 1mL of wash buffer at 4 °C and reconstituted in 400 µL of wash
buffer. The binding of the constructs was analyzed using flow cytometry by counting 5000 events
for each concentration.
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We further investigated whether the identified specific aptamer candidates compete with
an anti-IgM Ab for the binding site. The validation of the target using competition against the
corresponding antibody has been used earlier80,

87

. We performed competition by first pre-

incubating Ramos cells with anti-IgM Ab or anti-CD20 Ab. CD20 is uniquely expressed in mature,
normal B-cells in early developmental stages. CD-20-positive B-cells are the source of a variety
of B-cell neoplasms, including Ramos cells, which is a B-cell Non-Hodgkin’s Lymphoma.
Therefore, the use of anti-CD20 antibody as a control to investigate the antigen specificity further
confirms the specificity of the aptamers toward mIgM127. Ramos cells pretreated with Ab were
then incubated with individual aptamer sequences. After washing, the binding of each aptamer was
analyzed using flow cytometry. As expected, the introduction of anti-IgM Ab diminished the
binding of the aptamer for R1, R10, and R15 (Figure 2.9A red line), which is indicated by the
diminished binding of each aptamer in the presence of anti-IgM but not when anti-CD20 is present
in the corresponding histograms (Figure 2.9A blue line). R1 and R10 showed substantial
competition with anti-IgM based on the diminished aptamer fluorescence intensity compared with
Ramos cells preincubated with anti-CD20 antibody, whereas R15 did not show substantial
competition, suggesting that the binding of R15 might be stabilized by a secondary epitope that is
specific for Ramos cells. The competition with only anti-IgM but not with anti-CD20 demonstrates
that R10 and R1 are specific for mIgM. Also, we have investigated whether each aptamer can
block the binding of the anti-IgM. Since post-SELEX modification of aptamers is essential to
increase the homogenous fold and to obtain better yields in chemical synthesis, we optimized the
structure of R1 and R10 by systematically truncating bases from 3´ and 5´ ends. We used a
truncated and improved version of R1.1 (Bmax/2 ≈ 82 nM) and R10.T1 (Bmax/2 ≈ 160 nM) for
blocking experiments (see Table 2.1 for sequences of R1.1 and R10.T1). Interestingly, we
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observed that R1.1 blocked at lower concentrations of anti-IgM, but no significant blockage of the
binding of the anti-IgM to Ramos cells was observed at higher concentrations of anti-IgM (Figure
2.9B). We did not observe any significant difference in the binding of anti-IgM when R10.T1 was
present compared with the randomized control. Antibodies are bivalent in nature; therefore, the
avidity of an antibody is higher than monovalent aptamers, and, thus, antibody binding is
kinetically more favored than the aptamers.
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Figure 2.9. Investigation of epitope identity of R1,10 and R15 aptamers. Flow cytometric
competitive binding analysis of R1, R10, and R15 in the presence of IgM (a) and competitive
blocking of anti-IgM binding by R 1.1 (b). Each FITC-labeled library (0.5 µM for R10 and 0.4
µM for R1, and R15) was incubated for 60 min on ice with 1 x 105 Ramos cells that were preincubated with either anti-IgM or anti-CD20 followed by washing with 3mL of wash buffer; they
were subsequently analyzed by flow cytometry. Aptamer fluorescence intensity on the x-axis is
indicative of binding of each aptamer. Thus, an increment of fluorescence intensity directly
translates into aptamer binding to pretreated Ramos cells. When the cells are pre-incubated with
anti-CD20, all three aptamers show an increase in fluorescence intensity (blue line). Aptamer
fluorescence intensity on the x-axis shifts to a lower value in the presence of the anti-IgM antibody
(red line), indicating that the anti-IgM substantially blocks R1, R10 and effects R15 binding to its
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target. No difference in fluorescence intensity was observed for the random control (gray–black),
when Ramos cells were preincubated with anti-IgM antibody or anti-CD20, compared with an unevolved pool from round 0 (black line). Binding of the corresponding antibody indicated in the
lower panel. (b) 10 x 104 Ramos cells were incubated with either the random control or R1.1 for
45 min on ice and added to a serially diluted anti-IgM solution. The competitive blocking was
allowed for an additional 35 min. followed by wash and were analyzed by flow cytometry. FITC,
fluorescein isothiocyanate.
Since we observed a similar pattern of molecular recognition of R10 and R1, we
investigated whether these two aptamers are competing for binding to the same epitope. In doing
so, we incubated fivefold excess of unlabeled R1.1 and fluorescently labeled R10 with Ramos
cells. Washing of unbound aptamer followed by flowcytometric analysis revealed that R1.1
replaces R10, suggesting that the aptamers are binding to the same epitope (Figure 2.10). This
evidence further confirms that the aptamers can be identified by utilizing LIGS binding to the same
epitope on Ramos cells.

Figure 2.10. Investigation of competition between R10 and R1 aptamers. 7.5 x 104 of Ramos
cells were incubated with either fluorescently labeled R10 or a cocktail of fluorescently labeled
R10 and unlabeled R1.1 for 1 h. Cells were washed with 1.5mL of wash buffer, and the binding
of R10 was analyzed by flow cytometry. When R10 alone was incubated with Ramos cells (blue),
aptamer binding was observed. However, when R10 and five times excess of unlabeled R1.1 was
incubated with Ramos cells, the binding of R10 (orange) was diminished, suggesting that R1.1 and
R10 competes to binding to the same protein antigen.
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Theoretically, aptamer interactions are specific toward one target; therefore, the set of
aptamers generated in the end of the cell-based selection are expected to correlate to the altered
levels of molecules in the positive cell line. Using this approach, a number of aptamers had been
selected. We and others have shown that aptamers selected using cell-SELEX compete with the
cognate antibody for binding to its target epitope. For example, the aptamer TD05, selected using
the cell-SELEX method targeting Burkitt’s lymphoma, binds to the heavy chain of
membranebound IgM (mIgM) and competes with the anti-IgM antibody, permitting the bound
aptamer from the target to be eluted into the solution97. Similarly, an RNA aptamer selected against
CD71-expressing cells using the hybrid-SELEX method competes with the anti-transferrin
antibody (87). A cell-SELEX selected aptamer against myeloid leukemia binds to the sialic acidbinding Ig-like lectin protein and competes with its respective antibody128. These reported
observations suggest that the aptamers can bind to a region of the receptor that is close to an Abbinding site. The decrease in aptamer binding when the respective cognate ligand is present can
be due to steric hindrance resulting from the large size or the high affinity of the ligand, eluting
the aptamer, or the structural changes in the receptor protein induced by ligand (Ab) binding. Also,
the bivalent nature of an antibody with favorable kinetic parameters enables antibody binding
compared with monovalent aptamers. It has been already shown that aptamers usually bind to
ligand-binding sites on receptors or to active sites of proteins129,130. Therefore, a partially evolved
cell-SELEX aptamer library can also be utilized to identify epitope-specific aptamers, by simply
using a ligand against the desired target to elute the respective aptamer sequences.
In this study, we selected aptamers against mIgM. The mIgM molecule is considered the
hallmark of B-cells, plays a major role in B-cell development, and is a major player in
transformation of B-cells into malignant B-cells131–133. Also, mIgM plays a major role in
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autoimmune disorders and 95% of human lymphomas originate from B-cells131–133. There is
evidence of activated protein kinase stimulated downstream of B-cell receptor (BCR),
demonstrating the significance of developing therapeutics against BCR131–133. Currently, there are
no successful targeting agents available against mIgM. We have identified three different aptamer
candidates with specificity toward mIgM.
The LIGS is a simple approach for generating aptamers toward predetermined epitopes
expressed on the cell membranes. Previously, it was not possible to select aptamers against
predetermined epitopes of target proteins without post- or pre-SELEX sample manipulation,
demonstrating the novelty and significance of this method. Determination of ligands to outcompete
the specific aptamers could be done based on the application of the generated aptamers. For
example, either ligands could be growth factors interacting with their cognate growth factor
receptors expressed on the cell surface, or the interaction of ligands such as hormones and
neurotransmitters to activate signaling of G-protein-coupled receptors could also be chosen as a
secondary ligand134. Enzyme substrates binding to enzymes, any pre-existing ligand’s interaction
with its cognate receptor could be exploited in LIGS to generate specific aptamers.
In conclusion, we report on a novel strategy, that is, LIGS, for selecting aptamers against
desired epitopes on extracellular receptors using Ab binding as a model ligand. This simple method
could also be modified and utilized as a selective screening platform not only to select aptamers
but also in phage-display libraries, peptide libraries, and small-molecular libraries to identify
artificial molecules toward active sites of macromolecules utilizing pre-existing molecular and
cellular interactions as a guide.
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Chapter 3: Ligand-guided selection of aptamers against T-cell Receptor cluster of
differentiation 3 (TCR-CD3) expressed on Jurkat.E6 cells
Disclaimer: Reprinted (adapted) with permission from: Analytical Biochemistry, 512, Zumrut,
H.E., Ara, M.N., Maio, G.E., Van, N.A., Batool, S., and Mallikaratchy, P.R., Ligand-guided
selection of aptamers against T-cell Receptor-cluster of differentiation 3 (TCR-CD3) expressed on
Jurkat.E6 cells, 1-7., Copyright © Elsevier Inc. 2016 91.

3.1

Introduction
DNA aptamers are small synthetic nucleic acid strands that specifically bind to a target

molecule with high affinity5,6. The method of aptamer selection known as SELEX (Systematic
Evolution of Ligands by Exponential enrichment) was originally introduced by two independent
groups5,6. SELEX screens short single-stranded oligonucleotides against a variety of target ligands
via an iterative and evolutionary process of continuous enrichment to identify target-specific
binders. A typical SELEX library is vastly heterogeneous with a large number of distinct nucleic
acid molecules (~approximately 1013 molecules). Each molecule folds into a unique secondary
structure, which leads to a distinct geometrical shape. Depending on shape complementarity and
noncovalent electrostatic or hydrophobic interactions, a few nucleic acid sequences can
specifically bind to the desired target. Subsequently, bound sequences are separated and amplified
using Polymerase Chain Reaction (PCR) to generate an evolved library. The process is repeated
until high-affinity binders are enriched, resulting in a homogeneous library with high-affinity
nucleic acid aptamers against the target of interest.
SELEX has resulted in generating a significant number of aptamers against targets ranging
from small molecules to whole cells; however, translational applications of aptamers have been
limited135. Therefore, steps to improve SELEX have been introduced, for example, cell-SELEX,
which was introduced as a method to select aptamers against membrane receptors in their
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endogenous state24. In addition, a bead-based selection method has been introduced to increase
selection diversity aimed at generating therapeutic aptamers122. To expand target specificity,
“internalizing cell-SELEX technology” and hybrid-SELEX have also been introduced. HybridSELEX incorporates the enrichment of the SELEX library against the purified protein target first,
followed by cell-SELEX, utilizing cells that express the same protein, while cell-internalizationSELEX is designed to select aptamers towards RNA molecules capable of internalizing into
cells123,136,137. To increase the clinical practicality of aptamer selection, development of methods
to identify aptamers able to specifically recognize predetermined epitopes in their endogenous
state with no prior- or post SELEX sample manipulations on receptor proteins would be most
desirable.
To address this, we recently developed a method called Ligand-guided Selection, (LIGS),
which selects aptamers that specifically bind a predetermined epitope expressed on the target cell
surface93. LIGS takes advantage of the partition step in cell-based SELEX and introduces a
secondary, pre-existing high-affinity ligand, in effect a monoclonal antibody (mAb), to
outcompete and elute specific aptamers binding to the receptor target of the antibody, not the cell.
Conventional SELEX is designed to winnow out low-affinity binders through a competitive
process whereby high-affinity binders move on by repeated rounds of partition and amplification
through the selection process. We hypothesized that the addition of a secondary stronger specific
ligand in excess against a specific epitope of interest will selectively outcompete specific aptamers
competing to bind to the same epitope or a related epitope from an evolved pool pre-incubated
with the whole cell. Therefore, at a partial enrichment stage in the cell-SELEX iterative process,
LIGS interrupts the process and exploits this competitive selection by introducing a stronger,
known high-affinity ligand against a specific protein receptor (epitope) target of interest in order
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to 1) directly outcompete and replace aptamers specific towards the target of interest and, more
importantly in terms of LIGS, 2) elute aptamers resulting from conformational changes induced
through the interaction of the secondary ligand with its target epitope at its endogenous state.
Therefore, based on the specificity of a natural pre-existing ligand towards its target and the
conformational changes induced through antibody-protein receptor binding, the aptamers
identified by LIGS are expected to show higher specificity towards the target protein or a protein
co-expressed with the target protein compared to those aptamers evolved as binders through cellSELEX (Figure 3.1).

Figure 3.1. LIGS. Conventional cell-SELEX is ﬁrst employed against target cells until a partial
enrichment of DNA aptamer library is achieved. Next, the partially enriched library is divided into
fractions. The ﬁrst fraction is PCR-ampliﬁed, cloned and sequenced. These sequences are enriched
towards target cells. An excess of mAb is then introduced on the second fraction, which is
preincubated with target cells to selectively outcompete and elute potential aptamers that would
tend to bind to the cognate epitope less strongly compared to mAb. The sequences outcompeted
by antibody are next PCR-ampliﬁed, cloned, and sequenced. By virtue of antibody-cognate epitope
binding, these LIGS-generated sequences are speciﬁc towards the target surface protein of the
antibody. Finally, sequences obtained from DNA sequencing of both fractions are aligned using
the ClustalX.2 program, and based on set criteria, speciﬁc aptamer candidates against respective
epitopes on the target cells are identiﬁed.
Here, we utilized LIGS to identify aptamers against CD3ε expressed on Jurkat.E6 cells
from a partially enriched SELEX library. Using high-affinity anti-CD3 antibody against a specific
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epitope on the CD3ε chain as the secondary ligand, we successfully identified three specific
aptamers against CD3ε, one of the domains of the T-cell Receptor (TCR) complex expressed on T
lymphocytes. CD3ε is one of the ectodomains of the TCR complex expressed on T-cells. The TCR
complex is a multidomain, transmembrane protein consisting of an αβ heterodimer and both
CD3εγ and CD3εδ ectodomains. The main αβ heterodimer consists of a variable and constant
domain, while the CD3ε domain is conserved and non-glycosylated, making CD3ε an attractive
target for aptamer development109.
3.2

Materials and Methods

3.2.1 Cell Culture
Cell lines, Jurkat.E6 (T lymphocyte) and Ramos (Burkitt's lymphoma), HL60 (Myeloid
Leukemia) were generously provided by David Scheinberg and Morgan Huse labs, Memorial
Sloan Kettering Cancer Center. All cells were cultured in RPMI 1640 medium supplemented with
100 units/mL penicillin-streptomycin and 10% fetal bovine serum (heat-inactivated; Invitrogen).
Cell lines were validated by flow cytometric assays utilizing antibodies against surface markers
uniquely expressed on each cell line.
3.2.2

DNA Synthesis and Buffer Formulations
Washing buffer was composed of 1x DPBS containing 4.5 g Glucose/ 1 L and 5 mL of 1

M MgCl2 /1 L. DNA Binding Buffer (DB) was composed of 1x DPBS containing 4.5 g Glucose/1
L, 5mL of 1M MgCl2 /1 L, and 100 mg/1 L tRNA. Cell Suspension Buffer (CSB) was composed
of 1x DPBS containing 4.5 g Glucose /1 L, 5 mL of 1 M MgCl2 /1 L, 100 mg /1 L tRNA, and 2 g
/1 L BSA.
All of the DNA reagents needed for DNA synthesis were purchased from either Glen
Research or ChemGenes. The DNA oligo sequences were chemically synthesized with a FAM-dT
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at the 30-end using standard solid phase phosphoramidite chemistry on an ABI394 DNA
(Biolytics) synthesizer using a 0.2 µmol scale. Aptamer candidates were synthesized in house
using a solid phase DNA synthesizer according to the manufacturer's protocol (Applied
Biosystems, Inc. Model 394). The completed DNA sequences were deprotected using conditions
required for modifications and purified using HPLC (Waters) equipped with a C-18 reversed phase
column (Phenomenex). DNA concentration was determined by a UV-VIS spectrophotometer
(Thermo Scientific; Evolution 300) and stored in DNA Binding Buffer (DB) at -20 °C.
3.2.3

Cell-SELEX Procedure
We routinely conducted PI staining of the cells and flow cytometric analysis of CD3ε

expression utilizing PE-labeled anti-CD3ε antibody (BD Pharmingen mouse antihuman) along
with an isotype control (mouse IgG1, BioLegend) to ensure high-quality cells expressing CD3ε
prior to performing each round of SELEX.
The ss-SELEX DNA library in DB buffer was heated at 95 °C for 5 min and “snap-cooled”
in ice for 30 min prior to selection. Cells were washed three times with the wash buffer to remove
cell debris and apoptotic cells and subsequently re-suspended in 100 µL of a cell suspension buffer
prior to incubation with 100 µL of an ss- DNA library for 40 min on ice. The first round of selection
was done with 7 x 106 cells and 100 nmol of ss-DNA SELEX library.
Cells that bound to the library were washed with wash buffer (12 mL) to remove weak or
nonspecifically bound DNA strands in the first round. The bound DNA library was eluted by
heating at 95 °C for 10 min in 200 µL DNAse-/RNAse-free water. A two-step polymerase chain
reaction (PCR) was employed to expand the evolved library as reported elsewhere (25). A singlestranded DNA was made using avidin agarose beads (Pierce) and desalted using NAP-10 columns
(GE) as described by Sefah et al.83. Subsequent SELEX was performed as described in Chapter 2.
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3.2.4

Ligand-Guided Cell-Selection Protocol
Ligand Competition: As introduced in Chapter 2 LIGS was used to selectively elute

aptamers against TCR complex 93. Briefly, the enriched 16th library of ss-DNA cell-SELEX was
folded by heating and subsequent cooling for 20 min. Then, 1 x 105 cells were incubated with 250
nM 16th cell-SELEX-round ss-DNA of 25 µL for 40 min in ice and washed twice with1 mL and
0.5 mL wash buffer. Pretreated Jurkat.E6 cells with the 16th SELEX-pool were suspended in 50
µL of binding buffer and then incubated with (2.5 L) of APC mouse anti-human CD3 antibody
(BD Pharmingen; cat. no. 555342) 40 min on ice to compete and elute the potential aptamer
candidates. Following incubation, the eluted 16th fraction obtained through competition and found
in the supernatant was collected and amplified by PCR. A two-step PCR was performed as
described in Chapter 2. First, the whole fraction resulting from LIGS was amplified using 10-PCR
cycles. Then, a second PCR was employed, and the number of cycles was optimized to obtain
adequate yields necessary for the cloning step. To ensure the presence of CD3ε expressed on
Jurkat.E6 cells, 10 x 105 cells were incubated in parallel with an APC mouse anti-human CD3
antibody (BD Pharmingen; cat. no. 555342) or isotype control (APC mouse IgG1-k, BioLegend;
cat. no. 400121). 1 µl antibody/isotype was added per 1 x 105 cells and incubated at 4 °C for 30
min in cell suspension buffer. After incubation, all samples were washed and then analyzed by
FACSCalibur™ (Cytek) by counting 10,000 events.
Two different SELEX libraries were generated: 1) the DNA pool from the SELEX-16th
round specifically enriched against Jurkat.E6 cells and 2) the competitively eluted fraction of the
SELEX-16th round using ligand competition. These were both cloned into a bacterial cloning
system using a TOPO TA cloning kit (Invitrogen), and positive colonies were subsequently
sequenced by the DNA sequencing core facility at Albert Einstein College of Medicine.
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3.2.5

Specificity Assays
Assays conducted with individual aptamers were analyzed against a HPLC-purified FAM-

dT

labeled

random

DNA

(60mer)

control

with

the

sequence:

NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNN-NT purchased from IDT DNA technologies. The Cy5 labeled aptamers J4.1, J14.1 and
J7 were purchased from IDT-DNA technologies. Randomized Cy5 labeled aptamer construct
(approximately 70 in length) was use as a control. The specificity assays were performed by
incubating 50 µL of either aptamer or random control with 50,000 cells on ice for 1 h, followed
by washing twice with (750 µL each time) with wash buffer. The cells were then suspended in 250
µL wash buffer and binding was analyzed by flow cytometry.
The bindings of the aptamer sequences were evaluated by incubating Jurkat.E6 cells or
Ramos cells or HL 60 cells (~50-75 x 103) with FAM-dT-labeled aptamer in 100 µL of binding
buffer on ice for 45 min. The cells were then washed with 1.5 mL of wash buffer at 4 °C and
reconstituted in 250-300 µL of wash buffer. The binding of the constructs was analyzed using flow
cytometry by counting 5000 events for each concentration.
3.2.6

Determination of the Apparent Dissociation Constant of Aptamers
Using binding buffer, six different working concentrations of the aptamer and control

library were prepared: 1) 1000 nM, 2) 500 nM, 3) 250 nM, 4) 125 nM, 5) 20.8 nM, and 6) 3.46
nM. Cells were prepared for flow cytometry analysis by washing three times with wash buffer. 75
x 103 cells were incubated with each aptamer concentration and random library for 40 min on ice.
After washing cells with 1.5 mL of wash buffer, the cells were analyzed with the FACSCalibur™
flow cytometer by counting 5000 events. FlowJo software was used to determine median
fluorescence intensity for each concentration of aptamer sample and random control. Median
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fluorescence intensity of random control was subtracted from corresponding median fluorescence
intensity of each aptamer concentration. This assay was done in triplicate. Bmax/2 was calculated
using the method described in Sefah et al.83.
3.2.7

Competition Assay with Individual Aptamer Molecules
Fluorescently labeled 1 µM aptamer (50 µL) was incubated on ice with 75 x 103 Jurkat.E6

cells for 45 min. Then anti-CD3ε HIT3a clone (0.75 ng/µL) or anti-TCRαβ (0.1 µg/µL) was added
and incubated for an additional 45 min. At the end of incubation, cells were washed with 1.5 mL
of wash buffer and reconstituted in 300 µL of wash buffer. Binding of aptamer and antibody was
analyzed by flow cytometry.
3.3

Results and Discussion

3.3.1

Cell-SELEX against Jurkat.E6 cells followed by LIGS
To begin, the expression of CD3ε on Jurkat.E6 cells was confirmed by flow cytometry

using a fluorescently labeled anti-CD3ε antibody (Figure 3.2). The selection library consisted of
45 randomized nucleotides flanked by two primers, as reported in Tang et al.25, but PCR conditions
were further optimized to ensure high PCR efficiency of the library. The first round of cell-SELEX
employed approximately 7 million Jurkat.E6 cells to ensure that all potential binders were retained.
A total of 5 million cells were then used during the second round of selection, but the number of
cells used in cell-SELEX was decreased to 2.5 million in subsequent rounds to increase the
stringency of the selection. Again, we followed the cell-SELEX protocol described in Tang et al.25,
who showed that aptamers could be enriched towards a single cell type without incorporating
negative selection. Since LIGS is designed to selectively elute specific aptamers using a secondary
pre-existing ligand, anti-CD3ε mAb, in this example, we hypothesized that off-target sequences
would not hinder the selective elution of specific aptamers. We monitored the enrichment of the
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library first at the 5th round of cell-SELEX, continuing with five more rounds to enrich potential
aptamer sequences. After round 10 of cell-SELEX, we monitored the progress of the selection
every two rounds (Figure 3.3). We observed a significant enrichment against Jurkat.E6 cells at
round 16 compared to earlier rounds based on FACS analysis (Figure 3.4-A). At this point, cellSELEX was stopped, and LIGS was introduced to a fraction of round 16 from cell-SELEX. We
interrupted cell-SELEX at the very early stage of enrichment, as indicated by low fluorescence
shift for pool 16 (Figure 3.4-A). In such partially enriched library, it was hypothesized that
concentrations of individual sequences would be very low, below their Kd, and thus well suited
for competitive elution.

Figure 3.2. Flow cytometric analysis of expression of CD3ε on Jurkat.e6 cells. PE-labeled antiCD3ε antibody (2.5µL) incubated with 2.5 x 105 Jurkat.E6 cells on ice for 45min. After washing
with 1mL of PBS and reconstituting in 500uL of binding buffer, the sample was analyzed by flow
cytometry. Fluorescence intensity on the x-axis for FL1 shifts to a higher value in the presence of
the antibody, indicating CD3ε expression on Jurkat.E6 cells.
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Figure 3.3. Flow cytometric analysis of the enrichment of cell-SELEX pool against Jurkat.E6
cells. Each round of cell-SELEX was analyzed against a random library from 0 round by
incubating 250 nM of either library or the random control in DB with 1-2 x 105 cells suspended in
CSB for 1 hour on ice. Cells were washed with 1.5mL wash buffer and reconstituted in 300-500
µL of wash buffer for flow cytometric analysis.
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Figure 3.4. Flow cytometry of evolved library and LIGS. Fluorescence intensity on X-axis
indicates the binding of ﬂuorescently labeled evolved round 16 pool, or anti-CD3ε HIT3a clone.
(A) Analysis of binding of cell-SELEX round 16 (blue line) against Jurkat.E6 cells. The
background binding was analyzed utilizing a random DNA pool from the 0th round (gray). (B)
Cell-SELEX round 16 incubated with Jurkat.E6 cells and addition of anti-CD3ε HIT3a clone.
Supernatant was collected after introduction of LIGS, and cells were analyzed for binding for
round 16 of cell-SELEX after adding antibody. Fluorescence intensity corresponding to round 16bound Jurkat.E6 cells was decreased (dashed blue line) in comparison to round 16 without
antibody, suggesting that some sequences had, indeed, been outcompeted by antibody-receptor
binding. (C) Analysis of anti-CD3ε HIT3a clone binding to Jurkat.E6 cells (solid red line absence,
and the dashed red line presence of cell-SELEX round 16).
Accordingly, for the first step of LIGS, a total of 1 x 105 Jurkat.E6 cells were prewashed
with wash buffer and incubated 40 min with 6.25 pmol of round 16 of cell-SELEX. After
incubation, cells were washed twice, first with 1 mL wash buffer and then 0.5 mL wash buffer, to
remove unbound DNA molecules. Next, cells were reconstituted in 50 µL cell binding buffer, and
2.5 mL of anti-CD3ε HIT3 clone were added. Competitive elution of CD3ε-specific aptamers by
the antibody was allowed for 40 min on ice. Following incubation, cells were spun down, and
supernatant containing competitively eluted aptamers was collected. Cells were analyzed after
LIGS to confirm the interaction of anti-CD3ε HIT3a clone with CD3ε on Jurkat.E6 cells (Figure
3.4-C). We also, observed slightly decreased fluorescence intensity on the round 16 X-axis of cellSELEX binding to Jurkat.E6 after LIGS (Figure 3.4-B; compare solid blue versus dashed blue
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lines), suggesting that some of the potential specific DNA aptamer sequences may have been
replaced by the addition of the antibody.
Supernatant containing competitively eluted potential DNA molecules from LIGS were
then PCR-amplified. To ensure that all copies of competitively eluted potential DNA aptamers
were adequately amplified, a two-step PCR process was conducted. Finally, two libraries were
cloned into bacterial vector using TOPO TA cloning and subjected to DNA sequencing: round 16
of cell-SELEX, consisting of sequences enriched towards Jurkat.E6 cells and competitively eluted
pool, consisting of sequences specific for CD3ε.
3.3.2

Analysis of sequences generated from LIGS
Sequences were analyzed using ClustalX.2124, and results revealed an enrichment pattern

similar to that of an evolved cell-SELEX library (see the sequence alignment in Appendix 2).
Specifically, analysis revealed multiple copies of the same sequences, or repeated motifs shared in
common, but interrupted by segments of DNA bases unique to each sequence. Next, alignment
was performed on the competitively eluted sequences from LIGS and sequences from round 16 of
cell-SELEX containing all sequences evolved towards Jurkat.E6 cells. Three homologous patterns
were observed between the two libraries: 1) repetition of the same sequences within the pool
unique to the respective libraries; 2) repetition of the same sequences in both competitively eluted
library and round 16 of cell-SELEX library; and 3) repetition of sequences with common motifs
in both libraries (Appendix 2). In the case of 3), even though sequences were derived from two
different pools, they shared a common motif, differing only by a few bases (Figure 3.5, aptamer
J7). We hypothesized that specifically enriched sequences towards the Jurkat.E6 cell line would
dominate the library and that after subsequent cloning and DNA sequencing steps, these sequences
would still predominate such that round 16 of cell-SELEX library would contain all sequences

57

enriched towards Jurkat.E6 cells. Very importantly, however, the sequences obtained from LIGS
would favor sequences selectively eluted by anti-CD3 antibody binding to CD3ε epitope, or one
of the components of TCR. Therefore, we focused on the sequences that repeatedly appeared
within a family with common motifs from the two different pools. Since the objective of this study
is aimed at selecting the aptamers with most binding specificity based on LIGS, only the sequences
competitively eluted by anti-CD3ε antibody sharing common motifs within the library, or with
round 16 of cell-SELEX library, were selected for synthesis.

Figure 3.5. Sequence alignment of three hits: J14, J7 and J4. The sequences from Ligandguided Selection and sequences from Cell-SELEX round 16 were aligned using ClustalX2.
MainLib: sequences obtained from Cell-SELEX-round 16; ComLib: sequences obtained from
competitively eluted library (LIGS). The three speciﬁc aptamer candidates, including J4, J7 and
J14, were evaluated based on set criteria for selection and calculated Bmax/2.
3.3.3

Analysis of Specificity
A total of 27 individual sequences were synthesized with FAM-dT at the 30-end using

standard phosphoramidite solid-state synthesis, followed by reversed phase HPLC purification.
We first investigated aptamer specificity by analyzing the binding of individual fluorescently
labeled aptamers with Jurkat.E6, using Burkitt's lymphoma cell line Ramos as the negative control
cell line. Burkitt's lymphoma, which is from the B-cell lineage, does not express TCR-CD3
complex; therefore, sequences that do not bind to Ramos cells would be specific for TCR
complex131. Interestingly, out of 27 tested sequences (Figure 3.6), three sequences, J4, J7 and J14,
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showed specificity against Jurkat.E6 cells, but not control Ramos cells. In order to maximize the
fluorescence shifts observed for aptamer binding, we also analyzed the Cy5 labeled aptamers
binding towards Jurkat.E6 cells. The Cy5 labeled showed higher shifts than that of FAM-dT
labeled aptamers (Figure 3.7A).
A.
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B.

Figure 3.6. Analysis of binding specificity of aptamers selected using Ligand-guidedSelection against Jurkat.E6 (A) and Ramos cells (B). FITC-labeled aptamers and random library
were incubated with 1.0 or 0.75 x 103 Jurkat.E6 cells or Ramos cells on ice for 45 min-1 hr. After
washing with 1.5 mL of wash buffer and reconstituting the sample in 200-300 µL of wash buffer,
flow cytometry was performed by counting 5000 events.
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Figure 3.7. Binding of three speciﬁc aptamers identiﬁed in the validation assay. Aptamer
binding to Jurkat.E6 cells using Cy5 labeled aptamers (A) and analysis of speciﬁcity against
Ramos cells using FAM-dT labeled aptamers (B) from overall conclusions of data for three
different independent experiments with Y axis = ((MFI aptamer-MFI random/MFI aptamer)*100),
MFI = Median Fluorescence Intensity. Binding analysis was done by using a 1 mM solution of
respective aptamers against 50-75 x 103 cells, which were incubated for 1 h at 4 °C and
subsequently washed twice with wash buffer prior to ﬂow cytometry for binding analysis.
Twenty-four tested sequences from the competitively eluted library either bound to both
Jurkat.E6 cells and Ramos cells or did not bind to either cell line. Sequences not binding to either
cell line could be nonspecific background sequences from the partially evolved cell-SELEX pool,
or they might be sequences with high off-rates contaminating the LIGS pool. The sequences
binding to both cell lines might be targeting receptors common to both cell lines. Following this
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validation step, we focused on the three positive hits for further analysis of affinity and antigen
specificity.
3.3.4

Analysis of Affinity of J7, J4.1 and J14.1
During post-SELEX structure-activity relationship studies, it has been shown that

truncation of full-length aptamer is essential to optimize fold and increase affinity97. Therefore, in
order to maximize the most favorable fold of our LIGS aptamers, we systematically truncated from
the 3´ and 5´ ends of J4 and J14 (truncated J4.1 and J14.1 in Table 3.1) for use in later studies. All
three sequences were analyzed in triplicate for their binding constant against Jurkat.E6 cells. We
observed considerably high Bmax/2 for J14.1, suggesting that J14.1 approached high specificity
against Jurkat.E6 cells, but not affinity, while J4.1 and J7 showed comparable binding affinities to
aptamers generated from cell-SELEX in other reports25, suggesting that aptamers J4 and J7
approached affinity and specificity towards CD3-positive Jurkat.E6 cells (Figures 3.6 and 3.8).
This example and that of Zumrut et al.93 show much less aptamer affinity than aptamers selected
from cell-SELEX. This could be explained by the interruption of cell-SELEX at a partially
enriched stage, in accordance with the standard LIGS procedure, thus blocking the complete
evolution of aptamers. Therefore, we are currently investigating degree of enrichment as a function
of affinity of sequences eluted using LIGS.
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Table 3.1. Tested aptamer candidates for binding specificity against CD3ε
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Figure 3.8. Affinity curves for J4.1, J7 and J14.1 aptamers. The affinities of aptamer sequences
eluted from LIGS were evaluated by incubating Jurkat.E6 cells (75 × 103) with a series of
concentrations (1 µM to 20.8 nM) of FITC- labeled aptamer in 100 µL of binding buffer on ice for
45 minutes to one hour. Cells were then washed once with 1.5 mL of wash buffer at 4 °C and
reconstituted in 400 µL of wash buffer. The binding of the constructs was analyzed using flow
cytometry by counting 5,000 events for each concentration. Bmax/2 was calculated by the method
described in Sefah et al., using one-site saturation binding kinetics83.

3.3.5

Analysis of Binding Specificity of J4.1, J14.1 and J7 towards CD3ε
Next, we investigated the specificity towards the epitope on CD3ε by utilizing competitive

binding experiments against anti-CD3ε antibody, which was used in LIGS. Anti-TCRαβ antibody
was employed as a control to investigate if aptamer binding would be affected by adding the
epitope-specific secondary anti-CD3ε HIT3a clone. Antibody displacement assays have
previously been used as a valid tool to confirm epitope-specific aptamers selected against whole
cells80,87,128. Here, 50 pmol of aptamer and equal number of pmol of random sequences were
incubated with 75,000 cells for 40 min at 0 °C. Then, either anti-CD3ε HIT3a clone or anti-TCRαβ
antibody in excess was added to allow competitive binding for an additional 40 min. Cells were
subsequently washed and analyzed for aptamer binding using flow cytometric assay (Figure 3.9).
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Figure 3.9. Epitope identity. Flow cytometric competitive binding analysis of J4.1, J7 and J14.1
without (A) or with anti-CD3ε (B) or with anti-TCRαβ antibody (C) and overall conclusion from
data presented in A, B and C from two independent experiments normalized to the aptamer binding
to Jurkat.E6 cells with no added antibody (D). Each FAM-dT-labeled random control or J4.1, J7
or J14.1 (1 µM) was incubated for 40 min on ice with 75 x 103 Jurkat.E6 cells. Then, binding
buffer or anti-CD3ε HIT3a clone (panel B) or anti-TCRαβ antibody (panel C) was added and
incubated for an additional 40 min. The cells were washed with 1.5 mL of wash buffer and the
binding of respective aptamer analyzed by ﬂow cytometry. Aptamer ﬂuorescence intensity on Xaxis indicates the binding of each aptamer. Thus, increment of ﬂuorescence intensity can be
directly compared to baseline random control as an indicator of aptamer binding. Aptamer
ﬂuorescence intensity on the X-axis shifted to background when anti-CD3ε HIT3a was added to
all three aptamers preincubated with Jurkat.E6 cells, and binding of J7 and J14.1 was affected
when anti-TCRαβ antibody was added. On the other hand, no difference in ﬂuorescence intensity
was observed for random control (gray-black); therefore, competitive binding experiments against
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aptamer J7, J4.1 and J14.1 using anti-CD3ε antibody showed that the stronger binder to CD3ε,
effectively displaces all three aptamers.
The displacement assay, as illustrated in Figure. 3.10, suggested the variability and loss of
binding of LIGS aptamer candidates when either anti-CD3ε or anti-TCRαβ antibody, as secondary
ligands, was added to aptamer-bound Jurkat.E6 cells. In the presence of both anti-CD3ε antibody
and anti-TCRαβ antibody, aptamer J7 completely lost its binding affinity, as indicated by the
decrease in fluorescence shift for aptamer binding on the X-axis. To account for this, it is possible
that conformational changes induced by anti-TCRαβ or anti-CD3ε upon binding the TCR-CD3
complex weakened the J7-TCR complex, resulting in displacement of the aptamer. In contrast,
when anti-CD3ε, but not anti-TCRαβ, antibody was added, binding of aptamer J4.1 was lost,
suggesting that aptamer J4.1 bound to an epitope unique to CD3ε in a manner independent of antiTCRαβ. Finally, aptamer J14.1 lost binding affinity when anti-CD3ε was added and only slightly
when anti-TCRαβ antibody was added. Fluorescence shift on the X-axis is very high by the
addition of antibodies, most likely because one antibody contains multiple fluorophores, leading
to higher signal (Figure 3.10). Taken together, all three aptamers, including J7, J14.1, and J4.1,
showed binding affinity to Jurkat E6 cells.
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Figure 3.10. Binding of anti-CD3ε HIT3a clone (left) and anti-TCRαβ (right) to Jurkat.E6
cells in the presence of respective aptamer (solid line) or random control DNA (dashed line) during
competition assays for J7(A), for J 4.1(B) and for J 14.1 (C).
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Importantly, however, when anti-CD3ε was added, all three aptamers lost their binding to
Jurkat.E6 cells as the aptamer fluorescence intensity on the X-axis shifted to background
suggesting the specificity of aptamers generated by LIGS towards CD3ε. Therefore, these findings
prove that LIGS can be utilized to identify aptamers specific to a predetermined epitope, or closely
related epitope, from a multiple-domain complex, in this case TCR-CD3 complex, on the target
cell, Jurkat.E6 cells.
Aptamers are synthetic molecules; therefore, their shelf-life is longer, and they are stable
against heat and compatible with a variety of solvents117. Initially, aptamers were selected using
SELEX against purified proteins in solution. However, these aptamers have shown limited
applicability by their failure to identify endogenous protein targets in vitro and in vivo, as noted
above138. The breakthrough cell-SELEX83,119 allows the selection of aptamers towards membrane
receptor targets in their native state at their endogenous levels with no prior requirement for the
overexpression of a protein. Nevertheless, proteomic identification of the receptor protein ligand
of aptamers generated from cell SELEX is a challenge. With such limitation, therapeutic and
diagnostic applications of aptamers remain challenging. Therefore, to address this challenge, we
have introduced LIGS, a simple technique to selectively separate aptamers binding to a specific
epitope using a secondary ligand specific to the same epitope. From a fundamental point-of view,
LIGS technology pushes separation efficiency to a remarkably high level. That is, the competition
strategy allows us to separate out a few aptamer molecules that bind to a specific site of a specific
receptor molecule in its endogenous state from a complex library evolved against a whole cell.
Since the aptamers selected using LIGS are selectively eluted based on the interaction of the
secondary ligand with its target at its endogenous state, LIGS-generated aptamers will have higher
potential in identifying the same receptor in a clinical setting. Moreover, apart from selecting
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aptamers against epitopes in a multidomain protein complex, LIGS can be applied to a number of
platforms, including peptide libraries. LIGS-generated aptamers can also be selected toward a
small-molecule ligand-binding site, utilizing small molecule ligand-receptor interaction as a guide.
In conclusion, by using an antibody against one of the domains of multi-domain complex,
we have shown that specific aptamers could be selectively eluted, demonstrating the significance
of LIGS in generating highly specific nucleic acid ligands toward a broader range of receptor
molecules already characterized as surface markers. LIGS can be differentiated from other
SELEX strategies because it selectively outcompetes a set of already partially enriched cellSELEX aptamers against a predetermined epitope at their endogenous native state by ligandreceptor, i.e., antibody-protein receptor, interactions. This approach can be extended to a number
of combinatorial screening platforms, including phage display libraries and small-molecule
libraries.
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Chapter 4: Structural optimization of an aptamer generated from Ligand-Guided Selection
(LIGS) resulted in high affinity variant toward mIgM expressed on Burkitt's lymphoma
cell lines
Disclaimer: Reprinted (adapted) with permission from: Biochimica et Biophysica Acta (BBA) General Subjects, 1861 (7), Zumrut, H.E., Batool, S., Van, N., George, S., Bhandari, S., and
Mallikaratchy, P.R., Structural optimization of an aptamer generated from Ligand-Guided
Selection (LIGS) resulted in high affinity variant toward mIgM expressed on Burkitt's lymphoma
cell lines, 1825-1832., Copyright © Elsevier Inc. 2017 139.
4.1

Introduction
Aptamers are synthetic, short nucleic acid molecules capable of specific target

recognition140. Based on their ability to self-assemble via intra- and intermolecular interactions
leading to unique three-dimensional conformations, aptamers can specifically bind to a wide range
of target molecules. Some of these molecules do not contain endogenous binding sites towards
nucleic acid ligands141. Versatility in synthesis, coupled with facile chemical manipulation, makes
aptamers attractive in designing molecular tools for biomedical applications31,117. Aptamers
possess two attributes that contribute to their potential success in designing molecular tools. First,
their small, compact structure enables the design of multi-specific molecular modulators without
significantly altering pharmacokinetics properties in vivo. Second, their synthetic nature affords
compatibility with a variety of functionalities enabling precise manipulation. Aptamers are
identified using an in vitro selection method known as Systematic Evolution of Ligands by
Exponential enrichment, or SELEX. SELEX isolates and enriches high-affinity binders from a
library of nucleic acid molecules against a target5,6. The process involves three stages: target
binding, separation of high- from low-affinity binders, and amplification to multiply copies of
binders with the highest affinity5,6. Finally, a library of nucleic acid molecules is evolved into a
pool of high-affinity binders against the target utilized in the selection and finally identified as
aptamers.
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Recently, much progress has been made to improve the selection of aptamers against
complex targets75,85. For example, cell-SELEX technology was introduced utilizing whole cells,
demonstrating the adaptability of SELEX in generating aptamers against cell-surface receptors at
their native environment23,24,119. In particular, the use of endogenous membrane protein receptors
in their native state is preferable to their purified form based on reduced solubility and
susceptibility to misfolding85. Undeniably, such precise targeting is essential in developing
therapeutic and diagnostic molecules. To this end, we introduced a variant of SELEX called
“Ligand-Guided Selection” (LIGS) that allows the identification of specific aptamers against
known (i.e., SELEX) cell-surface proteins91,93. In particular, LIGS identifies aptamers specific for
a predetermined epitope expressed on the cell surface at its native environment. In terms of
protocol, LIGS interrupts the selection process of SELEX and introduces a strong, high-affinity
bivalent antibody (Ab), which interacts with its cognate epitope to outcompete and replace specific
aptamers from an enriched SELEX pool91, 93. Therefore, based on the specificity of a natural preexisting ligand towards its target, the aptamers identified by LIGS are expected to show higher
specificity towards the target ligand than those succeeding as target-specific binders via the typical
cell-SELEX route91,93.
Utilizing LIGS, we recently introduced three specific aptamers against membrane-bound
IgM (mIgM), which is the hallmark of B-cells93. Out of the three aptamers selected against mIgM,
an aptamer termed R1, in particular, was found to be interesting by its ability to recognize mIgM
on target cells and then block anti-IgM antibodies binding their antigen. At the same time,
however, we found that the affinity of R1 is too low to be utilized as a diagnostic tool for cells
expressing mIgM. Therefore, we herein report the systematic application of structure-activity
relationship (SAR) studies against R1 that, in turn, enabled the design of novel variants of R1 with
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improved affinity. Moreover, the optimized structure of aptamer R1 variant (R1.2) did not
diminish the aptamer's specificity towards mIgM-expressing panel of B-cell lines, indicating that
the functional fold of aptamer R1 was retained, despite the truncations employed. The antibody
utilized in selective elution of aptamer R1 binds to both sIgM and mIgM. We found that the variant
of R1, termed R1.2 also binds to sIgM as well as mIgM demonstrating that the specificity of
secondary ligands utilized in selective elution of the aptamer governs the aptamer's epitope
specificity. Since the sIgM and mIgM are identical in their amino acid composition, except the
constant μ4 (Cμ4) region at the 3′-end of mIgM, demonstration of variant R1.2 binding to both
sIgM and mIgM confirms that aptamers can be generated against predetermined epitopes guided
by secondary ligands, a hallmark mechanism of LIGS142. Finally, the most optimized variant of
R1 showed binding to mIgM-positive human B lymphoma BJAB cells at physiological
temperatures, proving that LIGS-generated aptamers could be re-optimized into higher affinity
variants, thus demonstrating the significance of LIGS in generating epitope-specific aptamers with
potential applications in biomedicine.
4.2

Materials and Methods

4.2.1 Cell culture
Cell lines, including Ramos (Burkitt's lymphoma), BJAB (Burkitt's lymphoma), CA-46
(Burkitt's lymphoma), SKLY-16 (B-cell lymphoma) and Jurkat.E6 (acute T-cell leukemia), were
a generous gift from the David Scheinberg Lab and Huse Lab, Memorial Sloan Kettering Cancer
Center. Daudi (Burkitt's lymphoma) and MOLT-3 cell lines (acute lymphoblastic leukemia) were
purchased from American Type Culture Collection (ATCC). All cells were cultured using RPMI
1640 medium supplemented with 100 units/mL penicillin–streptomycin and 10% fetal bovine
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serum (heat-inactivated; Invitrogen). All cell lines were routinely assessed for the expression of
appropriate CD markers to authenticate the cell line.
4.2.2

DNA synthesis and binding buffers
All DNA reagents needed for DNA synthesis were purchased from Glen Research or

ChemGenes. The variants of R1 were chemically synthesized by attaching a fluorophore at the 3′end using standard solid phase phosphoramidite chemistry on an ABI394 DNA (Biolytics)
synthesizer using a 0.2 μmol scale. The completed DNA sequences were de-protected according
to the base modification employed and purified using HPLC (Waters) equipped with a C-18
reversed phase column (Phenomenex/Waters/Thermo Fisher). All in vitro experiments were
performed using a binding buffer composed of DPBS, 4.5 g/L glucose, 5 mM MgCl2, 100 mg/L
tRNA, and 1 g/L BSA, all from Sigma-Aldrich. The wash buffer was composed of DPBS with 5
mM MgCl2 and 4.5 g/L glucose (Sigma-Aldrich).
4.2.3

Preparation of solutions and folding conditions
First, 10 μM solutions of R1.1, R1.2 and R1.3 were prepared by dilution of the respective

stock solutions with the diluting buffer containing 550 μM KCl. Then, 1 μM working solutions of
variant R1.1 were prepared by diluting the 10 μM solution with binding buffer. The 1 μM working
solutions of R1.2 and R1.3 were prepared by diluting the 10 μM solution using binding buffer
containing 0.2 M KCl. Random controls were prepared in a manner similar to that of each R1
variant. The folding of random control and aptamer solutions was done by heating at 95 °C for 10
min and maintaining on ice for 1 h. The maximum time of 1 h for folding was strictly followed
because aptamer binding diminishes if the folded aptamer is kept on ice any longer.
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4.2.4

Specificity
Specificity assays were conducted with individual aptamers against HPLC-purified

random DNA (60-mer) control purchased from IDT DNA Technologies. The specificity of
aptamer sequences was evaluated by incubating truncated analogues separately with seven
different cell lines accompanying the B-cell lines BJAB, Ramos, Daudi, SKLY-16 and CA46,
while the negative cell lines were Jurkat.E6 and MOLT-3. These assays were performed by
incubating 100 μL of either aptamer (500 nM) or random control with 100,000 cells in 100 μL of
cell suspension buffer on ice for 45 min, followed by washing twice with 1.5 mL wash buffer each
time. Cells were reconstituted in 250 μL wash buffer. Finally, binding was analyzed by flow
cytometry by counting 10,000 events for each concentration. Expression of mIgM on all seven cell
lines was also analyzed by incubating 100,000 cells in 100 μL volume using a final concentration
of 0.5 μg/mL anti-IgM monoclonal antibody (Alexa Fluor® 647, mouse anti-Human, Novus
Biologicals), followed by flow cytometric analysis. Specificity assays at physiological temperature
(37 °C) were performed similar to 4 °C, except 1.5 x 105 BJAB or Jurkat cells were used, and
incubation was performed in a 37 °C incubator in a final volume of 200 μL. Cell washing and flow
cytometry analysis were performed at room temperature using reagents stored at room
temperature.
4.2.5

Determination of binding affinities
4.2.5.1

At 4 °C

Aptamer dilutions and folding were performed as described in the previous section.
Binding affinities of R1 variants towards targets cells were determined by using either Ramos
(1.0 × 105) or BJAB (0.75 × 105) cells. A range of fluorescently labeled aptamer concentrations
was used, and the cells were incubated in either 200 μL or 150 μL of aptamer solutions in binding
buffer for 45 min on ice. The wash buffer at 4 °C (2 mL for Ramos cells and 3 mL for BJAB cells)
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was added for one wash, and the cells were then reconstituted in 250 μL of wash buffer. Aptamer
binding towards targets cells was analyzed with flow cytometry for each concentration by
recording 5000 events. The calculation of Bmax/2 was done using the same method as described
previously.
4.2.5.2

At 37 °C

Binding affinities at physiological temperature (37 °C) were determined using conditions
similar to those at 4 °C, except 1.5 × 105 BJAB cells were used, and incubation was performed in
a 37 °C incubator in a final volume of 200 μL. Also, cell washing and centrifugation were
performed at room temperature using reagents stored at room temperature.
4.2.6

Soluble IgM preparation
Slide-A-Lyzer™ Dialysis Cassettes from Thermo Scientific (cat. no: 66373) were used for

buffer exchange of human sIgM. Soluble human IgM was purchased from Sigma (cat. no: 18260)
as a 0.8 mg/mL solution in a storage buffer consisting of 0.05 M Tris-HCl, 0.2 M NaCl, pH 8.0,
and 15 mM sodium azide. Human soluble IgM lyophilized from the same storage buffer was
purchased from Innovative Research (IR-HUM-GF-LY-20992). One milligram of lyophilized
sIgM was dissolved in 0.5 mL sIgM solution (Sigma, 0.8 mg/mL) to formulate 2.8 mg/mL of
sIgM. Dialysis was performed at 4 °C overnight in 500 mL of DPBS buffer with constant stirring.
The Quick Start Bradford Protein Assay Kit from BioRad (cat. no: 500-0201) was used to
determine the concentration of sIgM after buffer exchange, using non-dialyzed soluble sIgM as a
standard. We used the standard protocol in a 1 mL cuvette assay in which five concentrations of
protein standard (sIgM, Sigma) and the dialyzed sample were incubated for 30 min with 1x dye
reagent. Absorbance at 595 nM was recorded using a UV–vis spectrophotometer (Evolution 300,
Thermo Scientific). Standard curve was generated using the 3rd order polynomial trendline
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(Microsoft Excel), and the concentration of the unknown dialyzed sIgM was calculated using the
3rd order polynomial equation generated from the trendline.
4.2.7

Antigen specificity
4.2.7.1 Competition against anti-IgM antibody
To determine antigen specificity, a competition experiment between R1.1 and anti-IgM

antibody was performed, as described in Chapters 2 and 3 with the following modifications. A
total of 5 × 105 Ramos cells were incubated in a 400 μL cell suspension buffer with 5 μL of Alexa
Fluor® 647 isotype control (Biolegend) or 5 ng/μL Alexa Fluor® 647 anti-IgM antibody (Goat anti
human μ-chain, Life Technologies) for 30 min on ice. The cells were then mixed thoroughly, and
50 μL of cells was incubated with 50 μL of 0.5 μM aptamer and random solutions for an additional
30 min on ice to allow competitive binding of the aptamers and antibody against the target. The
cells were washed with 2 mL wash buffer and reconstituted in 200 μL of wash buffer for binding
analysis using flow cytometry. Three replicates were performed, and percent binding of the
aptamer in the presence of anti-IgM antibody was determined by comparing binding without
antibody, which was defined as total binding.
4.2.7.2 Investigation of blocking of anti-IgM antibody binding
For antibody blocking experiments, 4 × 105 Ramos cells were first incubated with Cy3labeled R1.2, or random control (1 μM), on ice for 45 min. Then, the preincubated cells, with either
aptamer or random control, were added into antibody (Alexa Fluor® 647-conjugated Affinity Pure
F(ab′)2 fragment goat anti-human IgM (Jackson ImmunoResearch)) dilutions ranging from 10
ng/μL to 0.01 ng/μL. After additional incubation for 35 min, the cells were washed once with 2
mL wash buffer and re-suspended in 250 μL wash buffer. The binding of antibody in the presence
of R1.2 or random control was analyzed using flow cytometry by counting 5000 events.
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4.2.7.3 Competition with soluble IgM
Antigen specificities of R1 analogues were further analyzed by cell binding assay in the
presence of sIgM. BJAB cells (0.5 × 105) were incubated in 50 μL of final volume for 45 min in
the presence of human sIgM (48.5 μg per tube, at 1 μM concentration), or the same amount of
BSA as control, against three different FAM-dT-labeled R1.2 concentrations (500 nM, 250 nM
and 125 nM). Cells were then washed once using 1 mL wash buffer, reconstituted in 250 μL wash
buffer, and analyzed using flow cytometry by counting 5000 events. Also, binding of anti-IgM
antibody (Alexa Fluor® 647, Goat anti-human μ-chain, Life Technologies), with or without sIgM,
was tested by incubating 1.5 × 105 BJAB cells with a final concentration of 2 μg/mL antibody in
the presence of 37 μg sIgM or BSA as a control.
4.2.7.4 Determination of binding affinity against soluble-IgM
Binding affinity of R1.2 against sIgM was determined by nitrocellulose filter binding
assays using 32P labeled R1.2 and random control against serially diluted concentrations of sIgM.
One picomole of R1.2 aptamer or random was radiolabeled using T4 PNK (Thermo Scientific,
#EK0031) according to manufacturer's protocol. Labeled aptamer or random DNA was purified
using Illustra MicroSpin G-25 columns (GE Healthcare, #27-5325-01). The aptamer was then
folded in 1xDPBS containing 5 mM MgCl2 and 2 mM KCl by heating for 10 min at 95 °C and
snap-cooled on ice. A final concentration of 0.2 nM labeled R1.2 or random control was used in
50 μL DPBS containing 5 mM MgCl2 buffer and incubated with soluble-IgM (1 μM to 1 nM) for
45 min. Bound R1.2 was separated from unbound aptamer by passing through nitrocellulose and
nylon filters under vacuum followed by two subsequent washes with 200 μL DPBS containing 5
mM MgCl2. Filters were exposed to phosphor screens overnight which were then imaged using a
Storm Molecular Imager Phosphorimager (GE Healthcare, Piscataway, NJ). The image was
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analyzed by ImageQuant software, and non-specific interaction of aptamer with the filter
membrane (no sIgM) was subtracted from aptamer signal at each sIgM concentration. The data
was plotted using GraphPad Prism software to obtain the dissociation constant.
4.3

Results

4.3.1

Truncation and analysis of affinity
The reported original parent aptamer R1 is 79 bases in length with an affinity of 315 nM.

By removing the nucleic acid segment corresponding to the forward primer of R1, termed R1.1
(59 mer), a truncated variant was also introduced93. Here, variant R1.1 was further evaluated for
affinity (73.2 ± 13.7 nM) against BJAB, a cell line derived from Burkitt's lymphoma, which is also
known to express high levels of mIgM (affinity curve, Figure 4.1a). Based on the observed
improvement in affinity upon truncation of full-length R1 aptamer, the binding of R1.1 with BJAB
cells was evaluated at physiological temperature of 37 °C. Interestingly, an affinity of 186 ± 31.6
nM was observed for R1.1 (Figure4.1b) against mIgM-positive BJAB cells at 37 °C, suggesting
that the functional secondary structure of R1.1 had been retained and was stable at both 4 °C and
37 °C, despite the removal of 20 bases from the 5′-end. It is well known that aptamers tend to show
highest affinity at the temperature utilized during the selection step and that change in temperature
could potentially lower affinity towards its target. Therefore, the affinity of R1.1 at physiological
conditions proved acceptable. However, we reasoned that affinity could be further improved by
designing multivalent analogues. Therefore, we further truncated a second variant based on R1.1
by removing an additional 17 bases from the 3′-end to generate R1.2 (Figure4.2). Variant R1.2
showed a slightly improved affinity of 35.5 ± 8.94 nM at 4 °C compared to R1.1 (Figure 4.3).
Also, at physiological temperature, variant R1.2 showed a trend similar to that of R1.1, with a
slightly increased affinity of 65.6 ± 5.88 nM, suggesting that R1.2 might be the most optimized
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version of parent R1 aptamer (Figure 4.3A–B). Binding analysis of R1.2 against control Jurkat
cells showed slightly higher nonspecific binding or uptake, however, specific binding is still
significantly higher suggesting that R1.2 had also retained its specificity at 37 °C (Figure 4.3 D
and E). We next evaluated the possibility of removing bases from the 3′-end without disrupting
the region of the aptamer molecule which involves functional fold (Figure 4.2), and, thus, a third
variant R1.3 was developed by truncating 7 bases from the 3′-end of R1.2. However, aptamer
variant R1.3 only showed an affinity of 134 ± 23.8 nM (Figure 4.1C) at 4 °C, which was
approximately four-fold less than that of R1.2. The reduced affinity of R1.3, suggested that
additional truncation of R1.2 at the 3′-end resulted in destabilizing the functional fold of the
aptamer, thereby lowering its affinity.
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Figure 4.1. Analysis of binding of R1 variants at 4 °C and 37 °C against mIgM positive
Burkitt’s lymphoma cell lines. A range of fluorescently labeled aptamer concentrations was used
and the cells were incubated with A) 1.0 x 105 Ramos cells in 200 μL binding buffer B) 1.5 x 105
BJAB cells in 200 μL binding buffer and C) 0.75 x 105 BJAB cells in 150 μL binding buffer for
45 minutes on ice (A and C) or in 37 °C incubator (B). The cells were washed after the incubation
using 2ml (if Ramos cells were used) or 3ml (if BJAB cells were used) with wash buffer and
reconstituted in 250 μL of wash buffer. (D) Histograms show the binding specificity of R1.1
against mIgM positive BJAB cells at 37 °C. Aptamer binding towards targets cells was analyzed
with flow cytometry for each concentration by recording 5000 events. (The calculation of Bmax/2
was done using the same method as described in Chapters 2 and 3). (E) Control for sIgM binding
assay using 32P labeled molecules. 32P random control do not show any binding towards sIgM.
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Figure 4.2 Truncation of parent aptamer R1 to generate variants with shorter lengths.
Twenty bases were removed from parent aptamer R1 to design R1.1, followed by 17 bases from
the 3′-end of R1.1 to design R1.2. Finally, 7 more bases were removed from the 3′-end of R1.2 to
generate R1.3. Arrow indicates truncated position in each sequence. The 2-dimensional structures
(A) were obtained from http://rna.urmc.rochester.edu/RNAstructureWeb/index.html. Complete
list of sequences is shown (B).
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Figure 4.3. Analysis of R1.2 binding against mIgM-positive BJAB cells. Binding affinities of
R1.2 were determined by using BJAB (0.75 x 105 for 4 °C and 1.5 x 105 for 37 °C) cells incubated
with 2.5 nM to 500 nM of R1.2, or random control, solutions for 45 min on ice (A) or 37 °C (B)
incubator. After washing with 3 mL wash buffer, cells were reconstituted in 250 μL of wash buffer,
and aptamer binding was analyzed with flow cytometry for each concentration by recording 5000
events. (C) Binding affinity of R1.2 against sIgM using nitrocellulose filter binding assay-utilizing
32
P labeled R1.2 against 1 μM–1 nM sIgM. Serially diluted concentrations of sIgM were incubated
with 32P-labelled R1.2 or random DNA for 45-min on ice. The bound versus unbound molecules
were separated on nitrocellulose filter device by washing twice by 200 μL of wash buffer. Bound
R1.2 was quantified utilizing a phosphorimager. The calculation of Bmax/2 was done as described
in Chapters 2 and 3. (D) R1.2 shows specific binding to BJAB cells at 37 °C. (E) Bar diagrams
represent overall conclusion from six independent binding assays. (⁎⁎⁎: P≤ 0.001, obtained using
Student's t-test.)
Next, we analyzed whether variant R1.2 could recognize soluble IgM (sIgM). Two IgM
forms are present in humans143. Membrane form (mIgM), which is expressed on the cell
membrane, and the soluble form, or sIgM, is produced by B-cells143–145. Interestingly, both mIgM
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and sIgM have nearly identical amino acid composition, the only difference being that mIgM
contains an additional 42 amino acids142. This additional 42 amino acid sequence has been shown
to span from the juxtaposition to the membrane at the C-terminal of the heavy μ-chain to the
transmembrane region142. The anti-IgM antibody utilized to selectively elute aptamer R1 binds to
both versions of mIgM 97. Therefore, the affinity of the most optimized variant R1.2 towards sIgM
was evaluated. In doing so, variant R1.2 or the corresponding random DNA was labeled with 32P,
and purified labeled molecules were incubated with a range of concentrations of sIgM on ice.
Unbound sequences subsequently separated using a nitrocellulose filter, and binding of R1.2 to
sIgM was analyzed using a phosphorimager. Analysis of binding of labeled variant R1.2 showed
an affinity of 102 ± 42.4 nM towards sIgM (Figure 4.3C, and control random Figure 4.1E),
suggesting that R1.2 does indeed recognize sIgM but with a slightly lower affinity than that
towards mIgM.
4.3.2

Analysis of specificity against IgM-positive and IgM-negative cell lines
We evaluated the specificity of the truncated variants R1.1, R1.2 and R1.3 utilizing B-cell

lines known to express mIgM. Two cell lines lacking mIgM were used as controls. Using 3′-FAMdT-labeled aptamers and a corresponding random DNA sequence to address background sticking,
the binding of each variant with cell lines was quantified using flow cytometry. We also performed
a positive control using fluorescently labeled anti-IgM antibody against the cells to ensure that the
cell lines used in this assay were indeed positive or negative for mIgM (Figure 4.4). Evaluation of
whether the truncation of the full-length aptamer led to an increase in background binding revealed
no significant increase in non-specific binding of variant R1.2 (Figure 4.5C). While variant R1.2
show ~ 25% increment of background compared to full-length aptamer, the specific binding
towards BJAB cells is also increased by ~ 66% suggesting that specificity of the aptamer is retained

83

despite the truncation. In addition, all cell lines that tested positively bound to anti-IgM antibody
were also positive for all variants of parent aptamer R1 (Figure 4.5 for specificity of R1.2; Figure
4.6A for specificity R1.1; and Figure 4.6B for specificity of R1.3).

Figure 4.4. Analysis of expression of mIgM on positive and negative cells using anti IgM
antibody. A final concentration of 0.5 μg/mL anti-IgM monoclonal antibody (Alexa Flour® 647,
mouse anti-Human, Novus Biologicals) was incubated with 100.000 cells in 100 μL volume. The
cells were then washed with 1.5 mL wash buffer and reconstituted in 250 μL wash buffer and the
binding was analyzed by flow cytometry counting 10,000 events. Median Fluorescence Intensity
(MFI) of isotype was subtracted from that of anti-IgM antibody and the bar diagram was
constructed based the histograms for each cell line.
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Figure 4.5. Binding analysis of aptamer R1.2 against mIgM-positive B-cell lines and mIgM-negative T-cell lines.
(A) Histograms of R1.2 binding against B- and T-cell lines. The assays were performed by incubating either aptamer, or random control,
on ice for 45 min, followed by washing twice with 1.5 mL wash buffer each time. Binding was analyzed by flow cytometry by counting
10,000 events for each concentration. (B) Overall conclusion from three independent R1.2 binding assays for each cell line. The % of
aptamer binding was calculated as described as described in Chapters 2 and 3. (C) Comparison of R1 and R1.2 binding to targeting
BJAB cells and non-targeting Jurkat cells.
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A.

B.

Figure 4.6. Analysis of R1.1 (A) and R1.3 (B) binding towards B- and T- cell lines. The assays
were performed by incubating 100 μL of either aptamer (500 nM) or random control (500 nM)
with 100,000 cells in 100 μL of cell suspension buffer on ice for 45 minutes, followed by washing
twice with 1.5 mL wash buffer each time. The cells were reconstituted in 250 μL wash buffer and
the binding was analyzed by flow cytometry by counting 10,000 events for each concentration.
Histograms show one representative binding towards each cell line, whereas bar diagrams are
obtained by three independent experiments for each given cell line. The % binding of the aptamer
was calculated as described as described in Chapters 2 and 3. (*:P ≤ 0.05, obtained using student’s
T- test by comparing %binding for BJAB and Ramos with %binding for Jurkat separately.)
86

4.3.3

Competition of variant R1.2 with soluble IgM
Soluble IgM is present in high concentrations in human plasma, and concentrations of sIgM

can be altered by conditions such as bacterial or viral infection. That is, such infections can lead
to immune response by B-cells, triggering secretion of sIgM. Since both mIgM and sIgM are
essentially identical, anti-IgM antibody is also known to interact with both forms of IgMs, a
characteristic we analyzed using flow cytometry. To evaluate the binding of anti-IgM to both sIgM
and mIgM, we added an excess sIgM to the binding buffer in place of BSA, and BJAB cells were
suspended in this modified buffer prior to incubating with anti-IgM antibody. Subsequently, the
binding, or lack thereof, of fluorescently labeled anti-IgM antibody was investigated against BJAB
cells (Figure 4.7). As expected, the anti-IgM antibody showed diminished binding towards BJAB
cells when sIgM was present in the binding buffer compared to the control, suggesting that antiIgM binds to both the soluble and membrane IgM (Figure 4.7).

Figure 4.7. Analysis of binding of anti-IgM antibody to mIgM positive BJAB cells in the
presence of soluble IgM. The 1.5 x 105 BJAB cells were incubated with a final concentration of
2 μg/mL antibody in the presence of 37 μg soluble IgM or BSA as a control. Presence of soluble
IgM diminished anti-IgM binding to the cells compared to control BSA.
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Using a similar approach, we next evaluated whether aptamer R1.2 could sustain its
specific recognition of mIgM in the presence excess sIgM. To perform this assay, the binding of
high-affinity variant R1.2 in three different concentrations was tested against mIgM-positive
BJAB cells in the presence excess sIgM (1 μM) or BSA (Figure 4.8). If aptamer R1.2 was found
to bind both soluble and membrane IgM, we would then observe diminished fluorescence intensity
on BJAB cells compared to cells without sIgM. We observed a ~ 80 % decrease in the binding to
BJAB cells at 125 nM R1.2, ~ 76% decrease in the binding of R1.2 at 250 nM and, finally, a 66%
decrease in the binding of R1.2 at 500 nM when sIgM was present in the binding buffer, suggesting
that variant R1.2 does indeed bind to both IgM forms and the difference in affinity towards mIgM
and sIgM seems to play a minimal role when an excess sIgM is present, challenging potential
applications of R1.2 as a therapeutic delivery agent in vivo (Figure 4.8). Furthermore, the
diminished fluorescence intensity (compare blue and red histograms in Figure 4.8) indicates that
aptamer R1.2 is distributed between both mIgM and sIgM, leading to lower fluorescence signal on
the cells, suggesting that the epitope of R1.2 is exclusive to both sIgM and mIgM and no coreceptor molecules on the cell membrane stabilize the binding of R1.2 leading to higher affinity.
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Figure 4.8. Binding analysis of R1.2 with BJAB cells in the presence of 1 μM sIgM. Antigen
specificity of R1.2 was further analyzed by cell binding assay in the presence of sIgM. BJAB cells
(0.5 ×105) were incubated for 45 min in the presence of human solubleF IgM (48.5 μg per tube),
or the same amount of BSA as a control, against three different FAM-dT-labeled R1.2
concentrations (500 nM, 250 nM and 125 nM). Cells were then washed once using 1 mL of wash
buffer, followed by analysis of R1.2 binding by flow cytometry. Bar diagram is the overall
conclusion from two independent experiments. Asterisks represent adjusted P values from Sidak's
multiple comparisons test based on comparing BSA vs. sIgM data for each concentration. (⁎⁎: P
≤0.01; ⁎⁎⁎: P ≤0.001).

4.3.4

Competition of variant R1.1 with anti-IgM antibody
We previously showed that parent aptamer R1 competes with anti-IgM antibody93. It was

hypothesized that the affinity of R1 would be substantially lower than that of anti-IgM antibody.
Therefore, in the case of an aptamer (R1) competing with the same antigen or antigen near an
antibody binding site, the addition of a high concentration of anti-IgM antibody should decrease
the binding of aptamer R1. We investigated whether the reasonably improved variant R1.1 would
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also compete with the anti-IgM antibody. To make this determination, we performed an
experiment similar to that of previously reported by utilizing an isotope control antibody. Results
showed about 55 ± 7.1% decrease in aptamer binding in the presence of high concentration of antiIgM antibody (5 ng/μL) (Figure 4.9). Interestingly, we did not observe such competitive
displacement of variants R1.2 and R1.3, which might be explained by the shorter aptamer sequence
having a more favorable fit with the binding epitope.

Figure 4.9. Anti-IgM antibody outcompetes R1.1. In the presence of isotype control, R1.1 binds
to BJAB cells, but not when anti-IgM is present. Bar diagram on the right is overall conclusion
from three independent competition experiments. % of binding values in the presence of anti-IgM
antibody
compared
to
isotype
control
was
calculated
as
(Specific aptamer binding with anti - IgM)
𝑥𝑥 100, where specific binding= Aptamer Mean
(Specific aptamer binding with isotype control)
Fluorescence Intensity (MFI) − Random MFI. (⁎⁎⁎: P≤ 0.001, obtained by two-tailed t-test).

We reported that R1.1 blocks anti-IgM binding, but only when lower concentrations of
anti-IgM were used. Therefore, a reverse competition experiment (blocking) utilizing low
concentration of anti-IgM was conducted to evaluate whether variant R1.2 could also block antiIgM antibody binding to BJAB cells. Utilizing six different concentrations of F(ab′)2 fragment
goat anti-human IgM, ranging from 10 ng/μL to 0.01 ng/μL, the binding of anti-IgM was evaluated
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against BJAB cells, which were pre-incubated with 1 μM R1.2, or random control. Results showed
that aptamer R1.2 did block the binding of the antibody (Figure 4.10). At low concentrations of
F(ab′)2 (< 1 ng/μL of anti-IgM), variant R1.2 showed its highest blocking of anti-IgM of binding
by about 46.94 ± 6.62%. We observed no blocking (0% of blocking) by randomized control. The
percentage of blocking decreased as a function of increasing antibody concentration; suggesting
that when antibody concentration is below its Kd towards mIgM, binding of aptamer R1.2 is
prominent and can block anti-IgM binding to BJAB cells, whereas at high anti-IgM concentrations,
antibody binding predominates (Figure 4.10).

Figure 4.10. R1.2 aptamer blocks anti-IgM binding to BJAB cells. Binding of antibody to
BJAB cells preincubated with R1.2 aptamer or random control. In the presence of random control,
antibody bound to the cells by 100%; hence, anti-IgM blocking is zero. In contrast, the presence
of aptamer inhibited anti-IgM binding to BJAB cells when lower concentration of anti-IgM was
used. For each antibody concentration, % blocking of antibody binding by the aptamer compared
(Antibody MFI with random DNA− antibody MFI with R1.2)
to random DNA was calculated as:
𝑥𝑥 100.
(Antibody MFI with random DNA)

Results from three independent experiments were plotted against log antibody concentration.
(MFI: Median Fluorescence Intensity).
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4.4

Discussion
Nucleic acid aptamers are versatile synthetic ligands with high potential for the

development of molecular tools for a variety of biomedical applications146–149. Aptamers have been
selected by traditional SELEX since 1990 by coupling combinatorial library screening with in vitro
evolution5,6. Among many variants of SELEX, our group recently introduced a derivative of
“complex target SELEX” which we termed Ligand-Guided Selection, or LIGS91,93. The core
principle of LIGS is rooted in introducing higher affinity secondary competing ligands to either
induce a conformational switch of the receptor to destabilize the aptamer-receptor complex or
exploit the fundamental differences in concentrations of individual molecules in a combinatorial
library as an avenue to selectively elute highly specific aptamer molecules from a partially evolved
SELEX library. Using this method, we have selected highly specific aptamers against mIgM
utilizing anti-IgM antibody interacting with mIgM as the secondary ligand. Membrane IgM is the
major subunit of the BCR complex uniquely expressed on B-cells and B-cell NHL97. However,
since these selected aptamers generally showed lower affinities, this study aimed to optimize the
structure of one of the LIGS-generated aptamers to determine if such optimization would lead to
aptamers against mIgM with higher affinity, but without compromising specificity. To do this, we
first truncated aptamer R1 from both 3′ and 5′ ends, removing primer regions, which were shown
to play a limited role in stabilizing the structure. After systematic truncation of aptamer R1, the
affinity and specificity of its variant and those that followed were evaluated against cells
expressing target mIgM. Typically, DNA and RNA aptamer lengths are in the range of 75–90
bases, with fixed primer regions contributing to 50% of the length. The randomized region of an
aptamer is shown to be contributing to the functional fold of the aptamers. Therefore, subsequent
systematic structure-activity-relationship studies are essential to optimize the length of the
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aptamer. The first truncation of parent aptamer R1 was done by removing 20 bases contributed
from the forward primer yielding variant R1.1. The subsequent affinity analysis suggested that the
forward primer did not contribute to stability of the functional fold. We then truncated 17 bases
from the reverse primer region, and subsequent affinity analysis suggested that removed bases did
not affect the binding motif of the aptamer. Finally, further reduction of 7 bases from 3′ end, led
to a decrease in affinity suggesting that the double-stranded segment in variant R1.2 (Scheme 1)
may be stabilizing the binding motif of the aptamer. Truncation of aptamers to enhance their
affinity has been widely applied150,151. For example, an aptamer discovered against PTK7 utilizing
live cell-SELEX was truncated and then modified to yield high affinity second-generation
aptamers95. Also, an aptamer against transferrin receptor was subjected to minimization to yield
better variants. The “minimized” variant resulted in an aptamer with higher affinity, indicating that
the untruncated version might have contained a low concentration of functional fold, leading to its
lower overall affinity87. In the present paper, the binding of variants R1.1 and R1.2 to mIgMpositive BJAB cells at physiological temperatures indicates that the functional fold of the aptamer
had been retained, despite the truncations employed or the change in temperature. The two-fold
decrease in affinity compared to 4 °C could have resulted from the change of the aptamer or the
change of lateral angle of mIgM as a function of increasing temperature97. Nevertheless, the
affinity of R1.2 could be further improved by designing bivalent or multivalent analogues as shown
before97.
All variants were analyzed against five B-cell lymphoma cell lines and two non-B-cell
lines. The B-cell lines appeared to show different expression levels of mIgM based on anti-IgM
antibody staining, and all variants showed a similar trend, indicating that both aptamers and
antibody had identical binding patterns. With specificity and affinity having been confirmed,
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epitope specificity analysis revealed that truncated versions of R1 also retained their epitope
specificity. Binding analysis of R1.1 in the presence anti-IgM antibody showed that aptamer
binding was diminished by 50%, suggesting that 1) R1.1 was displaced by antibody, 2) antibody
destabilized R1.1, or 3) aptamer variant R1.1 could not bind its target as a result of steric
constraints of the antibody. At the same time, however, we did not observe competitive
displacement of variant R1.2 or R1.3, indicating that the compact nature of the shorter variants can
recognize their epitope and that anti-IgM cannot displace these shorter variants. Interestingly,
when variant R1.2 was used at higher concentrations (1 μM) and pre-incubated with BJAB cells
prior to adding anti-IgM, R1.2 blocked antibody binding. This blocking effect is prominent at
lower antibody concentrations, suggesting that anti-IgM can no longer recognize its epitope when
R1.2 is bound to the cells. However, we did not observe this effect with higher concentrations of
anti-IgM antibody. We selected the parent aptamer from a partially evolved pool using the same
antibody. Therefore, the difference in concentration might have played a role in the binding
kinetics. The bivalent nature of an antibody favors high affinity as a consequence of lower entropic
penalty caused by the binding than that of the monovalent version. However, when the aptamer is
at high concentration and the antibody is at concentrations lower than its affinity constant, aptamer
binding appears to predominate over that of the antibody.
The binding evaluation of variant R1.2 against sIgM revealed that the affinity of R1.2
towards sIgM is approximately 3-fold lower than the affinity towards mIgM. It is well known that
aptamers are highly specific towards the fold of the protein that was used in the SELEX method.
While, this aptamer could bind to an epitope common to both soluble and membrane IgM, there
might be slight structural variants between mIgM and sIgM leading slightly different affinities
towards sIgM and mIgM. Of the two forms of IgM, sIgM is secreted by B-cells during
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differentiation. It has been shown that both sIgM and mIgM contain the same mRNA coding up to
the fourth-constant region Cμ4 142. Since the anti-IgM antibody specific for both mIgM and sIgM
was used in selective elution of the aptamer during selection, it is possible that the aptamer binds
to a region of mIgM distal to its Cμ4 region. Membrane IgM is a key molecule of the BCR complex
uniquely expressed in B-cells144. Because of this unique expression, anti-IgM antibody can be used
to detect B-cells. Soluble IgM is present in normal human serum with an approximate range of
concentration of 45–150 mg/dL, while mIgM is exclusively expressed in B-cells and B-cell
lymphoma and leukemia152,153. During the early stage of infection, the concentration of sIgM is
elevated owing to its main role in primary immune response. Also, immune deficiency disorders,
such as meningitis, pneumonia and gram-negative sepsis, can lead to the suppression of sIgM
antibody production143. Therefore, the use of molecular probes based on variants of R1.2 could be
attractive for the detection of both sIgM and mIgM ex vivo.
In conclusion, we have systematically truncated parent aptamer R1, as identified through
the novel Ligand-Guided-Selection, to enhance affinity. Specificity analysis using B-cell lines
demonstrated that the specificity of the truncated version was not compromised. Furthermore,
binding analysis using sIgM showed that aptamer variant R1.2 bound to both soluble and
membrane IgM, indicating that the specificity of the ligand utilized in selective elution of the
aptamer determines the specificity of the aptamer. To enhance affinity in future studies, dimeric
aptamers will be designed, and ligand-induced receptor internalization will be evaluated. Also,
aptamer variant R1.2 will be further evaluated for its utility as a diagnostic agent to measure
infectious levels of virus/bacteria or measure levels of sIgM and as a potential diagnostic tool for
B-cell lymphoma.
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Chapter 5: Integrating Ligand-Receptor Interactions
Streamlined Discovery of Artificial Nucleic Acid Ligands

and In Vitro Evolution

for

Disclaimer: Reprinted (adapted) with permission from: Molecular Therapy Nucleic Acids, 17,
Zumrut, H.E., Batool, S., Argyropoulos, K.V., Williams, N., Azad, R., and Mallikaratchy, P.R.,
Integrating Ligand-Receptor Interactions and In Vitro Evolution for Streamlined Discovery of
Artificial Nucleic Acid Ligands. 150-163., Copyright © Elsevier Inc. 2019 92.
5.1

Introduction
Empirical evidence generated over 5 decades demonstrates that cells undergo structural

changes at the molecular level in response to environmental cues that change cell-surface and cellreceptor interactions with their ligands, leading to a modified cell state154,155. Owing to their
accessibility, membrane proteins remain the most attractive targets in developing molecular
therapeutic tools. However, when cell membrane proteins are purified, their resultant conformation
can be very different from that in their native state, thus making cell-surface proteins challenging
as targets for the development of artificial ligands, drugs, or diagnostics156,157. Essentially, this
means that the identification of functional ligands against membrane proteins in their purified state
may not lead to molecules that can recognize the same protein in its native expression levels on
the cell membrane. One way to address these challenges is to use cells as the whole target in highthroughput screening technologies, such as phage display or SELEX (systematic evolution of
ligands by exponential enrichment), to discover functional ligands based on the peptide or nucleic
acid aptamers5,6. Cell-based SELEX, for example, is designed to evolve and enrich a library of
DNA aptamers against a whole cell without modifying the biological state of the cell22,24,76. After
successive selection iteration in cell-SELEX, nucleic acid (NA) ligands are enriched against
multiple receptor proteins expressed in their native state22,24,76,85.
Recently, we introduced a unique variant of SELEX, termed ligand-guided selection
(LIGS), which exploits the inherent evolutionary step of competition between weak and strong
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binders in a SELEX library to discover specific DNA ligands91,93. This method allows the
identification of highly specific DNA ligands against precise sites of cell-surface receptors in their
native state, guided by an external competitor, such as a monoclonal antibody (mAb). However,
based on our early LIGS experiments, we observed that this method could be biased toward the
elution of low-affinity aptamers. Consequently, an extra step of post-SELEX modification is
required to improve the affinity of LIGS-generated aptamers139,158. In a previous LIGS study by
our group, aptamers selected against T-cell receptor-cluster of differentiation epsilon (TCR-CD3ε)
showed moderate affinity at 4 °C, and they did not bind to cells beyond 4 °C, preventing their use
in therapeutic applications91. Therefore, we herein optimized LIGS to identify aptamers with
higher affinity and specificity against TCR-CD3ε.
The TCR-CD3 complex expressed on T-cells is a multi-domain transmembrane protein,
consisting of a heterodimer, αβ, and two ectodomains, CD3εγ and CD3εδ159. The main αβ
heterodimer consists of a variable and a constant domain, while the CD3ε domain is conserved
and non-glycosylated, making CD3ε a suitable target for ligand development109,160. The optimized
LIGS, as reported here, was modified to facilitate the identification of universal aptamers against
TCR-CD3ε. Apart from the use of higher temperatures, we accomplished this by incorporating
primary cell samples to SELEX and LIGS while expanding the number of mAbs to eliminate offtarget sequences and, hence, streamline the ligand discovery process.
Consequently, we utilized two specific, clinically relevant mAbs—OKT3 and UCHT1—
against the TCR-CD3 complex expressed in cultured T-cell leukemia (Jurkat.E6) cells and primary
human T-cells to elute specific aptamers. Next, we evaluated the apparent binding affinities of the
evolved cell-SELEX library and the mAbs to optimize the conditions used in LIGS to facilitate
the elution of high-affinity aptamers. Additionally, Illumina high-throughput (HT) DNA
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sequencing was used to sequence multiple LIGS libraries. Combining this with the use of
FASTAptamer, a toolkit designed for primary sequence analysis from HT sequencing of
combinatorial selection populations, and GALAXY, a web-based platform for accessible,
reproducible, and transparent computational biomedical research, a total of five aptamer
candidates emerging from a single family against a single receptor molecule were identified161,162.
These aptamers show apparent affinities ranging from 3.06 ± 0.485 nM to 325 ± 62.7 nM toward
TCR-CD3ε, demonstrating the feasibility of LIGS in generating high-affinity aptamers with high
specificity. The specificity of the aptamer family was validated by using multiple competitive
ligand-binding strategies. To further confirm the antigen specificity, a double-knockout Jurkat cell
line generated by CRISPR targeting of the genes encoding TCR alpha constant chain and CD3epsilon polypeptide was used163–165. Two of these aptamers with the highest affinity show specific
recognition of isolated primary T-cells, which could be useful in designing novel DNA aptamerbased immunotherapies.
5.2

Materials and Methods

5.2.1

Cell Culture
Jurkat (Clone E6, acute T-cell leukemia) and BJAB (human Burkitt’s lymphoma B-cell

line) were a generous gift from the Huse Lab and the David Scheinberg Lab at Memorial Sloan
Kettering Cancer Center [MSKCC], New York, NY, USA. MOLT-3 (acute lymphoblastic
leukemia) and Toledo (non-Hodgkin’s B-cell lymphoma) were purchased from the American Type
Culture Collection (ATCC; Manassas, VA, USA). Double-knockout (CRISPR-Cas9-targeting
CD3E and TRAC genes) Jurkat cells were purchased from Synthego (Redwood City, CA, USA).
All cell cultures were maintained in RPMI-1640 medium (25 mM HEPES, L-glutamine; HyClone)
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supplemented with either 10% or 20% fetal bovine serum (FBS), penicillin-streptomycin (100
U/mL), and 1% nonessential amino acids.
5.2.2

Preparation of Primary T-Cells
All experiments using primary cells were conducted at the MSKCC, using institutional-

review-board (IRB)-approved protocols. PBMCs were isolated from whole blood of two different
healthy donors using Ficoll-Paque PLUS (GE Healthcare, Chicago, IL, USA). B-cells were
separated from PBMCs by using human CD19 microbeads, according to the manufacturer’s
manual (Miltenyi Biotec, Bergisch Gladbach, Germany). The B cell-depleted PBMCs were then
subjected to fluorescence-activated cell sorting (FACS) using a FACSAria (BD Biosciences, San
Jose, CA, USA) high-speed cell sorter to obtain CD5+ cells. These cells were then sorted to collect
CD4+ and CD8+ T-cell populations that were subsequently pooled together to be used in
experiments.
5.2.3

SELEX Library and Primers
SELEX library and primers were adapted from Parekh et al.166 and consisted of 37-nt-long

sequences (N37) in the randomized region flanked by two constant primer-annealing regions at
each end: (5′-ATC GTC TGC TCC GTC CAA TA-N37-TTT GGT GTG AGG TCG TGC-3′). A
fluorescein isothiocyanate (FITC)-labeled forward primer (5′-FITC-ATC GTC TGC TCC GTC
CAA TA-3′) and a biotinylated reverse primer (5′-biotin-GCACGACCTCACACCAAA-3′) were
used. SELEX library and primers were purchased from Integrated DNA Technologies (IDT;
Coralville, IA, USA).
5.2.4

Buffer Formulations
The selection was performed using cell suspension buffer (CSB) consisting of RPMI-1640

medium containing tRNA (200 mg/L) and BSA (2 g/L). tRNA and BSA were added to block
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nonspecific binding sites on the cell surface. For the selection containing primary T-cells, the wash
buffer was formulated by adding salmon sperm DNA (200 mg/L) to the RPMI-1640 medium.
5.2.5

Antibodies
In vivo anti-CD3 mAbs UCHT1 (mouse anti-human, isotype IgG1, catalog #BE0231),

OKT3 (mouse anti-human, isotype IgG2a, catalog #BE0001-2), anti-CD28 mAb (mouse antihuman, isotype IgG2a, clone 9.3, catalog #BE0248), and in vivo mouse IgG1 isotype control
(clone MOPC-21, catalog #BE0083) were obtained from BioXCell (West Lebanon, NH, USA)
and used for LIGS experiments. Alexa Fluor® 647-conjugated goat anti-mouse IgG (catalog #115605-062) was obtained from Jackson ImmunoResearch Laboratories (West Grove, PA, USA).
Allophycocyanin (APC)-conjugated mAbs, Mouse anti-Human TCRαβ (BD PharMingen,
563826), Mouse anti-Human CD3 (clone UCHT1, BD PharMingen, 555335), Mouse anti-Human
CD3 (clone OKT3, eBioscience, 17-0037-41), and Mouse anti-Human CD28 (eBioscience, 170289-41) were used for routine flow cytometry analysis.
5.2.6

Cell-SELEX
Target Jurkat.E6 cells were analyzed for the expression of TCR-CD3ε by utilizing

respective antibodies via flow cytometry. Each round of SELEX was performed using cells at logphase growth (6.0 × 105 to 8.0 × 105 cells per milliliter), and flow-cytometric analysis was
performed to confirm the presence of a single homogeneous cell population. The first round of
SELEX was performed by incubating 10.8 nmol denatured HPLC (high-performance liquid
chromatography)-purified single-stranded DNA (ssDNA) library with 1.0 × 107 cells in a final
volume of 500 μL. The DNA library suspended in 250 μL RPMI was denatured by heating at 95
°C for 5 min, followed by folding for 45 min at 25 °C in order to allow the formation of proper
secondary structures. Cells were washed three times with wash buffer and resuspended in CSB to
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obtain 1.0 × 107 cells in 250 μL CBS. The incubation was performed at 25 °C for 1 h by gently
shaking at 450 rpm. After 1 h, cells were washed with 9 mL RPMI to remove unbound sequences.
The cells were reconstituted in 300 μL DNase-free water, and the bound sequences were eluted by
heating at 95 °C for 10 min, followed by centrifugation for 10 min at 14,800 rpm. The collected
supernatant was amplified with 5 PCR cycles, and the resulting library was converted to ssDNA
to obtain FITC-labeled sense strand as reported83. Starting from the second round of SELEX, the
number of PCR cycles was optimized for each round and scaled up accordingly. When necessary,
a two-step PCR was utilized in which product of the first PCR was used as a template for the
second PCR to optimize the number of cycles. The process was repeated until the SELEX library
was enriched with survivors. In order to increase the stringency of the selection, the total number
of cells was gradually decreased to 5.0 × 106 for round 2 and to 2.5 × 106 for subsequent rounds of
SELEX. 250 nM of the final library was used from round 3 onward. The washes were increased
to 2× 3-mL washes at round 2, increasing to 3× 3-mL washes for subsequent rounds. UV-visible
(UV-vis) spectroscopy was used to determine the final yield of the amplified library after
conversion to ssDNA, starting at round 2. One round of negative selection was used against BJAB
cells. To accomplish this, the ssDNA library eluted from Jurkat.E6 cells was divided into two equal
fractions and incubated with 1.0 × 106 BJAB cells separately. The selection was concluded after
16 rounds of cell-SELEX.
5.2.7

Monitoring Selection Progress
The progress of the selection was monitored in three-round intervals, starting from round

7, by incubating 2.0 × 105 Jurkat.E6 cells with FITC-labeled ssDNA of an unselected control
library and the libraries after rounds 7, 10, 13, and 16 at a final concentration of 250 nM in 50 μL
total volume. After 1 h of incubation at 25 °C, cells were washed twice, using 1 mL RPMI and
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reconstituted in 250 μL RPMI. Binding events were analyzed using flow cytometry (BD
FACScan).
5.2.8

Cell-SELEX against Primary T-Cells
One round of selection was performed against isolated primary T-cells by incubating 5.0 ×

105 cells with 27.25 pmol of the library after 14 rounds of enrichment against Jurkat.E6 cells, at a
final library concentration of 250 nM. Prior to incubation, the cells were prepared by washing
twice with RPMI containing 200 mg of salmon sperm DNA per liter. The library was prepared
using the same protocol as that for initial rounds, and the incubation was performed at 25 °C for 1
h of shaking at 300 rpm. The cells were washed twice with 2 mL RPMI, and bound sequences
were recovered by using 250 μL DNase-free water. A two-step PCR procedure was used for
amplification of the eluted sequences. PCR cycle optimization was carried out to determine an
optimum number of cycles for the second PCR, and optimized conditions were used in preparative
PCR.
5.2.9

LIGS
5.2.9.1 LIGS against Primary T-Cells
The enriched, FITC-labeled ssDNA library, after 1 round of selection against primary T-

cells (R15T), and unselected control ssDNA library were heated at 95 °C for 5 min and equilibrated
at 25 °C for 45 min. 60 μL ssDNA was incubated with an equal volume of 5.0 × 104 primary Tcells at a final library concentration of 250 nM for 50 min at 25 °C, and this step was performed
in four individual tubes. After incubation, the cells were washed twice with 2 mL RPMI, and cells
were resuspended in 100 μL CSB containing one of the following: CSB only, CSB supplemented
with OKT3 antibody, CSB supplemented with UCHT1 antibody, or CSB supplemented with the
anti-CD28 antibody. Each mAb was used at a final concentration of 15 nM. All four samples were
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incubated for an additional 40 min at 25 °C to promote competitive elution of target-specific
aptamer candidates. After incubation, the supernatant containing competitively eluted sequences
was collected, and the eluted sequences were preserved for PCR amplification, followed by
Illumina sequencing library preparation. The cells were then incubated with Alexa Fluor® 647conjugated goat anti-mouse IgG at a final concentration of 5 μg/mL and analyzed by flow
cytometry to evaluate the binding of mAbs.
5.2.9.2 LIGS against Jurkat.E6 Cells
Before performing LIGS against Jurkat.E6 cells, the dissociation constant (KD) of the
library was determined, utilizing the evolved 16th round of the cell-SELEX library against target
cells with and without washing free ligands. The affinity analysis was done by performing a serial
dilution of the 16th-round cell-SELEX library and the unselected control library with 250-nM, 125nM, 50-nM, 25-nM, 10-nM, and 2-nM concentrations.
5.2.9.3 Library Affinity Determination and LIGS without Washing Free Ligands
Cells were prepared by washing with RPMI containing 200 mg salmon sperm DNA per
liter. 25 μL of each concentration of both libraries was incubated with 25 μL of 7.5 × 104 Jurkat.E6
cells for 1 hr, with gentle shaking. After incubation, cells were centrifuged at 7,000 × g for 1 min,
and 45 μL of the supernatant was removed. The cells were then reconstituted in 300 μL RPMI, and
binding was analyzed by flow cytometry. LIGS was performed by adding 20 μL of 7.5 ×
104 Jurkat.E6 cells, 5 μL mAbs, and 25 μL 16th-round ssDNA library and then allowing
competitive binding by incubation for 1 hr, with gentle shaking. After incubation, the supernatant
containing eluted sequences was collected, kept on crushed ice, and immediately PCR-amplified
for Illumina sequencing preparation. An additional LIGS was performed by preincubating
Jurkat.E6 cells with mAbs at 66.6-nM concentrations for 30 min and washing off the unbound
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mAbs by adding 3 mL RPMI. The cells were then reconstituted in CSB to obtain 7.5 ×
104 Jurkat.E6 cells in a 25-μL volume, and 25 μL of the16th-round ssDNA library was added into
the pre-mAb-treated cells. After 45 min incubation, the supernatant containing non-binding
sequences was collected, kept on crushed ice, and immediately PCR-amplified for Illumina
sequencing preparation.
5.2.9.4 Library Affinity Determination and LIGS Involving Washing Step
LIGS with the washing step was performed in a manner similar to that mentioned earlier,
except that incubation was performed with 3.0 × 105 cells for 45 min, followed by a washing step
using 3 mL RPMI. After removing the supernatant, cells were reconstituted in 300 μL CSB. 50 μL
resulting cell mixture was removed and analyzed by flow cytometry in order to mimic conditions
for LIGS. During LIGS, 50 μL CSB containing 5.0 × 104 cells were incubated with 5 μL mAbs for
30 min at 25 °C. At the end of this second incubation, cells were pelleted by centrifugation, and
the supernatant was kept on crushed ice for PCR amplification and Illumina sequencing
preparation.
For all LIGS conditions (except when pre-mAb-treated cells were utilized), final mAb
concentrations of 33.3 nM, 30.6 nM, 27.3 nM, and 33.3 nM were used for isotype control, antiCD3 clone OKT3, anti-CD3 clone UCHT1, and anti-CD28 antibodies, respectively. Antibody
binding was analyzed by secondary staining, utilizing Alexa Fluor® 647-conjugated goat antimouse IgG secondary antibody at a final concentration of 5 μg/mL.
5.2.10 Preparation of Samples for Illumina HT Sequencing
Eluted molecules obtained from LIGS and enriched cell-SELEX libraries were prepared
for Illumina HT sequencing using a two-step PCR approach. First, PCR was performed to
introduce Illumina’s overhang adaptor sequences to the primer sequences. The amplicon PCR was
104

performed using 6 or 8 PCR cycles, and the resulting PCR product was purified using 1.8×
Agencourt AMPure XP beads (Beckman Coulter). Amplicon primers consisting of Illumina’s
overhang adaptor and SELEX primer (in italics) sequences were ordered from IDT. The primer
sequences are as follows:
Forward amplicon: 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATCGTCTGCTCCGTCCAATA
Reverse amplicon: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCACGACCTCACACCAAA
The second PCR (Index PCR) was performed to add Illumina indices for multiplexing and
Illumina sequencing adapters using the Nextera XT Index Kit (Illumina, FC-131-1001) by 7 PCR
cycles. These PCR reactions were done using KAPA HiFi HotStart ReadyMix (2X) (KAPA
Biosystems, KK2601). For multiplexing, a single indexing strategy was used when fewer than six
samples were pooled, and dual indexing was used when more than six samples were pooled
together. The PCR product was purified and characterized by agarose gel electrophoresis and
submitted to the Genomics and Epigenomics Core Facility at Weill-Cornell Medicine (WCM) for
Illumina HT DNA sequencing. Sequencing of samples was performed after further characterizing
the product using Bioanalyzer (Agilent 2100 Bioanalyzer System).
In order to maintain high sequencing coverage of each sample, a maximum of 10 samples
were pooled together and sequenced by the Illumina HiSeq 4000 instrument in a single-read mode
using 100 cycles as reading length. Sequence data were demultiplexed at the Genomics Core at
WCM and provided as gzipped FASTQ files. These files (listed in Table 5.1) can be accessed on
the NCBI Sequence Read Archive (SRA) with the accession number NCBI: PRJNA523255
(https://www.ncbi.nlm.nih.gov/sra/PRJNA523255).

105

5.2.11 Bioinformatics Analysis
Initial analysis of the sequencing data was performed by the Computational Genomics Core
at the Albert Einstein College of Medicine. Preprocessing of Illumina HT sequencing data was
performed

using

cutadapt

and

a

local

copy

of

the

FASTX-Toolkit

(http://hannonlab.cshl.edu/fastx_toolkit/), as reported previously. After trimming 5′ and 3′
constant regions and eliminating sequences without the constant regions, sequences that were not
between 30 and 44 bases were removed. The remaining sequences were then filtered to keep only
high-quality reads by discarding any read that had a Phred quality score of less than 20 at a single
position. Pre-processed data were further analyzed by using the FASTAptamer toolkit v1.0.11
(https://github.com/FASTAptamer/FASTAptamer) at the Computational Genomics Core at the
Albert Einstein College of Medicine. First, FASTAptamer-Count for each library was performed
for individual sequence files to obtain read count for each sequence and their normalized read
count (reads per million; RPM) (Table 5.2). The count data were further analyzed in order to assess
the enrichment of individual SELEX pools. Here, the diversity of a library is first defined as
(number of unique sequences/total number of sequences) based on previously published
methods68, the enrichment is defined as 1 − diversity, and the percent enrichment is calculated as
(1−numberofuniquesequences/total number of sequences) x100.
Results from the count were used as input for FASTAptamer-Compare and FASTAptamerEnrich to calculate fold-enrichment for each sequence. Since FASTAptamer-Enrich can run for
three input files, these files were defined as x = final enriched cell-SELEX library (i.e., round 16),
y = LIGS library from isotype control antibody, and z = the specific mAb (anti-CD3 or anti-CD28).
(See Table 5.3 for a complete list of all files generated). The data from FASTAptamer-Enrich were
further analyzed by using the public GALAXY server (https://usegalaxy.org/). First, we used a
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filter cutoff in the GALAXY tool Filter (Galaxy Tool ID: Filter1) of ≥1 on the column
corresponding to the RPM value of each sequence in the final SELEX library (R16 for Jurkat and
R15 for primary T-cells). This tool removed any line that did not match the set criteria. This step
was applied to discard sequences with very low copy numbers. Remaining sequences were further
filtered against z/y in a second step to identify sequences that showed at least 4-fold enrichment in
anti-CD3 libraries (OKT3 and UCHT1) against isotype control. Sequences that showed any
enrichment toward CD28 against isotype control (enrichment z/y > 1) were also identified, and
these sequences were filtered from anti-CD3 libraries. Next, the GALAXY tool Compare Two
Datasets (Galaxy Tool ID: comp1) was used to find nonmatching rows between the datasets
obtained for anti-CD3 (OKT3 and UCHT1) and for anti-CD28 experiments to identify potential
CD3-specific sequences. The resulting sequences were added together using the Concatenate
Datasets tool (GALAXY Tool ID: cat1) and aligned by running ClustalW on the GALAXY server:
(GALAXY Tool ID: toolshed.g2.bx.psu.edu/repos/devteam/clustalw/clustalw/0.1).

5.2.12 Synthesis and Purification of Aptamer Candidates
DNA synthesis and purification were performed as described in chapters 2 and 3.
Randomized ssDNA control was obtained from IDT.
5.2.13 Synthesis and Purification of Aptamer Candidates
Initial aptamer screening was performed by incubating 500 nM fluorophore-labeled
aptamer candidates or random ssDNA molecules with 2.0 × 105 Jurkat.E6 (T-cell leukemia) and
MOLT-3 (acute lymphoblastic leukemia, TCR−/CD3−, CD28+) cells separately, in a total volume
of 100 μL at 25 °C for 1 h. After washing twice with 3 mL RPMI, cells were reconstituted in
250 μL RPMI, and binding events were analyzed using flow cytometry (BD FACScan). When
normalized against random control toward TCR-CD3ε-expressing Jurkat.E6 cells, potential
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aptamer candidates with binding above 25% were further screened, utilizing two additional
negative cell lines: BJAB (Burkitt’s lymphoma) and Toledo (non-Hodgkin’s B-cell lymphoma).
Percent fluorescent intensity values were determined by normalizing against a random control
as [(aptamer−random)/random] × 100 and analyzed using GraphPad Prism software.
5.2.14 Binding Affinity Determination
Binding affinities of selected aptamers against Jurkat.E6 cells were determined by
incubating a range of aptamer concentrations (1 nM to 250 nM) with 2.0 × 105 cells at 25 °C for
1 h. Cells were then washed once using 3 mL RPMI, and binding events were analyzed by flow
cytometry. KD values were obtained by plotting the specific median fluorescence
intensities (Aptamer Fluorescence Intensity − Random DNA Fluorescence Intensity) against each
concentration using GraphPad Prism software, as previously described (see chapters 2 and 3).
5.2.15 Cross-Competition
Unlabeled ZUCH-1 (the highest affinity aptamer) was purchased from IDT and used for
competitive binding experiments. The concentrations of fluorescent (5′FAM)-labeled aptamers
were chosen based on their binding affinities against Jurkat.E6 cells. 100 nM ZOKT-2, 200 nM
ZUCH-3, 300 nM ZUCH-4, and 500 nM ZUCH-5 were used. An excess concentration of 1 μM of
the competitor was used against each (5′FAM)-labeled aptamer. 2.0 × 105 Jurkat.E6 cells were
incubated with fluorescently labeled aptamers in the presence of the competitor, or CSB, as the
control in a total volume of 100 μL at 25 °C for 1 h. Cells were then washed once using 3 mL
RPMI, and binding events were analyzed by flow cytometry.
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5.2.16 Specificity Assay against TCR-CD3ε CRISPR Knockout Jurkat.E6 Cells
In order to evaluate the target specificity of the selected aptamers against TCR-CD3ε, a
specificity assay was conducted with TCR-CD3ε double-knockout Jurkat cells obtained from
Synthego. Jurkat.E6 cells used in Cell-SELEX (a gift from the Huse Lab, MSKCC), as well as
Synthego’s wild-type Jurkat cells, were used as positive cell lines. 250 nM of the highest affinity
aptamer, ZUCH-1, was incubated with 1.5 × 105 cells in a total volume of 150 μL at 25 °C for 1 h.
Cells were washed twice with 2 mL RPMI at the end of incubation and reconstituted in 250 μL
RPMI. Binding events were analyzed using flow cytometry. CSB used for this experiment
consisted of tRNA (200 mg/L), salmon sperm DNA (200 mg/L), and BSA (2 g/L) formulated in
RPMI-1640 medium.
5.2.17 Determination of Antigen Specificity by Aptamer/Anti-CD3 Antibody Competition
To further validate the specificity of the selected aptamers against CD3ε, competitive
binding experiments were performed using both anti-CD3 antibodies (OKT3 and UCHT1 clones)
and anti-CD28 antibody as the positive control. First, 8.0 × 105 Jurkat.E6 cells were incubated with
a 300-nM final concentration of each mAb at 25 °C for 30 min. The cells were then washed once
with 3 mL RPMI and reconstituted in 300 μL CSB. Then, 50 μL CSB, containing 1.0 × 105 mAbbound cells, was incubated with 50 μL of either ZUCH-5 or random ssDNA for an additional
30 min at 25 °C. The cells were washed once with 3 mL RPMI and analyzed using flow cytometry.
Secondary staining was also performed to analyze binding of the mAbs using Alexa Fluor® 647conjugated goat anti-mouse IgG secondary antibody for a final concentration of 5 μg/mL, and this
was followed by flow cytometry analysis.
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5.3

Results

5.3.1

Evolution of DNA Ligands against TCR-CD3ε-Positive Cells
LIGS

integrates

antibody-antigen

interactions

or

receptor-ligand

interactions

and in vitro evolution to robustly identify functional NA ligands against predetermined cellular
receptors. The LIGS method is outlined in Figure 5.1, and the workflow of bioinformatics analysis
performed is shown in Figure 5.2.
Prior to cell-SELEX, the target Jurkat.E6 cells were prepared by routine analysis of CD3ε
and TCR expression levels, with the same conditions as those used in cell-SELEX and LIGS using
respective OKT3 and UCHT1 mAbs and anti-human TCR αβ, by flow cytometry. Next, cellSELEX was carried out to evolve potential DNA ligands against Jurkat.E6 cells. After 10 rounds
of cell-SELEX, significant binding of the fluorescein-labeled cell-SELEX library from the
10th round, when compared to that from round 0, was observed based on flow-cytometric analysis
(Figure 5.3A). After this point, to remove nonspecific binders potentially present in the cellSELEX library, a negative SELEX step was introduced, utilizing BJAB (Burkitt’s lymphoma)
cells at round 12. BJAB cells were used because they express variants of immunoglobulins (Igs),
but they do not express the TCR-CD3 complex itself. Thus, the DNA sequences enriched in the
cell-SELEX library interacting with Igs expressed in hematopoietic cells could be removed by this
negative selection step while enriching DNA ligands with an affinity for the desired target TCRCD3ε. Following the negative selection, one more round of positive selection was conducted.
Specific enrichment of DNA ligands toward Jurkat.E6 cells, but not BJAB cells, was observed at
the 13th round of cell-SELEX (Figure 5.3B). Three additional cell-SELEX cycles were performed
to increase the number of copies of unique sequences in the evolved SELEX library against
Jurkat.E6 cells (Figure 5.3C).
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Figure 5.1. Overall Workflow of LIGS Step one: SELEX was performed against Jurkat.E6 cells up to the 11th round. At the 12th
round, a negative SELEX step was introduced, using BJAB cells to remove nonspecific DNA sequences. Step two: the enriched cellSELEX library against Jurkat.E6 cells was divided into two fractions. The first fraction was utilized in LIGS, using multiple mAbs and
Jurkat.E6 cells. The second fraction was used for an additional SELEX cycle, utilizing primary T-cells isolated from peripheral blood
mononuclear cells (PBMCs). The resulting library from this step was then used in LIGS with multiple mAbs and primary T-cells. Step
three: the resulting eluted sequences from each mAb were subjected to Illumina high-throughput sequencing (HTS), followed by
bioinformatics analysis. Step four: specific aptamer sequence hits against TCR-CD3 expressed on T-cells were identified and validated.
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Figure 5.2. Flowchart describing the steps involved in bioinformatics analysis of LIGS
sequencing data. First, raw sequencing data was pre-processed to remove two types of reads: 1)
Low-quality reads (Q < 20 at a single position) and the reads without intact SELEX primer regions,
2) The reads that are not within 20% range of the randomized SELEX region. Second,
FASTAptamer-Count tool was used to obtain read counts and normalized read counts, RPM (reads
per million), of each unique sequence (see Table 5.2 for a summary of FASTAptamer-Count
results). These data were then analyzed with FASTAptamer-Enrich tool to obtain fold-enrichment
values. Inputs for each FASTAptamer-Enrich run were defined as: x= final enriched cell-SELEX
library (i.e., Round 16), y= LIGS pool from isotype control antibody, and z= the specific
monoclonal antibodies (OKT3, UCHT1 or anti-CD28). A total of 18 tabular FASTAptamer Enrich
files as listed in Table 5.3 were generated using the combinations as outlined by the numbered
arrows. Then the downstream analysis was performed on the tabular FASTAptamer-Enrich files
using GALAXY server. Analysis of sequences in GALAXY server included following steps: first,
the filter tool was applied as RPM ≥ 1 to x. Then a second filter was applied as RPM (z/y) ≥ 4 to
identify sequences enriched in mAb eluted pools compared to the isotype control. This filter was
used as RPM (z/y) > 1 for positive control antibody (anti-CD28) to eliminate sequences eluted by
anti-CD28 binding to cells. Finally, the compare tool was used to remove matching sequences
between CD3 specific sequences and the sequences identified as hits for anti-CD28.The resulting
sequences were converted to FASTA format, concatenated and aligned using ClustalW. Finally,
the aptamer candidates were picked based on the multiple sequence alignment results.
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We used flow cytometry to compare the binding of the 16th-round cell-SELEX library to
that of the 13th-round cell-SELEX library, and the results show a slight decrease in median
fluorescence intensity for the former. This could be explained by the variation of expression levels
of TCR-CD3ε on Jurkat cells among the different culture flasks (compare Figures 5.3B and 5.3C).
In addition to flow-cytometric analysis, we investigated the change of copy numbers of individual
unique sequences in the evolved cell-SELEX libraries using bioinformatics analysis. To do this,
multiple libraries from cell-SELEX were sequenced, and the enrichment of cell-SELEX libraries
was analyzed using previously reported methods68. To elucidate the enrichment of SELEX
libraries, the percent enrichment was defined as (1−number of unique sequences/total number of
sequences) × 100 (Figure 5.3D)68. As SELEX progresses, the diversity of the pool decreases, and
the enrichment of sequences toward the whole cell increases. Based on our results (Figure 5.3D),
the 7th-round library was still diverse, possessing only ∼25% enrichment. Following the 7th
round, however, a rapid increase of enrichment was observed, reaching ∼65% at the 9th round and

finally reaching a plateau at ∼82% by the 12th round. In successive SELEX rounds, no further

enrichment against target cells was observed.
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Figure 5.3. Analyses of the Evolution of the SELEX Library against Jurkat Cells
(A) Flow-cytometric analysis of the evolved cell-SELEX library from 7th and 10th rounds against
Jurkat cells. Higher fluorescence signal on the x axis indicates the higher binding of the
fluorescence-labeled SELEX library from the 10th round against Jurkat cells compared to that of
the fluorescence-labeled SELEX library from the 7th round and round 0. (B) Specificity analysis
of the evolved cell-SELEX library by flow cytometry. The specificity of the 13th round of the cellSELEX library was analyzed against Jurkat cells, using BJAB cells as the negative control. For
the 13th round of the cell-SELEX library, the fluorescence signal on the x axis was higher against
Jurkat cells, compared to that in round 0, but not against BJAB cells. This indicates that the cellSELEX library evolved with sequences specific for Jurkat cells. (C) Flow cytometry analysis of
binding of the 16th-round cell-SELEX library against a different batch of Jurkat cells. (D)
Enrichment analysis of the sequencing data from cell-SELEX libraries based on FASTAptamerCount results. Enrichment is defined as: [1- (number of unique sequences/total number of
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sequences)] x 100; enrichment of the SELEX library increased as a function of cell- SELEX rounds
until round 12, with no significant change in enrichment values beyond the 12th round.

5.3.2

LIGS to Elute CD3ε-Specific Ligands
In LIGS, it is assumed that an evolved cell-SELEX library contains specific DNA ligands

against the desired receptor, i.e., TCR-CD3ε, and that the concentration of each DNA ligand in the
evolved cell-SELEX library is below its apparent affinity. Since this method is rooted in
differences in apparent affinities of ligand-receptor interactions, the affinity constant for each
antibody and apparent affinity constant of the evolved cell-SELEX library toward Jurkat.E6 cells
were determined prior to LIGS. The calculated affinities for mAbs are 1.5 nM ± 0.27 nM for antiCD3 clone OKT3, 1.4 nM ± 0.36 nM for anti-CD3 clone UCHT1, and 1.6 nM ± 0.22 nM for antiCD28 antibody (affinity curves are shown in Figure 5.4). The affinity of the cell-SELEX library
against Jurkat.E6 cells was measured by considering two conditions. First, the apparent affinity
toward Jurkat.E6 cells was determined in the presence of free ligands, which was calculated as
19.5 nM ± 1.96 nM, with a calculated apparent maximum binding (Bmax) value of 4.47
(Figure 5.5A). Second, the apparent affinity of the cell-SELEX library was determined in the
absence of free ligands, which was 78.3 nM ± 14.3 nM, with a calculated apparent Bmax value of
4.01 (Figure 5.5B). To enable the identification of high-affinity aptamers toward TCR-CD3ε, we
used two concentrations of the evolved cell-SELEX library for LIGS and used each condition
described earlier. Thus, LIGS was performed at 10 nM (equal to half the apparent affinity) and
20 nM (equal to the apparent affinity) in the presence of free DNA ligands and at 40 nM (equal to
half the apparent affinity) and 80 nM (equal to the apparent affinity) in the absence of free DNA
ligands.
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Figure 5.4. Affinity analysis of OKT3, UCHT1 and anti-CD28 antibodies against Jurkat.E6
cells at 25 °C. Binding curves are shown for each monoclonal antibody used during LIGS; (A)
OKT3, (B) UCHT1 (C) anti-CD28. Affinity analyses were performed by incubating 2.0 x 105
Jurkat.E6 cells with a serially diluted unlabeled antibody for 45 min at 25 °C in cell suspension
buffer used in SELEX. For each mAb the following final concentrations were used: 0.04 nM, 0.2
nM, 1 nM, 5 nM 10 nM and 30 nM. The assay was performed in triplicates. The isotype control
antibody was used at 30 nM. After the incubation with primary antibodies, the cells were washed
twice using 2 mL of RPMI, followed by secondary antibody staining using Alexa Fluor 647®conjugated Goat Anti-Mouse IgG at a final concentration of 5 μg/mL for 30 min. on ice. The cells
were then washed again twice with 2 mL RPMI and reconstituted in 300 μL of RPMI. And the
binding events were analyzed using flow cytometry (BD FACScan). The specific binding of mAbs
was calculated by subtracting the median fluorescence intensity obtained by isotype control from
that of mAbs at each concentration. The binding curves were constructed by plotting the specific
median fluorescence intensity values for each concentration as a function of mAb concentration
on GraphPad Prism software using one-site specific binding. The Kd values were calculated by
Bmax∗X
GraphPad Prism software using the formula: Y = (Kd+X) .
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Figure 5.5. Apparent Affinity Analyses of Cell-SELEX Libraries from Round 16 and LIGS
against Primary T-Cells (A) Apparent affinity analysis of the 16th-round cell-SELEX library
against Jurkat.E6 cells in the presence of free ligands (free unbound DNA ligands not removed by
washing prior to flow cytometry) calculated as 19.55 nM ± 1.957 nM, using GraphPad Prism with
a nonlinear fit, one site total and nonspecific binding. (B) Apparent affinity analysis of the 16thround cell-SELEX library in the absence of free ligands (free unbound ligands washed prior to
flow cytometry) calculated as 78.28 nM ± 14.34 nM, using GraphPad Prism with a nonlinear fit,
one site total and specific binding. (C) Flow-cytometric analysis of T-cells isolated from PBMCs
against the 15th round of cell-SELEX and LIGS against T-cells from PBMCs. Histograms indicate
the binding of the round-0 library (gray), binding of the 15th round of the cell-SELEX library
(purple), and binding of the 15th-round SELEX library after adding UCHT1 and OKT3 antibodies
(green and red, respectively). Binding of the 15th round of cell-SELEX library to the T-cells after
adding anti-CD28 antibody (orange). See Figure 5.6 for corresponding antibody staining.
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Next, we used several antibodies in LIGS. First, an isotype control antibody was used to
account for the high off-rate DNA ligands. Second, two mAbs against CD3ε receptor (clones
OKT3 and UCHT1) were used to competitively elute specific DNA ligands against the desired
receptor. Third, the mAb anti-CD28, targeting a different receptor expressed on the target cells,
was used to identify off-target sequences eluted by the reorganization of the cell membrane owing
to mAb interaction with CD28 receptor rather than true, specific competition. Fourth, an additional
LIGS was performed by collecting the supernatant containing free DNA ligands after incubation
with mAb-treated Jurkat cells. Fifth, a fraction of the cell-SELEX library from the 14th round of
cell-SELEX was utilized in one round of SELEX against TCR-CD3ε-positive primary T-cells
isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors, followed by LIGS
against T-cells isolated from PBMCs (see Figures 5.5C and 5.6 for antibody staining on primary
T-cells). The supernatants containing competitively eluted sequences were collected and PCRamplified for Illumina HT sequencing. All the conditions utilized in LIGS and their corresponding
sequence files are listed in Table 5.1.
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Figure 5.6. Flow cytometric analysis of CD3 and CD28 expression of T-cells isolated from
PBMCs. Following LIGS, the PBMCs were subjected to secondary antibody staining. The Alexa
Fluor 647®-conjugated goat anti-mouse IgG at 5 μg/mL incubated for 30 min on ice, washed and
analyzed by flow cytometry to evaluate the binding of mAbs. Histograms obtained at round 0
library (gray) and 15th round library (purple) did not contain any primary mAbs, hence they
represent the background fluorescence signal. Red, green and orange histograms correspond to
samples incubated with OKT3, UCHT1 and anti-CD28 mAbs during LIGS respectively. Increased
fluorescence signal after secondary antibody staining is observed for all samples with OKT3 and
UCHT1 mAbs (red and green histograms) and to a lesser degree with anti-CD28 mAb (orange
histogram) compared to the background signal, confirming the CD3 and the CD28 receptor
expression on T-cells isolated from PMBCs, which was used during LIGS.
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Table 5.1. List of all sequencing library pools with sample names and descriptions.
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5.3.3 Bioinformatics Analysis of LIGS Sequencing Data to Identify CD3ε-Specific
Sequences
We used a previously reported bioinformatics toolkit called FASTAptamer to analyze
sequences resulting from Illumina HT sequencing of LIGS libraries161. Using FASTAptamer, the
read counts of every unique sequence within each sequencing library were normalized against the
total number of sequences obtained by Illumina HT sequencing as reads per million (RPMs). The
sequencing data were then compared between LIGS libraries for fold-enrichment ratios:
RPMy/RPMx, RPMz/RPMy, or RPMz/RPMx, where x = total number of enriched sequences
resulting from the final round of cell-SELEX, y = sequences nonspecifically eluted when isotype
antibody was used, and z = specifically eluted sequences by mAbs (OKT3, UCHT1, or CD28) and
tabulated using the FASTAptamer-Enrich tool. Data files obtained from processing raw data by
FASTAptamer (shown in Tables 5.2 and 5.3) were further subjected to downstream analysis to
identify target-specific sequences using the public GALAXY server. The fold-enrichment values
(RPMz/RPMy) were plotted as a function of the abundance in mAb-eluted libraries (see Figure
5.7A for OKT3 and UCHT1 mAb and Figure 5.8 for anti-CD28 mAb). A distinct population of
sequences was observed above the fold-enrichment ratio value of 4, and based on this information,
a set criterion was defined as RPMz/RPMy ≥ 4 to filter off-target sequences and identify sequences
potentially outcompeted by each specific mAb (Figure 5.7A).
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Table 5.2. Summary of results from FASTAptamer-Count for each library that has been
sequenced.
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Table 5.3. List of 18 files obtained by FASTAptamer-Enrich and the summary of results obtained after filtering sequences on
GALAXY.
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Figure 5.7. Bioinformatics Analyses of Illumina HT Sequencing Data from LIGS Libraries
(A) The fold-enrichment ratios (RPMz/RPMy) against isotype control antibodies (y) and (z)
represent either OKT3 (blue circles) or UCHT1 (red triangles) antibody, plotted as a function of
the abundance of sequences. Here, the abundance values on the x axis are the log of normalized
read counts (RPM) multiplied by 100., See Figure 5.8 for fold-enrichment ratios for anti-CD28.
Based on the distribution of sequences, a fold-enrichment ratio value of 4 was chosen as a criterion
for specificity (dashed line). (B) The schematic diagram summarizes downstream analysis using
the GALAXY platform on FASTAptamer-Enrich data. LIGS libraries from the mAbs, including
OKT3, UCHT1, and anti-CD28, were individually analyzed. After sequential filtering of
sequences, 533 sequences in total were obtained for three mAbs used in LIGS. (C) Venn diagram
summarizing the findings of downstream analyses using the GALAXY platform. Four hundred
eighty-five sequences were identified in total by two different anti-CD3 antibodies, and 33
sequences were found to be common to both (OKT3 and UCHT1). (D) Multiple sequence
alignment (CLUSTALW) of the identified aptamer family with their dissociation constants against
Jurkat cells. The exceptional bases are highlighted in gray for each sequence. N.B., not binding.

Figure 5.8. Fold enrichment ratio vs. abundance plots for LIGS using anti-CD28 mAb.
Fold enrichment ratios were obtained using the formula: (RPMz/RPMy) where z = anti-CD28
mAb and y= isotype control, and abundance values were obtained using: log (RPM x 100) for each
sequence. A distinct population of sequences were observed above the fold enrichment value of 4
as shown by the dashed line.
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The filtering of sequences as a function of experimental conditions, i.e., control mAb
versus specific mAb used in LIGS, was performed using GALAXY, as shown in Figure 5.7B.
Application of a filter cutoff of 1 RPM for parameter x against the final 16th round of cell-SELEX
in the tabular FASTAptamer-Enrich files removed sequences with very low frequencies. After this
step, we obtained 65,085 sequences for the 16th round of cell-SELEX and 42,182 sequences in
round 15 for primary T-cells, as the total number of sequences enriched against whole cells.
Second, based on the previously defined set criterion, the cutoff value of 4 for RPMmAb / RPMIso
was applied to remove nonspecifically eluted sequences from the total sequences. In a third step,
any sequence with RPMCD28/RPMIso ˃ 1 was removed from the sequences obtained in step two for
both UCHT1 and OKT3. This stepwise nonspecific sequence elimination strategy resulted in 485
(452 unique sequences and 33 sequences were common to both OKT3 and UCHT1 mAbs)
sequences in total, as shown in the Venn diagram (Figure 5.7C). In the fourth and final step, all
485 sequences were aligned using ClustalW, with the addition of 48 sequences identified as CD28
specific to determine individual aptamer families124. Despite the three steps used to remove offtarget sequences, we observed that some sequences with mutations resulting from anti-CD28
competition appeared among the families from the 485 sequences identified against CD3ε. We
attribute this result to the compare tool on the GALAXY platform, which does not eliminate
sequences with one or more point mutations as identical hits.
Interestingly, based on ClustalW alignment, we identified one family of sequences that
appeared in five out of six conditions of LIGS using either OKT3 or UCHT1, and these were
synthesized first (Figure 5.7D). Additionally, we have evaluated the appearance of the sequences
from this family in the sequenced libraries of cell-SELEX (Figure 5.9). Interestingly, starting from
the 9th round of cell-SELEX, sequences belonging to this family consistently appeared in each
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round. Next, we picked sequences that appeared in two different LIGS conditions with high foldenrichment values, followed by synthesis and testing for binding. However, these sequences did
not bind to Jurkat.E6 cells, suggesting that bioinformatics analysis needs to be further refined to
eliminate sequences with high off-rates.

Figure 5.9. The appearance of five aptamers during the progress of selection. Appearance of
five aptamer sequences that are identified by LIGS were evaluated in each round of cell-SELEX
that was sequenced. Normalized read counts (Reads per Million) on the Y-axis of each aptamer
were obtained from FASTAptamer-Count data corresponding to each round of cell-SELEX.
Starting from 9th round members of this family started to appear, and at 13th round of SELEX, all
the members of this family were present with the exception of the ZUCH-3 aptamer. ZUCH-3
aptamer was identified from the LIGS experiment using primary T-cells and this sequence only
appeared in the SELEX round after primary T-cells were incorporated.
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5.3.4

Characterization of Aptamer Candidates
Eight aptamer candidates were identified by bioinformatics analysis, all of which were

tested against TCR-CD3ε-expressing Jurkat.E6 cells, including three negative cell lines not
expressing

TCR-CD3ε.

Here, we

defined

the

criterion

for

positivity

as [(aptamer−random)/random)] x 100 > 25%, compared to random sequence against positive cells
(Figure 5.10A; histograms in Figure 5.11). We then tested the affinity of the five positive aptamers
against Jurkat.E6 cells. As expected, the affinities correlated to the LIGS conditions used to elute
each aptamer (Table 5.4), suggesting that manipulating the concentration of the evolved library
during LIGS leads to elution of aptamers with higher affinity. More specifically, ZUCH-1 shows
an apparent dissociation constant, KD, of 3.0 nM ± 0.48 nM, the highest affinity of all five
aptamers (see the affinity curve in Figure 5.12). This aptamer was eluted by UCHT1 in the absence
of free ligand at 40 nM of the cell-SELEX library in LIGS. The LIGS experiment performed in
the presence of free ligands at 10 nM cell-SELEX library with OKT3 yielded aptamer ZOKT-2,
with an apparent affinity of 16.1 nM ± 3.71 nM (see the affinity curve in Figure 5.12). As shown
by the affinity curve in Figure 5.12, aptamer ZUCH-4, with an apparent affinity of 52.5 nM ±
11.6 nM, was eluted when 20 nM of the cell-SELEX library was used in the presence of free
ligands in LIGS. Finally, one aptamer, ZUCH-3, was identified with an apparent affinity of
27.5 nM ± 5.86 nM via LIGS against primary T-cells (see the affinity curve in Figure 5.12).
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Figure 5.10. Characterization of Aptamers for Cell Specificity (A) The overall conclusion from
three independent flow-cytometric analyses of ZUCH-1, ZOKT-2, ZUCH-3, ZUCH-4, and
ZUCH-5 for cell specificity using Jurkat.E6 and three negative control cells: BJAB, MOLT-3, and
Toledo. Percent fluorescent intensity values on the y axis were determined by normalizing against
a random control sequence using the equation: [(aptamer-random)/random] x 100 (one-way
ANOVA using Tukey’s multiple comparisons test performed on GraphPad Prism to obtain
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statistical significance: ***p = 0.0001; ****p < 0.0001). (B) Cross-competition experiments
among ZOKT-2, ZUCH-3, ZUCH-4, and ZUCH-5, using unlabeled ZUCH-1 as a competitor
against Jurkat.E6 cells, demonstrating that all five aptamers compete toward the same target on
Jurkat cells. (C) The overall conclusion from three independent analyses of cross-competition
experiments with unlabeled ZUCH-1 against ZOKT-1, ZUCH-3, ZUCH-4, and ZUCH-5 (two way
ANOVA and the Holm-Sidak multiple comparisons test performed on GraphPad Prism to obtain
statistical significance: *0.01 % p % 0.05; **0.001 % p % 0.01;***0.0001 % p % 0.001).

Figure 5.11. Individual histograms from flow cytometric analysis of ZUCH-1, ZOKT-2,
ZUCH-3, and ZUCH-4 and ZUCH-5 aptamers. Binding of each aptamer (blue histograms) is
evaluated against Jurkat.E6 (A), MOLT-3 (B), BJAB (C) and Toledo (D) cells. These assays were
performed by incubating fluorophore-labeled aptamers or random ssDNA molecules with 2.0 x
105 cells in a total volume of 100 μL at 25 °C for 1 h. After washing twice with 3 mL of RPMI,
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cells were reconstituted in 250 μL of RPMI, and binding events were analyzed using flow
cytometry (BD FACScan). Red histograms show anti-CD3 mAb staining for each cell line. All
five aptamers showed specific binding against Jurkat.E6 cells (A) that express CD3 receptor (A,
red histogram). No significant binding was observed against the control cell lines negative for CD3
(red histograms for B, C and D).

Figure 5.12. Affinity analysis of ZUCH-1, ZOKT-2, ZUCH-3, ZUCH-4 and ZUCH-5 against
Jurkat.E6 cells at 25 °C. A range of fluorophore labeled aptamer and random DNA
concentrations (1 nM to 250 nM) were incubated with 2.0 x 105 Jurkat.E6 cells at 25 °C for 1 h.
Cells were then washed once using 3 mL of RPMI, and binding events were analyzed by flow
cytometry (BD FACScan). These experiments were performed in triplicates for each aptamer.
Apparent affinity values were obtained by plotting the specific median fluorescence intensities
(Aptamer fluorescence intensity – Random DNA fluorescence intensity) against each
concentration value on GraphPad Prism software based on the one-site specific binding model
𝐵𝐵𝐵𝐵𝑎𝑎𝑥𝑥 ∗ 𝑋𝑋
using the formula: Y = 𝐾𝐾𝐾𝐾 + 𝑋𝑋 .
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Table 5.4. Summary of the LIGS conditions used to identify each aptamer discovered by
LIGS along with the antibody that eluted each sequence and their apparent affinity values
towards target Jurkat.E6 cells.
Aptamer
Name

LIGS Condition

The Antibody used
during LIGS

Apparent Dissociation
Constant (Kd)

ZUCH-1

40 nM Round 16 Library
without free ligands

UCHT1

3.0 ± 0.48 nM

ZOKT-2

10 nM Round 16 Library
with free ligands

OKT3

16.1 ± 3.71 nM

ZUCH-3

LIGS against primary Tcells

UCHT1

27.5 ± 5.86 nM

ZUCH-4

20 nM Round 16 Library
with free ligands

UCHT1

52.5. ± 11.6 nM

ZUCH-5

10 nM Round 16 Library
against pre-mAb treated
(capped) cells

UCHT1

325 ± 62.7 nM

ZOKT-6

LIGS against primary Tcells

OKT3

NA

ZUCH-7

LIGS against primary Tcells

UCHT1

NA

ZUCH-8

20 nM Round 16 Library
with free ligands

UCHT1

NA

Since five aptamers were identified by LIGS as specific and showed high sequence
homology, we reasoned that all five aptamers might bind to the same region of TCR-CD3ε. Thus,
we performed a cross-competition experiment using an unlabeled variant of ZUCH-1 aptamer with
the highest affinity as the competitor against all four aptamers with lower affinity and carrying
fluorescein amidite (FAM) labels. The cross-competition experiment showed that all four aptamers
with lower affinity competed with ZUCH-1 for the same epitope, suggesting that all five aptamers
had evolved against the same epitope of the TCR-CD3ε complex in Jurkat.E6 cells (Figures 5.10B
and 5.10C).
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5.3.5

Aptamer Specificity against TCR-CD3ε
The specificity of aptamers against TCR-CD3ε was further validated using two different

approaches. First, a double-knockout Jurkat cell line was generated by CRISPR to target the TRAC
gene that encodes the alpha constant chain of the TCR and the CD3E gene that encodes the CD3epsilon polypeptide. The binding of ZUCH-1 aptamer was then tested against wild-type Jurkat.E6
cells, and double-knockout cells were used as a negative control. Aptamer ZUCH-1 did not show
any binding toward the knockout cells (Figure 5.13A, right panel), but it did show binding to the
Jurkat cells utilized in LIGS (Figure 5.13A, left panel) and wild-type Jurkat cells utilized in
CRISPR (Figure 5.13A, middle panel), confirming the specificity against TCR-CD3ε
(Figure 5.13A; antibody staining in Figure 5.14). Second, antigen specificity was further
confirmed by competitive binding experiments with the mAbs used in LIGS, i.e., OKT3, UCHT1,
and anti-CD28 antibody. Here, the aptamer with the lowest affinity of all five, aptamer ZUCH-5,
was selected. A reduction in aptamer binding was observed in the presence of anti-CD3 mAbs
compared to the control anti-CD28 antibody (see Figures 5.13B and 5.15 for corresponding
antibody staining). Next, we tested ZUCH-1 and ZUCH-3 against isolated T-cells. Both aptamers
bound to human T-cells, suggesting that these two aptamers are specific to TCR-CD3ε in both
cultured and primary cells (Figure 5.13C).
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Figure 5.13. Characterization of Aptamer Specificity against TCR-CD3ε (A) Flow-cytometric
analyses of binding of the highest affinity aptamer, ZUCH-1, against Jurkat.E6 cells used in
SELEX (left), against wild-type Jurkat cells used for generating CRISPR knockout cell lines
(middle), against CRISPR double-knockout Jurkat cells (right), and the overall conclusion from
six independent specificity analyses (far right). Aptamer ZUCH-1 does not bind to knockout cells,
thereby demonstrating epitope specificity (ordinary one-way ANOVA, using Tukey’s multiple
comparisons test performed on GraphPad Prism to obtain statistical significance: ****p ≤ 0.0001).
(B) Flow-cytometric analysis of competitive binding of ZUCH-5 against Jurkat.E6 cells in the
presence of anti-CD28 antibody (left), OKT3 (middle) and UCHT1 (right) and overall conclusion
from three independent analyses (far right) (ordinary one-way ANOVA, using Tukey’s multiple
comparisons test performed on GraphPad Prism to obtain statistical significance: **0.001≤ p ≤
0.01; ***0.0001≤ p ≤ 0.001; ns, not significant). In the presence of OKT3 and UCHT1 antibodies,
aptamer ZUCH-5 binding is diminished, indicating that both OKT3 and UCHT1 displaced the
134

aptamer, but not anti-CD28. (C) Flow-cytometric analysis of binding of the APC-labeled anti-CD3
antibody against T-cells (left) and flow-cytometric analysis of ZUCH-3 (middle) and ZUCH-1
(right) aptamers against human T-cells isolated from donor PBMCs, indicating that both aptamers
bind to human T-cells.

Figure 5.14. Flow cytometry analysis of CD3 expression of cells used in specificity
experiments involving knockout cells in Fig. 513A. The Jurkat E.6 cells used in SELEX (A) and
wild-type Jurkat cells used for generating CRISPR knockout cell lines (B) are positive for TCRCD3 complex while the double knockout Jurkat cells obtained from Synthego do not express TCRCD3 complex (C). These assays were performed by incubating 1.0 x 105 of each cell type with 5
μL of APC-conjugated anti-CD3 mAb (clone OKT3, eBioscience™, 17-0037-41) in a total volume
of 100 μL at 25 °C for 30 min. The cells were then washed once with 3 mL RPMI, and the binding
events were analyzed using flow cytometry (BD FACScan).

135

Figure 5.15. Secondary antibody staining of Jurkat.E6 cells used for competitive binding
assays in Fig. 5.13B. Following the competitive binding assays, the same cells were secondary
antibody stained using Alexa Fluor 647®-conjugated goat anti-mouse IgG at 5 μg/mL final
concentration for 30 min on ice and the binding was analyzed by flow cytometry (BD FACScan).
Blue histograms showing binding of anti-CD28 mAb (A), OKT3 mAb (B) and the UCHT1 mAb
(C) towards Jurkat.E6 cells.

5.5

Discussion
SELEX

is

based

on

the

principles

governing

combinatorial

screening

and in vitro evolution85. The identification of aptamers against cell-specific receptors has
progressed rapidly in the past decade, owing to key advancements. First, if the epitope remained
unchanged, Morris and coworkers demonstrated that aptamers could be identified against isolated
membranes and that the diversity of a SELEX library is sufficient to enrich aptamers against
multiple targets76. Second, two contributions were made by introducing cell-SELEX, using whole
cells as the target in SELEX22,24,76. While previous methods facilitated progress in identifying
aptamers against cell-surface target, characterization of the target of the aptamer on the cell
membrane has been challenging.
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To identify specific aptamers against cell-surface receptor molecules, we introduced LIGS
earlier. However, the three aptamers identified against TCR-CD3ε utilizing LIGS in our previous
work showed no binding at higher temperatures, despite post-SELEX truncation of the selected
aptamers91. To address the potential bias of LIGS in generating low-affinity aptamers, we
optimized the LIGS method. Incorporation of a negative selection step facilitates the removal of
nonspecific sequences that are potentially enriched in the SELEX library. Therefore, we
incorporated a negative selection in a later cell-SELEX round to remove off-target sequences. We
next assimilated T-cells obtained from healthy donors to address potential aptamer bias in
recognizing epitopes present only in immortalized cultured cells. To address the observed
drawback of LIGS in generating low-affinity aptamers, we further manipulated conditions in LIGS
by using two concentrations of the cell-SELEX library in LIGS. The affinity of the aptamers
identified in each LIGS experiment correlates with the concentration of the enriched cell-SELEX
library used in LIGS. First, when the competing mAb was added after the aptamer-target binding
equilibrium was disrupted by washing away free ligands, aptamer ZUCH-1, with the highest
affinity, was eluted, with an apparent KD value of 3 nM. Two aptamers were then identified in the
LIGS experiment corresponding to the free competition when free ligands were not washed away.
In this case, aptamer ZOKT-2, with an apparent KD value of 16.1 nM, was obtained when the
concentration of the cell-SELEX library was kept at half of its apparent KD value (10 nM). A
second aptamer, ZUCH-4 (KD = 52.5 nM), was also discovered by using the same experimental
condition but keeping the concentration of the cell-SELEX library equal to its apparent KD value
(20 nM). Both aptamers show a substantial affinity toward target cells; however, aptamer ZOKT2 shows higher affinity compared to aptamer ZUCH-4. Based on these findings, we have herein
demonstrated the feasibility of LIGS for the identification of high-affinity aptamer ligands, as long
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as the concentrations of SELEX library, as well as the competing ligand, are manipulated to favor
this outcome. Next, in addition to TCR-CD3ε-specific clinically relevant UCHT1 and OKT3, we
utilized anti-CD28 and an isotype control to address off-target elution of the sequences during
LIGS. Finally, we used Illumina HT sequencing followed by bioinformatics analysis to analyze
sequences and identify the specific aptamers. These modifications demonstrate the simplicity of
LIGS in streamlining the identification of aptamer hits against predetermined cell-surface
receptors in their native functional state. In addition, the assimilation of LIGS in primary T-cells
reveals the feasibility and simplicity of this approach in expanding the repertoire of cells, including
primary cells.
The recent applications of HT sequencing platforms, such as Illumina, in SELEX have
enabled

unprecedented

depth

analysis

into

the

sequence

enrichment

process

in

SELEX167. However, we observed that the currently available sophisticated bioinformatics tools
are only capable of identifying highly abundant sequences in a library. The high repeat of a
sequence in a cell-SELEX library does not guarantee specificity or affinity toward a receptor. For
example, analysis of enriched aptamer libraries by HT sequencing, or Sanger sequencing, revealed
that high-affinity sequences do not necessarily appear in high repeats, as determined in several
studies83,106,168. Outcompeted molecules in LIGS pools can be divided into three types of DNA
ligands: those that specifically outcompeted DNA ligands resulting from specific mAb
competition, those weak binding DNA ligands with high off-rates, and those nonspecifically eluted
off-target sequences. Therefore, we postulated that the higher number of copies of irrelevant
sequences could challenge the identification of desired specific high-affinity sequences.
Consequently, in this study, we designed and applied specific experimental conditions during
LIGS to facilitate the identification of specific sequences, and the same experimental conditions
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were used to guide the bioinformatics analysis of sequencing data. Finally, we confirmed the
specificity of identified hits, using multiple validation strategies to enhance scientific rigor.
In conclusion, we have demonstrated a method that combines molecular interactions,
combinatorial screening, in vitro evolution, and Illumina HT sequencing to identify functional NA
ligands against a multi-component cell-surface receptor expressed on the cell membrane. We also
demonstrated that the incorporation of primary T-cells during cell-SELEX followed by LIGS
allowed identification of an aptamer against TCR-CD3ε expressed in primary T-cells, suggesting
that the repertoire of cell type can be expanded in LIGS. While affinity can vary based on LIGS
conditions, such as the order of incubation and concentration of the cell-SELEX library utilized,
or the order of incubation and concentration of competing ligands, the specificity of all five
aptamers, as described herein, confirms the significance of LIGS in generating target-specific
aptamers. The convenience of adding multiple mAbs during LIGS allowed the elimination of offtarget sequences, further strengthening the ability of LIGS technology to identify highly specific,
high-affinity aptamers. One limitation of LIGS, however, is that this approach is only applicable
to receptors with existing ligands. Here, we targeted the TCR-CD3 complex (TCR-CD3 epsilon),
which is a type I transmembrane protein that belongs to the Ig superfamily and a key receptor
expressed in T-cells that governs immune responses. All five aptamers selected could be utilized
for the development of DNA-based immunomodulators and T-cell engagers potentially leading to
DNA-based immunotherapeutic agents.
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Chapter 6: Conclusion
The discovery of aptamers, synthetic affinity reagents based on nucleic acids, through the
invention of the SELEX technique in the 1990s was followed by the development of aptamer
molecules effective against a variety of targets, including small molecules, amino acids, peptides,
and proteins. The utility of aptamers has been demonstrated in therapeutic and diagnostic
applications, among others. Because they are synthetic, aptamers are good candidates for targeting
cell surface proteins to develop diagnostic and therapeutic agents. Cell surface proteins are highly
accessible to drugs and are thus commonly used in targeted therapy.
Most SELEX techniques employ purified targets for aptamer development, and this is
appropriate for water-soluble intracellular proteins. Membrane proteins, however, are embedded
in the lipid bilayer and are not water soluble; consequently, the generation of high-quality purified
membrane proteins in sufficient quantities for SELEX is not straightforward. Moreover, the
artificial buffer systems used during purification can alter the conformation of the membrane
protein, and this may result in the selected aptamers not recognizing the target in its native
environment. This concern is even more prominent for multidomain membrane receptors, which
require the assembly of multiple subunits and coreceptors to function. A modified version of
SELEX that uses whole cells as targets was subsequently developed and named cell-SELEX. The
cell-SELEX method enables the identification of aptamers against cell surface proteins in their
native environment without the need for target purification. However, in cell-SELEX, the targeting
epitope is not predetermined by the researcher; additionally, aptamers are commonly evolved
against the most abundant proteins expressed on the target cells, which limits the applicability of
using the cell-SELEX approach to select aptamers against desired, therapeutically relevant targets
that are not highly expressed on the target cells. To successfully develop aptamers into therapeutic
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or diagnostic agents, it is imperative to identify the target protein that an aptamer binds. After the
completion of cell-SELEX, the target protein can be identified through affinity pull-down and
mass spectroscopy; however, due to the low solubility and high hydrophobicity of cell surface
proteins, these approaches are not always fruitful.
The research described in this dissertation aimed to develop an alternative cell-SELEX
approach named ligand-guided selection (LIGS). The LIGS method begins with selecting an
appropriate cell line that expresses the cell surface protein of interest. The random oligonucleotide
library is then subjected to multiple rounds of cell-SELEX against the target cells. An important
feature of conducting SELEX using complex targets (such as whole cells) is that even after
multiple rounds of selection towards the target, the combinatorial library remains highly
heterogeneous. This means that the library contains multiple unique potential aptamers against
individual epitopes expressed on the cell surface. Another feature of the SELEX method is that at
each round of selection, multiple structures compete each other to bind against the same target,
and thus, high-affinity binders survive to the next round by outcompeting low-affinity binders. In
developing the LIGS method, we exploited this feature by adding a secondary ligand that is known
to have a high affinity towards the target of interest. The secondary high-affinity ligand can be a
monoclonal antibody (mAb), a small molecule, or any ligand that is known to bind to the target of
interest. The use of a secondary ligand in LIGS is hypothesized to outcompete aptamer ligands
bound to the epitope by disrupting the equilibrium to favor the release of the aptamer ligands.
The first LIGS experiment was performed using Ramos cells that express membrane IgM
(mIgM), which is one of the isotypes of the B-cell receptor (BCR) that is expressed in B-cell
lymphomas. An mIgM-specific antibody was used as a competitor, and three aptamers specific
against mIgM were identified. The CD3/TCR complex expressed on T-cells was chosen as the
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next target of LIGS. Using cultured T-cells and an anti-CD3e antibody, we identified three
additional aptamers specific against CD3-TCR. The results from the first two LIGS experiments,
described in Chapters 2 and 3, demonstrated the applicability of the LIGS method for identifying
aptamers specific against predetermined cell-surface proteins. These aptamers achieved high
specificity towards their target, and this was confirmed by performing experiments involving
competitive binding between individual aptamers and antibodies; however, the affinities of these
aptamers were only moderate. Additionally, these aptamers were selected at 4 °C and did not
function at the physiological temperature that is necessary for advancing aptamers into diagnostic
or therapeutic agents.
Next, structure–activity relationship studies were performed to improve the affinity of the
mIgM-binding aptamer R1. As presented in Chapter 4, higher-affinity variants of the R1 aptamer
were obtained by retaining their specificities towards the target. The most optimized variant of the
R1 aptamer, R1.2, was also active at 37 °C, with a dissociation constant of 65.6 nM. However,
truncated CD3-TCR aptamer variants did not possess binding affinity at 37 °C.
Finally, as presented in Chapter 5, we further optimized the LIGS method to enable the
identification of higher-affinity aptamers that target the CD3-TCR complex. In this LIGS
experiment, cell-SELEX was performed at a higher temperature of 25 °C using CD3-TCRexpressing Jurkat cells. Additionally, to enhance the clinical relevance of selected aptamers, we
performed one round of cell-SELEX using primary T-cells. To promote the elution of higheraffinity aptamers, the following steps were taken. First, the binding affinity of the enriched cellSELEX library and the monoclonal antibodies against the target cells were evaluated. The binding
affinity of the cell-SELEX library was evaluated using two different scenarios: 1) washing away
the free ligands and 2) in the presence of free ligands. Second, for the LIGS, to promote the
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identification of high-affinity sequences, multiple LIGS experiments at different library
concentrations were performed by choosing a concentration equal to its Kd value as well as half
of its Kd value. Third, we used two anti-CD3-specific aptamers and two control antibodies to
identify hit sequences. These different LIGS conditions resulted in a total of 24 LIGS-derived
libraries, all of which were subjected to next-generation sequencing (NGS). To identify highaffinity aptamers specific to the CD3-TCR complex, we used extensive bioinformatics analysis of
the NGS-derived libraries. Using the FASTAptamer toolkit, we compared the abundance of each
sequence in the control versus the CD3-targeting monoclonal-antibody-derived libraries. These
data were further analyzed using available bioinformatics tools on the GALAXY platform to
sequentially filter out nonspecifically eluted sequences. On the basis of these, we identified a
family of aptamers with affinities toward the human CD3-TCR complex expressed on human Tcells ranging from 3.06 ± 0.485 to 325 ± 62.7 nM. As expected, the affinity of each aptamer
correlated with the LIGS condition utilized; higher-affinity aptamers were obtained using lower
concentrations of the cell-SELEX library and washing away the free ligands prior to introducing
competing mAb. The specificity of these aptamers was validated through competition experiments
as well as the use of a CD3e-TCRab double-negative cell line obtained through CRISPR-cas9
targeted gene knockdown. These experiments demonstrated the successful application of the LIGS
method for the identification of high-affinity and highly specific aptamers against predetermined
cell-surface proteins in their native environment and at natural expression levels. The aptamers
obtained from this study can be utilized for the development of therapeutic agents, especially
DNA-based immunotherapeutic agents.
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Appendix
1) Multiple Sequence Alignment Results for Chapter 2
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2) Multiple Sequence Alignment Results for Chapter 3
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